
<html lang="en"     class="pb-page"  data-request-id="a43461c3-03f7-4f81-bf4d-334967fdef39"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2012.55.issue-18;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm301024w"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors" /></meta><meta name="dc.Creator" content="James F.  Blake" /></meta><meta name="dc.Creator" content="Rui  Xu" /></meta><meta name="dc.Creator" content="Josef R.  Bencsik" /></meta><meta name="dc.Creator" content="Dengming  Xiao" /></meta><meta name="dc.Creator" content="Nicholas C.  Kallan" /></meta><meta name="dc.Creator" content="Stephen  Schlachter" /></meta><meta name="dc.Creator" content="Ian S.  Mitchell" /></meta><meta name="dc.Creator" content="Keith L.  Spencer" /></meta><meta name="dc.Creator" content="Anna L.  Banka" /></meta><meta name="dc.Creator" content="Eli M.  Wallace" /></meta><meta name="dc.Creator" content="Susan L.  Gloor" /></meta><meta name="dc.Creator" content="Matthew  Martinson" /></meta><meta name="dc.Creator" content="Richard D.  Woessner" /></meta><meta name="dc.Creator" content="Guy P.A.  Vigers" /></meta><meta name="dc.Creator" content="Barbara J.  Brandhuber" /></meta><meta name="dc.Creator" content="Jun  Liang" /></meta><meta name="dc.Creator" content="Brian S.  Safina" /></meta><meta name="dc.Creator" content="Jun  Li" /></meta><meta name="dc.Creator" content="Birong  Zhang" /></meta><meta name="dc.Creator" content="Christine  Chabot" /></meta><meta name="dc.Creator" content="Steven  Do" /></meta><meta name="dc.Creator" content="Leslie  Lee" /></meta><meta name="dc.Creator" content="Jason  Oeh" /></meta><meta name="dc.Creator" content="Deepak  Sampath" /></meta><meta name="dc.Creator" content="Brian B.  Lee" /></meta><meta name="dc.Creator" content="Kui  Lin" /></meta><meta name="dc.Creator" content="Bianca M.  Liederer" /></meta><meta name="dc.Creator" content="Nicholas J.  Skelton" /></meta><meta name="dc.Description" content="The discovery and optimization of a series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine compounds that are ATP-competitive, selective inhibitors of protein kinase B/Akt is reported. The initial design..." /></meta><meta name="Description" content="The discovery and optimization of a series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine compounds that are ATP-competitive, selective inhibitors of protein kinase B/Akt is reported. The initial design..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 18, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm301024w" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm301024w" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm301024w" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm301024w" /></link>
        
    
    

<title>Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm301024w" /></meta><meta property="og:title" content="Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0017.jpeg" /></meta><meta property="og:description" content="The discovery and optimization of a series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine compounds that are ATP-competitive, selective inhibitors of protein kinase B/Akt is reported. The initial design and optimization was guided by the use of X-ray structures of inhibitors in complex with Akt1 and the closely related protein kinase A. The resulting compounds demonstrate potent inhibition of all three Akt isoforms in biochemical assays and poor inhibition of other members of the cAMP-dependent protein kinase/protein kinase G/protein kinase C extended family and block the phosphorylation of multiple downstream targets of Akt in human cancer cell lines. Biological studies with one such compound, 28 (GDC-0068), demonstrate good oral exposure resulting in dose-dependent pharmacodynamic effects on downstream biomarkers and a robust antitumor response in xenograft models in which the phosphatidylinositol 3-kinase–Akt–mammalian target of rapamycin pathway is activated. 28 is currently being evaluated in human clinical trials for the treatment of cancer." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm301024w"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm301024w">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm301024w&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm301024w&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm301024w&amp;href=/doi/10.1021/jm301024w" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 8110-8127</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm300967g" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm301040s" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+F.++Blake">James F. Blake</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rui++Xu">Rui Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Josef+R.++Bencsik">Josef R. Bencsik</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dengming++Xiao">Dengming Xiao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicholas+C.++Kallan">Nicholas C. Kallan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Schlachter">Stephen Schlachter</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ian+S.++Mitchell">Ian S. Mitchell</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Keith+L.++Spencer">Keith L. Spencer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anna+L.++Banka">Anna L. Banka</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eli+M.++Wallace">Eli M. Wallace</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan+L.++Gloor">Susan L. Gloor</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++Martinson">Matthew Martinson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard+D.++Woessner">Richard D. Woessner</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guy+P.A.++Vigers">Guy P.A. Vigers</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Barbara+J.++Brandhuber">Barbara J. Brandhuber</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jun++Liang">Jun Liang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+S.++Safina">Brian S. Safina</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jun++Li">Jun Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Birong++Zhang">Birong Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christine++Chabot">Christine Chabot</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steven++Do">Steven Do</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leslie++Lee">Leslie Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Oeh">Jason Oeh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deepak++Sampath">Deepak Sampath</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+B.++Lee">Brian B. Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kui++Lin">Kui Lin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bianca+M.++Liederer">Bianca M. Liederer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicholas+J.++Skelton">Nicholas J. Skelton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Array BioPharma Inc., 3200 Walnut Street, Boulder, Colorado 80301, United States </span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Genentech Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: (303) 386-1262. E-mail: <a href="/cdn-cgi/l/email-protection#8ee4ece2efe5ebceeffcfceff7ece7e1fee6effce3efa0ede1e3"><span class="__cf_email__" data-cfemail="167c747a777d7356776464776f747f79667e77647b773875797b">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm301024w&amp;href=/doi/10.1021%2Fjm301024w" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 8110–8127</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 30, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 July 2012</li><li><span class="item_label"><b>Published</b> online</span>18 September 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 September 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm301024w" title="DOI URL">https://doi.org/10.1021/jm301024w</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8110%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJames%2BF.%2BBlake%252C%2BRui%2BXu%252C%2BJosef%2BR.%2BBencsik%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D18%26contentID%3Djm301024w%26title%3DDiscovery%2Band%2BPreclinical%2BPharmacology%2Bof%2Ba%2BSelective%2BATP-Competitive%2BAkt%2BInhibitor%2B%2528GDC-0068%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BHuman%2BTumors%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8127%26publicationDate%3DSeptember%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm301024w"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5625</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">84</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm301024w" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;F. Blake&quot;},{&quot;first_name&quot;:&quot;Rui&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Josef&quot;,&quot;last_name&quot;:&quot;R. Bencsik&quot;},{&quot;first_name&quot;:&quot;Dengming&quot;,&quot;last_name&quot;:&quot;Xiao&quot;},{&quot;first_name&quot;:&quot;Nicholas&quot;,&quot;last_name&quot;:&quot;C. Kallan&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Schlachter&quot;},{&quot;first_name&quot;:&quot;Ian&quot;,&quot;last_name&quot;:&quot;S. Mitchell&quot;},{&quot;first_name&quot;:&quot;Keith&quot;,&quot;last_name&quot;:&quot;L. Spencer&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;L. Banka&quot;},{&quot;first_name&quot;:&quot;Eli&quot;,&quot;last_name&quot;:&quot;M. Wallace&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;L. Gloor&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;Martinson&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;D. Woessner&quot;},{&quot;first_name&quot;:&quot;Guy&quot;,&quot;last_name&quot;:&quot;P.A. Vigers&quot;},{&quot;first_name&quot;:&quot;Barbara&quot;,&quot;last_name&quot;:&quot;J. Brandhuber&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;Liang&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;S. Safina&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Birong&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;Chabot&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;Do&quot;},{&quot;first_name&quot;:&quot;Leslie&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Oeh&quot;},{&quot;first_name&quot;:&quot;Deepak&quot;,&quot;last_name&quot;:&quot;Sampath&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;B. Lee&quot;},{&quot;first_name&quot;:&quot;Kui&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Bianca&quot;,&quot;last_name&quot;:&quot;M. Liederer&quot;},{&quot;first_name&quot;:&quot;Nicholas&quot;,&quot;last_name&quot;:&quot;J. Skelton&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;8110-8127&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm301024w&quot;},&quot;abstract&quot;:&quot;The discovery and optimization of a series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine compounds that are ATP-competitive, selective inhibitors of protein kinase B/Akt is reported. The initial design and optimization was guided by the use of X-ray structures of inhibitors in complex with Akt1 and the closely related protein kinase A. The resulting compounds demonstrate potent inhibition of all three Akt isoforms in biochemical assays and poor inhibition of other members of the cAMP-dependent protein kinase/protein kinase G/protein kinase C extended family and block the phosphorylation of multiple downstream targets of Akt in human cancer cell lines. Biological studies with one such compound, 28 (GDC-0068), demonstrate good oral exposure resulting in dose-dependent pharmacodynamic effects on downstream biomarkers and a robust antitumor response in xenograft models in which the phosphatidylinositol 3-kinase–Akt–mammalian target of rapamycin pathway is activated. 28 is currently being evaluated in human clinical t&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301024w&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301024w" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301024w&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301024w" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301024w&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301024w" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm301024w&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301024w&amp;href=/doi/10.1021/jm301024w" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm301024w" /></input><a href="/doi/pdf/10.1021/jm301024w" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm301024w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm301024w%26sid%3Dliteratum%253Aachs%26pmid%3D22934575%26genre%3Darticle%26aulast%3DBlake%26date%3D2012%26atitle%3DDiscovery%2Band%2BPreclinical%2BPharmacology%2Bof%2Ba%2BSelective%2BATP-Competitive%2BAkt%2BInhibitor%2B%2528GDC-0068%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BHuman%2BTumors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D18%26spage%3D8110%26epage%3D8127%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290753" title="Equilibrium constant">Equilibrium constant</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jmcmar.2012.55.issue-18/production/jmcmar.2012.55.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The discovery and optimization of a series of 6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidine compounds that are ATP-competitive, selective inhibitors of protein kinase B/Akt is reported. The initial design and optimization was guided by the use of X-ray structures of inhibitors in complex with Akt1 and the closely related protein kinase A. The resulting compounds demonstrate potent inhibition of all three Akt isoforms in biochemical assays and poor inhibition of other members of the cAMP-dependent protein kinase/protein kinase G/protein kinase C extended family and block the phosphorylation of multiple downstream targets of Akt in human cancer cell lines. Biological studies with one such compound, <b>28</b> (GDC-0068), demonstrate good oral exposure resulting in dose-dependent pharmacodynamic effects on downstream biomarkers and a robust antitumor response in xenograft models in which the phosphatidylinositol 3-kinase–Akt–mammalian target of rapamycin pathway is activated. <b>28</b> is currently being evaluated in human clinical trials for the treatment of cancer.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04284" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04284" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Protein kinase B (PKB)/Akt is a serine–threonine kinase, a downstream target for phosphatidylinositol 3-kinase (PI3K), which comprises three closely related isoforms (Akt1, Akt2, and Akt3). Akt functions as a pivotal node in the PI3K–Akt–mTOR pathway; once activated, Akt can control key cellular processes by phosphorylating substrates involved in apoptosis, transcription, cell cycle progression, and translation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Akt activity is frequently elevated in cancer due to amplification and/or gain-of-function mutations of upstream receptor tyrosine kinases and/or PI3K, as well as loss of PTEN function, a negative regulator of Akt.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Constitutive activation or overexpression of Akt isoforms has been identified in a wide variety of human tumors, including breast, prostate, ovarian carcinoma, and melanoma.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> shRNA knockdown of Akt in PTEN-null tumor xenograft models demonstrates antitumor effects with maximum efficacy achieved by inhibiting all three isoforms.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Combined, these factors contribute to the attractiveness of inhibiting Akt activity as a novel therapeutic approach to cancer treatment.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">Strategies for targeting Akt have included both ATP-competitive, active-site-directed inhibitors, and non-ATP-competitive allosteric compounds. Several advanced Akt inhibitors, representing both classes of compounds, were or are being tested in clinical trials for the treatment of human cancers.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Herein, we report on the discovery and preclinical characterization of <b>28</b> (GDC-0068), a highly selective pan-Akt inhibitor that targets the ATP-binding cleft.</div><div class="NLM_p">As detailed in previous work,<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> compounds exemplified by <b>1</b> and <b>2</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) demonstrated potent inhibition of Akt in biochemical assays (Akt1 enzyme inhibition, IC<sub>50</sub>, of 3 and 1 nM for <b>1</b> and <b>2</b>, respectively), reduced phosphorylation of Akt substrates in cellular assays (e.g., reduction of p-PRAS40 levels in LNCaP cells with IC<sub>50</sub> values of 160 and 137 nM for <b>1</b> and <b>2</b>, respectively), and down-regulation of Akt signaling in xenograft models of human cancer in nude mice. While the lack of kinase selectivity and resulting tolerability issues hindered the development of <b>1</b>, compound <b>2</b> displayed a significantly improved selectivity profile versus kinases such as PKA (PKA enzyme inhibition IC<sub>50</sub>/Akt1 enzyme inhibition IC<sub>50</sub> = 35), ROCK1, and other related AGC family members and was well tolerated while showing significant antitumor activity in PC3-NCI prostate cancer xenograft models.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The present work builds on our experiences with <b>1</b> and <b>2</b> and utilizes the dihydrocyclopentapyrimidine core (exemplified by <b>3</b>) as a platform to further explore the selective inhibition of Akt. With suitable substitution around this core, potent Akt-selective compounds have been identified that exhibit druglike properties and are suitable candidates for clinical evaluation.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Advanced proof-of-concept pan-Akt inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81306" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81306" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The general synthetic routes used to prepare 6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidine derivatives are outlined in the following schemes.</div><div class="NLM_p">As shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, preparation of the 5(<i>R</i>)-methyl-substituted cyclopenta[<i>d</i>]pyrimidine core requires rapid access to the β-keto ester intermediate <b>5a</b>. We decided to capitalize on the commercially available natural product chiral pool. Specifically, we searched for a starting material that could be readily manipulated into the desired β-keto ester, while allowing us to incorporate the desired methyl stereochemistry. Thus, commercially available (+)-pulegone (<b>4</b>) was sequentially reacted with bromine and sodium ethoxide to smoothly undergo ring contraction via a Favorskii rearrangement. Subsequent ozonolysis and reduction with zinc dust in acetic acid gave the desired chiral keto ester <b>5a</b> in excellent yield. Construction of the pyrimidine ring was carried out by initial conversion of β-keto esters <b>5a</b>, <b>5b</b>,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and <b>5c</b><a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> to enamines by ammonium acetate followed by cyclization upon heating with formamide and ammonium formate to deliver pyrimidones <b>6a</b>–<b>c</b>. Phorphorous oxychloride-mediated chlorination followed by SnAr introduction of the Boc-protected piperazine linker delivered <b>7a</b>–<b>c</b>. Olefin <b>7c</b> was converted to alcohol <b>7d</b> by ozonolysis, followed by reductive workup with NaBH<sub>4</sub> and chiral supercritical fluid chromatography (SFC) separation of the resulting racemic alcohol. <b>7d</b> was then further functionalized by treatment with <i>n</i>-perfluorobutanesulfonyl fluoride (PBSF) and HF–Et<sub>3</sub>N<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> to afford <b>7e</b>. Removal of the Boc group in <b>7a</b>–<b>e</b> provided <b>8a</b>–<b>e</b> as dihydrochloride salts.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 5-Substituted 6,7-Dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidine Cores<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) NaHCO<sub>3</sub>, Et<sub>2</sub>O, Br<sub>2</sub>, 0 °C; (ii) 21% NaOEt, EtOH, 0 °C to rt, 12 h; (iii) semicarbazide hydrochloride, NaOAc, H<sub>2</sub>O–EtOH (2:1), reflux to rt, 12 h (64%); (b) (i) ozone, EtOAc, −78 °C; (ii) zinc dust, acetic acid, 0 °C, 2 h (94%); (c) NH<sub>4</sub>OAc, MeOH, 12 h; (d) NH<sub>4</sub>CO<sub>2</sub>, formamide, 150 °C, 24 h; (e) POCl<sub>3</sub>, DCE, reflux, 6 h; (f) <i>tert</i>-butyl piperazine-1-carboxylate, DIEA, 1-BuOH, reflux, 16 h; (g) (i) ozone, DCM, −78 °C, 15 min; (ii) EtSMe, rt, 1 h; (iii) NaBH<sub>4</sub>, MeOH, 0 °C, 2 h (55%); (iv) chiral SFC separation; (h) PBSF, HF–Et<sub>3</sub>N, (80%); (i) 4 N HCl in dioxane, DCM, 12 h.</p></p></figure><div class="NLM_p">C7-hydroxylated and -fluorinated cyclopenta[<i>d</i>]pyrimidine cores were synthesized as illustrated in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Introduction of the C7-hydroxyl functionality was facilitated by <i>N</i>-oxide formation of <b>7a</b> followed by <i>N</i>-oxide acylation and concomitant rearrangement upon heating to give acetate <b>9</b> in a 3:2 <i>cis</i>–<i>trans</i> orientation. Hydrolysis of the acetate and subsequent Swern oxidation led to ketone <b>10</b>. Asymmetric transfer hydrogenation<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> using a ruthenium catalyst, RuCl(<i>p</i>-cymene)[(<i>R</i>,<i>R</i>)-TsDPEN], gave the desired (<i>R</i>)-alcohol <b>12a</b> in diastereomeric excess ranging from 94% to 98%. To obtain diastereomerically pure material, the alcohol was converted to the <i>p</i>-nitrophenyl ester, which enabled separation by either column chromatography or recrystallization. Hydrolysis of the <i>p</i>-nitrophenyl ester followed by acid-mediated <i>N</i>-Boc deprotection revealed the key amine intermediate <b>12b</b> in excellent diastereomeric excess (>99% by HPLC) as the dihydrochloride salt. The (<i>S</i>)-alcohol intermediate <b>13b</b> was prepared in a similar manner except for using the <i>S</i>,<i>S</i> ruthenium catalyst in the asymmetric hydrogenation step. Ketone <b>10</b>, (<i>R</i>)-alcohol <b>12a</b>, and (<i>S</i>)-alcohol <b>13a</b> were treated with DAST<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> to give the corresponding fluorinated products, which were deprotected under acidic conditions to yield the difluoro core <b>11b</b>, <i>cis</i>-fluoro core <b>14b</b>, and <i>trans</i>-fluoro core <b>15b</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of C7-Hydroxylated and -Fluorinated Cyclopenta[<i>d</i>]pyrimidine Cores<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>m</i>-CPBA, NaHCO<sub>3</sub>, CHCl<sub>3</sub>, 0 °C to rt, 2 h (100%); (b) acetic anhydride, 100 °C, 2 h (89%); (c) LiOH, THF–H<sub>2</sub>O (5:1), 16 h (99%); (d) oxalyl chloride, DMSO, Et<sub>3</sub>N, DCM, −78 °C to rt, 12 h (71%); (e) (i) RuCl(<i>p</i>-cymene)[(<i>R</i>,<i>R</i>)-TsDPEN] (for <b>12a</b>) or RuCl(<i>p</i>-cymene)[(<i>S</i>,<i>S</i>)-TsDPEN] (for <b>13a</b>), formic acid, Et<sub>3</sub>N, DCM, 12 h (ii) 4-nitrobenzoyl chloride, Et<sub>3</sub>N, DCM, 0 °C to rt, 4 h; (iii) LiOH, THF–H<sub>2</sub>O (2:1), 0 °C to rt, 1 h; (f) DAST, DCM, −20 °C, 1 h; (g) 4 N HCl in dioxane, DCM, 12 h.</p></p></figure><div class="NLM_p">In Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>, a convenient method for the preparation of optically active β-phenylalanine amino acids is described. The Evans auxiliary (<i>R</i>)-4-benzyloxazolidin-2-one (<b>16</b>) was coupled with 2-(4-chlorophenyl)acetyl chloride to give oxazolidin-2-one (<b>17</b>). Treatment of <b>17</b> with TiCl<sub>4</sub> at −78 °C followed by Mannich reaction of the resulting titanium enolate with <i>N</i>-acyliminium ions generated in situ from <i>N</i>-(alkoxymethyl)carbamates <b>18</b> afforded <b>19a</b>–<b>g</b> in good yield and diastereoisomeric ratio (for example, 14:1 diastereomeric excess (de) for <b>19a</b>). The diastereomers were easily separated by silica gel column chromatography. Basic hydrolysis of the chiral auxiliary provided the desired β-amino acids in excellent enantiopurity. <i>N</i>-Unsubstituted amino acid <b>20h</b> was synthesized by sequential cleavage of the <i>p</i>-methoxybenzyl ether (PMB) group and the chiral auxiliary in <b>19f</b>. In a similar manner, preparation of amino acids <b>23i</b>–<b>k</b> with cyclic amines was accomplished by stereoselective coupling of the Evans imide <b>17</b> with α-methoxy heterocycles <b>21i</b>–<b>k</b> followed by basic hydrolysis of the oxazolidinone auxiliary.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Stereoselective Synthesis of β-Phenylalanine Amino Acids<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>n</i>-BuLi, THF, −78 to −20 °C, 2-(4-chlorophenyl)acetyl chloride, 12 h (79%); (b) 1 M TiCl<sub>4</sub>, DCM, −78 °C, DIEA, rt, 1.5 h (72%); (c) DDQ, DCM, H<sub>2</sub>O, 19 h (100%); (d) LiOH–H<sub>2</sub>O, THF–H<sub>2</sub>O (3:1), 0 °C, H<sub>2</sub>O<sub>2</sub>, 12 h.</p></p></figure><div class="NLM_p">With the requisite cores and β-phenylalanine amino acids in hand, preparation of the desired compounds was achieved by amide coupling, followed by Boc deprotection under acidic conditions, as exemplified in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. The primary and secondary amines were further elaborated by reductive amination with Na(OAc)<sub>3</sub>BH and aldehydes or ketones to afford the corresponding substituted amines.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Amide Coupling and Further Elaboration of Amines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HBTU, Hünig’s base, DCM, 1 h; (b) 4 N HCl, DCM, rt; (c) aldehyde or ketone, Na(OAc)<sub>3</sub>BH, Hünig’s base, DCE, rt, 16 h.</p></p></figure><div class="NLM_p">Several analogues with CH<sub>2</sub>CF<sub>3</sub>- and <i>t</i>-Bu-substituted amines or cyclic tertiary amines were synthesized by an alternative route as outlined in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. Alkylation of the primary amine <b>55a</b> with trifluoroethyl triflate followed by saponification of the methyl ester with KO(TMS) afforded <b>58a</b> as a potassium salt. Alternatively, phenyl acetate esters <b>56a</b>,<b>b</b> were converted to the acrylates <b>57a</b>,<b>b</b> as previously reported.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> Michael addition of amines followed by hydrolysis of the methyl ester provided <b>58b</b>–<b>e</b> as racemates, which were then coupled with the C7-hydroxylated core <b>12b</b>. Finally, all diastereomeric pairs were resolved by chiral stationary-phase HPLC or chiral SFC to obtain desired compounds <b>37</b>, <b>39</b>, <b>40</b>, <b>51</b>, and <b>52</b>. The stereochemical assignments of compounds <b>37</b>, <b>39</b>, <b>40</b>, <b>51</b>, and <b>52</b> were based on the results of the Akt1 enzyme inhibition assay. All diastereomeric pairs were tested, and the active diastereomer was then assigned the stereochemistry shown in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a> on the basis of the activity of highly similar compounds prepared enantioselectively.</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Alternative Synthesis of Substituted Amines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CF<sub>3</sub>CH<sub>2</sub>OTf, Hünig’s base, THF–DMF (1:1), rt, 20 h, (93%); (b) KO(TMS), THF, rt, 18 h; (c) paraformaldehyde, 10% NaOMe, DMSO, rt, 12 h; (d) MsCl, TEA, DCM, 0 °C to rt, 12 h; (e) HNR′R″, THF, 0 °C, 12 h; (f) (i) HBTU, Hünig’s base, DMF, 18 h; (ii) chiral separation.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84624" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84624" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Analysis of a series of X-ray structures of the pyrrolopyrimidine and dihydrothienopyrimidine hinge-binding cores bound to Akt1 and PKA suggested that increased steric bulk near the gatekeeper residue tended to improve the selectivity profile relative to PKA and ROCK1/2. This was principally due to differences between Akt1 and PKA that include Thr211 (Akt1) to Val (PKA), Met281 (Akt1) to Leu, and Ala230 (Akt1) to Val, which lead to a narrower and less polar cavity in PKA, which should be less forgiving of larger hinge-binding functionality (cf. Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, ref <a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">7</a>). The saturated ring and larger sulfur atom of dihydrothienopyrimidine <b>2</b> confer 35-fold selectivity for Akt1 versus PKA, while pyrrolopyrimidine <b>1</b> is only 2-fold selective. The increased polarity of the Akt1 active site conferred by Thr211 could be exploited with complementary polar atoms on the inhibitor; for example, the dihydrofuranyl derivative of <b>2</b> showed >25-fold selectivity for Akt1 over PKA while maintaining druglike properties.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Inhibition by a series of spirochromane compounds has also revealed that PKA inhibition is much more dependent on the nature of the hinge-binding motif than Akt inhibition,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> again pointing to utility of this region of the Akt active site for generating selectivity. On the basis of these observations and a desire to further improve the selectivity profile of <b>2</b>, we decided to pursue additional changes to the hinge-binding motif designed to take advantage of these key insights. In previous analyses of the structure–activity relationship (SAR) for the amino amide portion of pyrrolopyrimidine and dihydrothienopyrimidine compounds, 4-chlorophenyl with an isopropylamine substituent afforded excellent potency, with reasonable animal pharmacokinetics (PK).<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> Thus, these features were maintained during our initial exploration of the hinge-binding motif.</div><figure id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structure of Akt1 in complex with a dihydrothienopyrimidine inhibitor (compound 26 from ref <a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">7</a>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OW4">3OW4</a>) at 2.6 Å resolution showing the molecular surface of the pocket in the vicinity of the hinge (hydrogens added for clarity).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From our previous efforts, methyl substitution at the 5- and 6-positions of the pyrrolopyrimidine core yielded a modest increase in selectivity over PKA.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Coupled with the selectivity data of the dihydrothienopyrimidine core, we targeted the dihydrocyclopentapyrimidine core as it afforded a better platform to explore additional substitution around the saturated ring. The first of these analogues prepared (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>, <b>3</b>) maintained the overall substitution pattern of <b>2</b> and proved to be potent, with Akt1 IC<sub>50</sub> = 6 nM, Akt2 IC<sub>50</sub> = 12 nM, Akt3 IC<sub>50</sub> = 5 nM, LNCaP cell p-PRAS40 IC<sub>50</sub> = 287 nM, and 6-fold selectivity over PKA (PKA IC<sub>50</sub> = 33 nM). Screening of <b>3</b> against a broad panel of 225 kinases found the compound displayed potent inhibition against only 5 additional kinases (>90% inhibition at 1 μM versus PRKG1α, PRKG1β, p70S6K, MSK1, and MSK2) and moderate potency against 14 kinases (>50% inhibition at 1 μM) and thus appeared to be reasonably selective.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Permeability of <b>3</b> was high, as measured in a Caco-2 assay: 13.2 × 10<sup>–6</sup> cm/s (apical to basolateral, A to B) and 19.2 × 10<sup>–6</sup> cm/s for the reverse direction (basolateral to apical, B to A). The compound also displayed a high predicted free fraction with 51% human plasma protein binding. Unfortunately, <b>3</b> possessed a rapid in vitro clearance in human hepatocytes (15 mL/min/kg). Given the excellent selectivity, potency, and permeability properties of <b>3</b>, it represented a good starting point for further optimization efforts.</div><div class="NLM_p">From inspection of the X-ray structure of a related dihydrothienopyrimidine inhibitor bound to Akt1, we reasoned that, in the absence of significant changes in the enzyme structure, only relatively small substituents would be tolerated at the 5- and 7-positions of the analogous dihydrocyclopentapyrimidine core (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Moreover, due to the proximity of protein atoms, there is more space available above the plane of the bicycle in the 5-position and below the plane of the bicycle in the 7-position. The environment above the plane of the bicycle is largely lipophilic (side chains of Ala177, Val164, Phe225, and Met227), while below the plane it is more hydrophilic (side chains of Thr211 and Thr291) and includes a water molecule coordinated by the backbone and side chain of Glu228. Interestingly, no water molecules are seen proximal to this site in 64 publicly available crystal structures of PKA (multiple inhibitor classes bound and with the majority of the crystals diffracting to better than 2.5 Å) except in cases where Val123 of PKA has been mutated to alanine (equivalent to Ala230 in Akt1), presumably because the increased hydrophobic bulk of valine makes this site unfavorable to water. We note that, in an aligned set of 470 human kinase sequences, only 5% have an alanine corresponding to Ala230 of Akt1, only 11% have a threonine corresponding to Thr211, and only Akt has both. Thus, hydrophilic ligand substituents in the vicinity of Thr211 and the water molecule would be expected to improve selectivity over not only PKA, but also most other kinases.</div><div class="NLM_p">Polarity at the 5-position of the dihydrocyclopentapyrimidine core (compound <b>27</b>) did not improve the selectivity and resulted in a loss of potency. Increasing the size of the C5 substituent with hydrophobic groups (<b>26</b>, <b>33</b>) tended to increase the potency slightly, but afforded no increase in selectivity over PKA. Note that disubstitution at C5 (<b>25</b>) resulted in a significant decrease in potency, which is consistent with the narrow nature of both the Akt and PKA active sites. One particularly interesting finding that emerged from substitution on the core is the profile of the <i>cis</i> configuration (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, compounds <b>29</b> and <b>31</b>) relative to the corresponding <i>trans</i> analogues. From this comparison, the <i>cis</i> substitution for both the fluoro and hydroxy substituents produces an equivalent profile, with high potency against Akt1 and much lower potency against PKA. However, for the <i>trans</i> configuration (compounds <b>28</b> and <b>30</b>), the profile diverges dramatically with over a 182-fold separation in PKA activities between the two analogues. The (<i>R</i>)-F substituent of <b>30</b> is small enough to fit within the cavity near the hinge of PKA; however, this is clearly not the case for the equivalent hydroxy substitution as both the size and polarity of the substituent lead to a significant loss of PKA activity. Interestingly, even though both the <i>R</i> and <i>S</i> configurations of both the fluoro and hydroxy groups at C7 are potent against Akt, the difluoro analogue (compound <b>32</b>) was poorly tolerated. The C7-(<i>R</i>)-hydroxyl combined with the C5-(<i>R</i>)-methyl substitution (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, compound <b>28</b>) gave ca. 620-fold selectivity versus PKA and afforded good cell potency. Testing against a broad panel of 230 kinases, <b>28</b> only inhibited 3 kinases by >70% at 1 μM concentration (PRKG1α, PRKG1β, and p70S6K, with subsequent IC<sub>50</sub> values determined to be 98, 69, and 860 nM, respectively).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> From our perspective, the dihydrocyclopentapyrimidinol core had the desired pan-AKT potency profile and achieved the level of selectivity we felt would ensure a wide safety margin on the basis of our prior efforts.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Development of the Dihydrocyclopentapyrimidine Core SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0012.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">Akt1 inhibition, IC<sub>50</sub>,<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> nM</th><th class="colsep0 rowsep0" align="center">Akt2 inhibition, IC<sub>50</sub>,<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> nM</th><th class="colsep0 rowsep0" align="center">Akt3 inhibition, IC<sub>50</sub>,<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> nM</th><th class="colsep0 rowsep0" align="center">Akt p-PRAS40 LNCaP IC<sub>50</sub>,<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> nM</th><th class="colsep0 rowsep0" align="center">PKA inhibition, IC<sub>50</sub>,<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> nM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>3</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">6 ± 2</td><td class="colsep0 rowsep0" align="left">12 ± 4</td><td class="colsep0 rowsep0" align="left">5 ± 3</td><td class="colsep0 rowsep0" align="left">287 ± 18</td><td class="colsep0 rowsep0" align="left">33 ± 9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>25</b></td><td class="colsep0 rowsep0" align="left">dimethyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">>2000</td><td class="colsep0 rowsep0" align="left">>2000</td><td class="colsep0 rowsep0" align="left">>2000</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>2000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>26</b></td><td class="colsep0 rowsep0" align="left">vinyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2 ± 1</td><td class="colsep0 rowsep0" align="left">6 ± 2</td><td class="colsep0 rowsep0" align="left">1 ± 0</td><td class="colsep0 rowsep0" align="left">176 ± 31</td><td class="colsep0 rowsep0" align="left">10 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>33</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3 ± 1</td><td class="colsep0 rowsep0" align="left">6 ± 2</td><td class="colsep0 rowsep0" align="left">5 ± 2</td><td class="colsep0 rowsep0" align="left">123 ± 32</td><td class="colsep0 rowsep0" align="left">35 ± 12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>27</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">81 ± 40</td><td class="colsep0 rowsep0" align="left">356 ± 53</td><td class="colsep0 rowsep0" align="left">83 ± 26</td><td class="colsep0 rowsep0" align="left">846 ± 202</td><td class="colsep0 rowsep0" align="left">957 ± 332</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>28</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-OH</td><td class="colsep0 rowsep0" align="left">5 ± 7</td><td class="colsep0 rowsep0" align="left">18 ± 10</td><td class="colsep0 rowsep0" align="left">8 ± 9</td><td class="colsep0 rowsep0" align="left">157 ± 30</td><td class="colsep0 rowsep0" align="left">3100 ± 705</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>29</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-OH</td><td class="colsep0 rowsep0" align="left">68 ± 38</td><td class="colsep0 rowsep0" align="left">249 ± 11</td><td class="colsep0 rowsep0" align="left">73 ± 27</td><td class="colsep0 rowsep0" align="left">740 ± 53</td><td class="colsep0 rowsep0" align="left">1552 ± 455</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>30</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-F</td><td class="colsep0 rowsep0" align="left">4 ± 2</td><td class="colsep0 rowsep0" align="left">14 ± 3</td><td class="colsep0 rowsep0" align="left">10 ± 2</td><td class="colsep0 rowsep0" align="left">152 ± 31</td><td class="colsep0 rowsep0" align="left">17 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>31</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-F</td><td class="colsep0 rowsep0" align="left">12 ± 4</td><td class="colsep0 rowsep0" align="left">35 ± 13</td><td class="colsep0 rowsep0" align="left">23 ± 5</td><td class="colsep0 rowsep0" align="left">901 ± 272</td><td class="colsep0 rowsep0" align="left">541 ± 179</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>32</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">diF</td><td class="colsep0 rowsep0" align="left">1169 ± 487</td><td class="colsep0 rowsep0" align="left">4177 ± 879</td><td class="colsep0 rowsep0" align="left">4160 ± 1466</td><td class="colsep0 rowsep0" align="left">8548 ± 550</td><td class="colsep0 rowsep0" align="left">>10000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Values are means of three or more experiments, and the standard deviation is given. ND = not determined.</p></div></div></div><div class="NLM_p">The binding mode of the 6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidine core was confirmed by crystallography: the crystal structure of <b>28</b> shows that the pyrimidine ring interacts via a hydrogen bond to the amide NH of Ala230 (the N–N distance is 2.97 Å), illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>. The hydroxyl donates a hydrogen bond to the backbone carbonyl of Glu228 (the O–O distance is 2.66 Å). The isopropylamine side chain interacts in the carbonyl-rich region with the carboxylate side chains of Glu234 (2.96 Å) and Glu278 (2.75 Å). The 4-chlorophenyl group occupies a small hydrophobic pocket under the P-loop that is formed when Phe161 is displaced toward the C-helix. As noted above, one of the key differences we targeted between Akt and PKA, or ROCK1, is the presence of Ala230 (Akt1) in the hinge. The small side chain of Ala230 in Akt1 creates a pocket that enables substitution of the dihydrocyclopentapyrimidine core with various groups that afford a high degree of selectivity.</div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structure of <b>28</b> bound to Akt1, solved at 2.0 Å resolution. Hydrogen atoms added for clarity (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EKL">4EKL</a>).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the previous dihydrothieno- and dihydrofuropyrimidine series, metabolism studies identified that amine dealkylation was the major metabolic reaction.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> On the basis of similar metabolite identification studies, <i>N</i>-dealkylation and oxidation of the core hydroxyl substituent to form the corresponding ketone were the primary routes of metabolism of <b>28</b> in vitro. The stability, assessed by predicted in vitro clearance in human hepatocytes for <b>28</b>, was 8 mL/min/kg. Given the nature of the amine metabolism, we sought to synthesize analogues with varying degrees of polarity, size, and basicity in an effort to reduce the oxidative loss of the isopropyl group, illustrated in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Development of the Amine SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0013.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0014.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Values are means of three or more experiments, and the standard deviation is given. ND = not determined.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">p<i>K</i><sub>a</sub> values were calculated using a custom p<i>K</i><sub>a</sub> model implemented in the MoKa software, version 1.1, from Molecular Discovery Ltd.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></p></div></div><div></div></div><div class="NLM_p">As we observed in the dihydrothienopyrimidine series of compounds,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> the secondary amines tended to possess better cell potency relative to the primary amines (e.g., <b>34</b> vs <b>35</b>), likely due to reduced permeability of the latter. The stability in human hepatocytes for <b>35</b> decreased significantly (predicted clearance of 11 mL/min/kg). Interestingly, inhibition of PKA does not change for the primary amines, giving rise to a reduced selectivity vs Akt1 for these compounds. Akt1 inhibition is tolerant of many small aliphatic amine substitutions (<b>35–38</b>), while predicted clearance ranged from 9 to 14 mL/min/kg in human hepatocytes for these compounds. Similarly, the tertiary amine analogue of <b>28</b> led to only a slight degradation of potency and selectivity (<b>42</b>); however, the predicted clearance increased to 11 mL/min/kg. Larger cyclic aliphatic substitutions of the amine are also well tolerated, with the enzyme potency, cell-based activity, and PKA selectivity all within ca. 5-fold of those of <b>28</b> (<b>41</b>, <b>44</b>, <b>45</b>, and <b>46</b>). Constraining the amine also had little effect on inhibition of Akt (<b>47</b> and <b>48</b>), although in the case of the pyrrolidine analogue (<b>43</b>) there was a degradation in PKA selectivity. Compound <b>43</b> did demonstrate improved stability (clearance in human hepatocytes, 3 mL/min/kg). Likewise, polar additions to the amine chain (<b>39</b>) produced lower clearance compounds (3 mL/min/kg); however, this came at the expense of PKA selectivity. The expected binding mode of these compounds has the amine situated at the lip of the ATP pocket such that these larger substitutions can project into the solvent, thus providing a potential mechanism to alter the physicochemical properties of the inhibitors without significantly compromising the potency. However, the basicity of the amine is an important driver of potency; reducing the p<i>K</i><sub>a</sub> below 6.5 led to an 8-fold drop in cell potency (<b>36</b>), while reducing the p<i>K</i><sub>a</sub> below 3.0 led to a 180-fold decrease in enzyme activity (<b>37</b>). Although some of the analogues in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> did show modest improvements in potency, none had dramatic improvements in metabolic stability while retaining cellular potency and selectivity.</div><div class="NLM_p">Finally, we explored the effect of amine substitution in conjunction with aromatic ring changes to probe the contacts with the underside of the P-loop of Akt1 (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Replacing the 4-Cl with a 4-CF<sub>3</sub> group improves the potency in the context of the primary amine (comparing <b>49</b> and <b>34</b>), although selectivity over PKA is still only moderate. Addition of a 3-F group to the secondary amines gives analogues with similar potency and selectivity over PKA (compare <b>50</b> to <b>28</b> or <b>54</b> to <b>44</b>). Combining the 3-F with the 4-CF<sub>3</sub> substitution led to a 3–4-fold improvement in enzyme and cellular potency; however, this substitution pattern reduces the selectivity ratio of PKA/Akt1 to be ca. 35-fold or less (e.g., comparing <b>53</b> to <b>35</b> or <b>52</b> to <b>39</b>). While compounds <b>52</b> and <b>53</b> did show improved cellular potency, the predicted stability (clearance of 7 and 13 mL/min/kg in human hepatocytes, respectively) decreased, presumably due to the increased lipophilicity of the 3-F-4-CF<sub>3</sub> substitution.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Development of the Cyclopentapyrimidinol Core SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0015.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0016.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Values are means of three or more experiments, and the standard deviation is given.</p></div></div><div></div></div><div class="NLM_p">From our exploration of the structure–activity relationship around the dihydrocyclopentapyrimidinol core, <b>28</b> remained one of the most selective compounds we have discovered, while maintaining good potency against all three Akt isoforms and high potency in cell-based assays. None of the analogues present in Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> and 3 offered any significant improvement of in vitro stability and selectivity over <b>28</b>, so <b>28</b> was advanced into additional profiling. As with the corresponding dihydrocyclopentapyrimidine (<b>3</b>), <b>28</b> is also predicted to have a high free-drug fraction in plasma for both human and preclinical species with 39% human plasma protein binding and 44% measured in monkey and 56% in mouse. Consistent with the plasma protein binding results, the solubility of <b>28</b> was very high, being greater than 10 mg/mL at three pH values (1.2, 6.5, and 7.4). <b>28</b> also possessed low to moderate predicted in vitro clearance in human, monkey, and mouse hepatocytes (8, 27, and 8 mL/min/kg, respectively).</div><div class="NLM_p">In keeping with observations with other ATP-competitive Akt inhibitors,<a onclick="showRef(event, 'ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21">(18-21)</a> there is an increase of phosphorylated Akt levels when cells are treated with <b>28</b>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> However, the data in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> clearly show that <b>28</b> potently inhibits Akt signaling in LNCaP cells (which have a high basal pAkt level due to loss of PTEN), indicating that the increased level of phosphorylated Akt is not functionally active in these cells.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Additionally, <b>28</b> has a potent antiproliferative effect on this cell line with an IC<sub>50</sub> of 95 ± 16 nM. We extended this analysis to other cell lines, including PC3, MCF7-neo/HER2, and BT474M1. In all three lines, <b>28</b> was able to inhibit overall viability with IC<sub>50</sub> values in the range of 1–4 μM. More detailed analysis demonstrated that <b>28</b> induces a dose-dependent block of the cell-cycle progression at the G1 phase and a dose- and time-dependent increase in apoptosis and necrosis in MCF7-neo/HER2 and BT474M1 cells (data not shown; a more complete discussion of these studies will be presented elsewhere). All four of the cell lines tested have elevated levels of basal Akt signaling due to loss of PTEN (PC3 and LNCaP), mutation of PI3Kα (MCF7-neo/HER2), or overexpression of Her2 (MCF7-neo/HER2 and BT474M1). Thus, the inhibition of signaling and reduced viability suggest that <b>28</b> will be useful in controlling human cancers in which PI3K/Akt signaling is overly active. <b>28</b> was able to inhibit phosphorylation of PRAS40 in all four of these cells lines with IC<sub>50</sub> values comparable to that observed in LNCaP cells (ca. 200 nM, data not shown).</div><div class="NLM_p">PK studies of <b>28</b> in nu/nu mice were performed to support pharmacodynamic and efficacy studies. The animals were given a single per os (po) dose of <b>28</b> at 12.5 and 50 mg/kg (0.5% methylcellulose with 0.2% polysorbate 80 (MCT) dose solutions). Systemic exposure increased in a more than dose-proportional fashion with increasing dose, leading to good exposures. Plasma concentrations were at or above 200 nM for the 12.5 and 50 mg/kg dose groups, respectively, within 1 h of drug administration. With the 50 mg/kg po dose, plasma concentrations were approximately 7.4 μM at 1 h postdose and 0.5 μM at 9 h postdose; the concentration of <b>28</b> was above 200 nM for approximately 9 h (this concentration is higher than the cellular IC<sub>50</sub> for p-PRAS40 knockdown in LNCaP cells; see Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). PK studies performed in rat and monkey also gave acceptable oral exposures (data not shown), suggesting that reasonable oral exposures in humans can be achieved.</div><div class="NLM_p">A pharmacodynamic (PD) and PK study was performed in nu/nu mice bearing subcutaneous PC3 prostate tumors to correlate plasma drug levels of <b>28</b> with PD changes in the tumors. Following administration of a single po dose, plasma and tumor samples were collected from the animals between 1 and 24 h for PK and PD analysis, respectively. As described above, robust Akt pathway inhibition with <b>28</b> was determined in vitro on the basis of the suppression of p-PRAS40. Therefore, this PD marker relative to the total protein level was also evaluated in vivo. Within 3 h of drug administration, there was a dose-dependent decrease in the ratio of p-PRAS40 to tPRAS40 compared with vehicle controls, with a >95% reduction achieved at 100 mg/kg (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A). At 8 h postdose, plasma levels of <b>28</b> of >2.6 μM were maintained with 100 mg/kg, and this correlated with an 87% inhibition of p-PRAS40/tPRAS40 (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B). Furthermore, pS6RP is also significantly reduced under these conditions (data not shown). These data demonstrate that <b>28</b> is able to significantly inhibit the Akt pathway in PC3 prostate tumors for at least 8 h postdose at 100 mg/kg.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. PK/PD of <b>28</b> in PC3 prostate tumors. Tumor ratios of p-PRAS40 to total PRAS40 (tPRAS40) were determined in female nude mice bearing PC3 prostate tumor xenografts (average of five animals ± SEM). Plasma concentrations of <b>28</b> were also measured. Samples were collected 3 h (A) or 8 h (B) following administration of 12.5, 25, and 100 mg/kg doses (free base equivalents formulated in 0.5% methylcellulose/0.2% Tween-80). The inhibition (%) of p-PRAS40/tPRAS40 is based on comparison to the vehicle control and stated in parentheses. Average drug levels ± SEM (μM) of <b>28</b> were determined by analysis of plasma from five animals. Two asterisks indicate <i>p</i> < 0.001, determined by Student’s <i>t</i> test to find differences in biomarker effects for dosing groups vs the vehicle control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Multiple doses of <b>28</b> were also administered daily (qd) or twice daily (bid) in nude mice bearing PC3 prostate cancer xenografts. Daily doses ranged from 25 to 100 mg/kg. Even the lowest dose resulted in statistically significant tumor growth inhibition (49%, <i>p</i> < 0.009) when administered qd for 11 days (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>); hence, the minimum efficacious dose was determined to be 25 mg/kg. The maximum tumor growth inhibition was obtained with qd dosing of <b>28</b> for 11 days at 100 mg/kg (79%, <i>p</i> < 0.0001). In addition, half-maximal doses of <b>28</b> (50 mg/kg) given orally bid resulted in a nearly equivalent tumor growth inhibition of 81% when compared with qd dosing of 100 mg/kg (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>, not statistically different). Thus, <b>28</b> is efficacious against human PC3 prostate cancer xenografts in vivo when dosed orally either qd or bid. Overall body weight loss, including the vehicle control group, was observed in all groups tested due to the cachexic nature of this model.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Doses of 0–100 mg/kg <b>28</b> qd caused less than 10% mean body weight loss, whereas doses of 150 mg/kg qd caused ≥20% loss of original body weight after eight doses, and the mice had to be euthanized before the completion of the study (data not shown).</div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of qd and bid oral dosing of <b>28</b> on PC3 prostate tumors (mean tumor volume in cubic millimeters ± SEM). Dose levels are expressed as free-base equivalents prepared in vehicle (0.5% methylcellulose/0.2% Tween-80).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23881" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23881" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have described the discovery of <b>28</b>, and related compounds, for the treatment of human tumors. The novel ATP-competitive, selective Akt inhibitors were optimized via structure-based design to target unique features of the Akt ATP binding cleft, resulting in exquisitely selective and potent inhibitors. In the specific case of <b>28</b>, this strategy led to good selectivity in a 230-enzyme kinase panel. Extensive in vitro profiling has shown that human cancer cell lines in which the PI3K/Akt pathway is upregulated are sensitive to inhibition by <b>28</b>; in spite of an increase in pAkt levels, downstream signaling in this pathway is inhibited by <b>28</b>, providing a mechanistic explanation of the antiproliferative and antisurvival effects. The in vitro effects are recapitulated in the in vivo models, wherein we see good oral exposures, a significant inhibition of Akt signaling following a single dose of <b>28</b>, and a robust inhibition of tumor growth following repeated qd or bid oral dosing in a mouse xenograft model of PI3K/Akt-driven cancer. Given all of these data, <b>28</b> is currently being investigated in human clinic trials for the treatment of cancers driven by aberrant PI3K/Akt signaling.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86171" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86171" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Enzymatic Assays</h3><div class="NLM_p last">The assay for the determination of Akt1/2/3 and PKA kinase activity employs the IMAP fluorescence polarization (FP) phosphorylation detection reagent (IMAP Screening Express Kit, catalog no. R8073, Molecular Devices, Sunnyvale, CA) to detect fluorescently labeled peptide substrates that have been phosphorylated by the respective kinases. The Akt enzymes employed in these studies consisted of recombinant baculovirus expressed, amino-terminal, polyhistidine-tagged, full-length, wild-type human forms (GenBank accession numbers <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=M63167">M63167</a>, <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=NP_001617">NP_001617</a>, and <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=NP_005456">NP_005456</a>) and were obtained from Millipore (Akt1, catalog no. 14 276, lot no. D8MN034U; Dundee, Scotland) or Invitrogen (Akt2, catalog no. PV3184, lot no. 28770P; Akt3, catalog no. PV3185, lot no. 28771K; Madison, WI). The PKA enzyme employed in these studies consisted of the recombinant untagged human isolated catalytic subunit of PKA (GenBank accession number <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=X07767">X07767</a>) expressed in <i>Escherichia coli</i> obtained from Invitrogen (catalog no. 14-440, lot no. 26698U). Inhibitor, enzyme (9 nM Akt1 or 100 pM PKA), and substrate (100 nM Crosstide, catalog no. R7110, Molecular Devices) were incubated with 5 μM ATP in assay buffer (10 mM Tris–HCl (pH 7.2), 10 mM MgCl<sub>2</sub>, 0.1% BSA (w/v), final DMSO 2% (v/v)) for 60 min at ambient temperature in a 5 μL reaction volume. Reactions were initiated by addition of enzyme + peptide substrate to ATP solutions. IMAP binding reagent (15 μL) was added to terminate the reaction, and the stopped reactions were incubated for a minimum of 30 min at room temperature (rt).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Cellular Assays</h3><div class="NLM_p">Phosphorylation of PRAS40 at Thr246 was measured in situ in LNCaP cells (American Type Culture Collection, catalog no. CRL-1740). The cells were plated in 96-well plates (Grenier, catalog no. 655946) at a density of 20 000 cells/well and incubated for 16–24 h at 37 °C and 5% CO<sub>2</sub>. The cells were treated with 0–25 μM inhibitor for 1.5 h at 37 °C. Medium above the cells was removed, and each well was supplemented with fixation solution (3.7% (v/v) formaldehyde in phosphate-buffered saline (PBS)) for 20 min at rt. The cells were permeabilized with a 10 min exposure to 100% methanol (−20 °C) and subsequently rehydrated in PBS and blocked in blocking buffer (catalog no. 927-40000, LI-COR Inc., Lincoln, NE) for 60 min at rt. A primary antibody solution consisting of an antibody specific for Thr246-phosphorylated PRAS40 (rabbit polyclonal antibody, 1:500 dilution, catalog no. AS1011, Calbiochem, San Diego, CA) and a signal-normalizing antibody against glyceraldehyde 3-phosphate dehydrogenase (GAPDH; mouse monoclonal, 1 μg/mL final concentration, catalog no. RDI-TRK5-6C5, Fitzgerald Industries Inc., Concord, MA) in blocking buffer was applied to each of the wells and incubated overnight at 4 °C. The wells were then washed with PBS containing 0.05% (v/v) Tween-20, treated with a secondary antibody solution containing fluorophore-conjugated antibodies specific for rabbit (Alexa680 fluorophore-conjugated goat antirabbit immunoglobulin G (IgG), catalog no. AS21109, Invitrogen) and mouse IgG (IRDye800 fluorophore-conjugated goat antimouse IgG, catalog no. 610-132-121, Rockland Inc., Gilbertsville, PA), and incubated for 1 h at rt. The wells were washed in PBS with 0.05% (v/v) Tween-20 and then imaged and quantified on an LI-COR Aerius imager (LI-COR Inc.). The phospho-PRAS40 signal was normalized to the GAPDH signal to control for well-to-well variation in cell number.</div><div class="NLM_p">Inhibition of cellular viability was measured in LNCaP cells (American Type Culture Collection, catalog no. CRL-1740) plated in black, clear-bottomed 96-well plates (Grenier, catalog no. 655946) at a density of 5000 cells/well and subsequently treated with 0–10 μM <b>28</b> for 72 h at 37 °C and 5% CO<sub>2</sub>. The extent of cell proliferation was determined by measuring the reduction of resazurin to resorufin as described in the manufacturer’s protocol (CellTiterBlue Cell Viability Determination Kit, catalog no. G8082, Promega, Madison, WI) using an excitation wavelength of 560 nm and an emission wavelength of 590 nm. Dose–response curves were generated using the four-parameter logistic model, and 50% inhibitory concentration (IC<sub>50</sub>) values were determined from these curve fits.</div><div class="NLM_p last">Inhibition of cellular proliferation was measured in PC3-NCI, MCF7-neo/HER2-neo/Her2, and BT474M1 cells plated in black, clear-bottomed 384-well plates (catalog no. 353962, Becton Dickinson, Franklin Lakes, NJ) at a density of 1500 cells/well and incubated overnight to 1.5 days at 37 °C and 5% CO<sub>2</sub>. Serial dilutions of inhibitor were added to the cells, which were then incubated for another 96 h. Cell viability was determined by measuring the cellular ATP levels as described in the manufacturer’s protocol (CellTiter-Glo Luminescent Cell Viability Assay Kit, catalog no. G7573, Promega, Madison, WI). Dose–response curves were generated using the four-parameter logistic model, and 50% inhibitory concentration (IC<sub>50</sub>) values were determined from these curve fits.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> In Vivo Efficacy and PK/PD</h3><div class="NLM_p">For in vivo tumor xenograft studies, female nu/nu (nude) mice were inoculated subcutaneously in the right hind flank with PC3 cells suspended in Hank’s balanced salt solution (HBSS). When tumors reached a mean volume of 150 mm<sup>3</sup>, the animals were size matched and distributed into treatment groups consisting of 10 animals/group. Tumor volume was calculated as follows: tumor size (mm<sup>3</sup>) = (longer measurement × (shorter measurement)<sup>2</sup>) × 0.5. Following data analysis, <i>p</i> values were determined using Dunnett’s <i>t</i> test with JMP statistical software, version 7.0 (SAS Institute). Mouse body weights were recorded twice weekly using an Adventura Pro AV812 scale (Ohaus Corp.). Mice were promptly euthanized when the tumor volume exceeded 2000 mm<sup>3</sup> or if body weight loss was ≥20% of the starting weight per IACUC protocol guidelines.</div><div class="NLM_p last">For PK/PD studies, blood and tumor samples were collected at 1, 3, 8, and 24 h after a single dose of <b>28</b> from PC3 tumor bearing mice. Blood samples (approximately 800 μL) were collected from each animal at the scheduled sample collection time by terminal cardiac puncture into tubes containing K<sub>2</sub>EDTA as an anticoagulant and centrifuged at 1500–2000<i>g</i> to isolate plasma. The concentration of <b>28</b> in each plasma sample was determined by a nonvalidated LC/MS/MS assay in the DMPK Bioanalytical Department at Genentech. The assay lower limit of quantitation (LLOQ) was 0.005 μM. Tumor samples were dissociated in Tris lysis buffer containing 150 mM NaCl, 20 mM Tris (pH 7.5), 1 mM EDTA, 1 mM EGTA, and 1% Triton X-100 (Meso Scale Discovery; Gaithersburg, MD). Protein concentrations were determined using the BCA Protein Assay Kit (Pierce, Rockford, IL). The Invitrogen (Camarillo, CA) human enzyme-linked immunosorbent assay (ELISA) kits were used to determine the levels of total PRAS40 and PRAS40 phosphorylated at Thr246 (p-PRAS40). The assay quantifies protein levels on the basis of measurements of absorbance. The colored product is directly proportional to the concentration of p-PRAS40 and tPRAS40 present in the specimen. The Meso Scale Discovery Multi-Spot Biomarker Detection System (Meso Scale Discovery) was used to determine the levels of total S6RP and S6RP phosphorylated at Ser235/236 (pS6RP). These assays quantify protein levels on the basis of measurements of electrochemiluminescence intensity. Levels of phosphorylated protein were normalized to total protein levels in <b>28</b>-treated tumors and compared to the vehicle control.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Chemistry</h3><div class="NLM_p">All reaction reagents and solvents (anhydrous grade) were purchased and used without further purification. <sup>1</sup>H NMR spectra were recorded on a Varian INOVA 400 instrument. Chemical shifts are reported in parts per million relative to an internal standard of TMS in CDCl<sub>3</sub> or DMSO-<i>d</i><sub>6</sub>. HPLC analysis was conducted according to methods A–E, with the retention time (<i>t</i><sub>R</sub>) expressed in minutes at UV detection of 254 nM. Chromatography was performed on a Varian Prostar with a YMC ODS-C18-AQ column (4.6 × 50 mm, 3 μm) at 40 °C with a flow rate of 2.0 mL/min. Mobile phase A was 10 mM NH<sub>4</sub>OAc in water with 1% isopropyl alcohol. Mobile phase B was 10 mM NH<sub>4</sub>OAc, 1% H<sub>2</sub>O, and isopropyl alcohol in acetonitrile. HPLC method A: The gradient was 5% B to 95% B in 5 min. HPLC method B: The gradient was 0% B to 95% B in 5 min. HPLC method C: Chromatography was performed on an Agilent HPLC instrument with a Zorbax SB C18 column (4.6 × 50 mm, 3 μm) with a flow rate of 2.0 mL/min. Mobile phase A was 0.1% TFA in water, and mobile phase B was 0.075% TFA in acetonitrile. The gradient was 5% B to 95% B in 9 min. HPLC method D: Chromatography was performed on an Agilent 6140 HPLC instrument with a Zorbax SB C18 column (2.1 × 30 mm, 1.8 μm) at 40 °C with a flow rate of 0.4 mL/min. Mobile phase A was 0.05% TFA in water, and mobile phase B was 0.05% TFA in acetonitrile. The gradient was 3% B to 95% B in 8.5 min. HPLC method E: Chromatography was performed on an Agilent 6140 HPLC instrument with a Zorbax SB C18 column (3.0 × 100 mm, 3.5 μm) at 40 °C with a flow rate of 0.7 mL/min. Mobile phase A was 0.05% TFA in water, and mobile phase B was 0.05% TFA in acetonitrile. The gradient was 2% B to 98% B in 25.5 min. Mass spectral analysis was conducted on a Thermo Separation Products (TSP) HPLC or Waters Micromass ZQ instrument.</div><div id="sec5_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> (2<i>R</i>)-Ethyl 2-Methyl-5-oxocyclopentanecarboxylate (<b>5a</b>)</h4><div class="NLM_p">To a 5 L round-bottom flask were added (<i>R</i>)-pulegone (600.0 g, 3.94 mol), anhydrous NaHCO<sub>3</sub> (165.0 g, 1.97 mol), and ether (2.0 L). The mixture was cooled to 0 °C using an ice bath, and bromine (206.0 mL, 4.02 mol) was added dropwise over 1 h. The reaction was allowed to stir for an additional 30 min after bromine addition was complete, and the mixture was filtered to give filtrate A. To a separate 12 L round-bottom reactor equipped with a mechanical stirrere and a thermocouple were charged 21% NaOEt (3.2 L, 8.7 mol) and EtOH (2.0 L). This reaction mixture was cooled to 0 °C, and filtrate A was added dropwise at a rate which maintained an internal temperature below 40 °C. <i>Caution: Addition is exothermic, and adequate cooling is required!</i> After complete addition of filtrate A, the reaction was allowed to warm to rt. The reaction was quenched by the addition of 1 N HCl (1.0 L) and water (1.5 L), followed by the addition of methyl <i>tert</i>-butyl ether (MTBE; 1.0 L). The organic layer was separated and the aqueous phase extracted with MTBE (3 × 1.5 L). The combined organic layers were concentrated to give a brown oil. To a second 12 L round-bottom reactor equipped with a mechanical stirrer were charged semicarbazide hydrochloride (300.0 g, 2.6 mol), NaOAc (300.0 g, 3.6 mol), and water (3.0 L). The crude oil from above was added slowly as a solution in ethanol (1.5 L). The mixture was then refluxed for 3 h and stirred at rt overnight. The mixture was treated with water (1.0 L) and MTBE (1.0 L). The organic layer was separated, and the aqueous phase was extracted with MTBE (3 × 1.5 L). The combined organic layer was washed with brine and concentrated to give a brown oil. The oil was distilled under vacuum to give (2<i>R</i>)-ethyl 2-methyl-5-propan-2-ylidenecyclopentanecarboxylate (497 g, 64% yield) collected at 73–76 °C at 0.5 mm as a clear oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 4.17–4.07 (m, 2H), 3.39 (d, <i>J</i> = 8.0 Hz, 0.5 H), 2.93 (d, <i>J</i> = 6.0 Hz, 0.5 H), 2.48–2.15 (m, 3 H), 2.03–1.98 (m, 1H), 1.79–1.72 (m, 1H), 1.65–1.59 (m, 6H), 1.25 (t, <i>J</i> = 8.0 Hz, 3H), 1.03 (dd, <i>J</i> = 12.0, 6.8 Hz, 3H).</div><div class="NLM_p last">A solution of (2<i>R</i>)-ethyl 2-methyl-5-propan-2-ylidenecyclopentanecarboxylate (220.0 g, 1.1 mmol) in EtOAc (1.0 L) was cooled to −78 °C using a dry ice/2-propanol bath. Ozone was bubbled into the reaction mixture until it turned purple in color. At this point ozone generation was stopped, and the reaction mixture was removed from the dry ice bath. Nitrogen was bubbled through the reaction solution until it turned yellow. The reaction was concentrated and the resulting residue dissolved in glacial acetic acid (200 mL). The solution was cooled to 0 °C, and zinc dust (113.0 g, 1.7 mol) was added in small portions over a 30 min period. The reaction was allowed to stir for 1.5 h, at which point the reaction mixture was filtered through Celite. The resulting solution was concentrated in vacuo to remove acetic acid, and the residue was diluted with MTBE (500 mL). The mixture was neutralized to pH 7.0 by careful addition of aqueous 6 N NaOH. The organic layer was separated, and the aqueous layer was extracted with MTBE (2 × 250 mL). The combined organics were washed with brine, dried with solid MgSO<sub>4</sub>, and concentrated by rotary evaporation to give a dark brown liquid. This liquid was passed through a plug of silica gel eluting with a small amount of MTBE. The combined filtrate was again concentrated by rotary evaporation to give the desired (2<i>R</i>)-ethyl 2-methyl-5-oxocyclopentanecarboxylate (180.1 g, 94% yield) as a light brown liquid which was used without any further purification: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 4.21 (q, <i>J</i> = 6.4 Hz, 2H), 2.75 (d, <i>J</i> = 11.2 Hz, 1H), 2.64–2.56 (m, 1H), 2.46–2.30 (m, 2H), 2.24–2.16 (m, 1H), 1.53–1.42 (m, 1H), 1.29 (t, <i>J</i> = 6.4 Hz, 3H), 1.19 (d, <i>J</i> = 6.4 Hz, 3H).</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> General Procedure for Formation of the Cyclopenta[<i>d</i>]pyrimidine Core: (<i>R</i>)-5-Methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-ol (<b>6a</b>)</h4><div class="NLM_p">To a solution of <b>5a</b> (150.1 g, 881 mmol) in MeOH (2.0 L) was added NH<sub>4</sub>OAc (268.2 g, 3.5 mol). The reaction mixture was stirred overnight and concentrated under reduced pressure. The resulting residue was dissolved in dichloromethane (DCM; 1.0 L) and partitioned with water (2.0 L). The organic layer was separated, and the aqueous layer was extracted with DCM (3 × 750 mL). The combined organics were washed with brine, dried over solid MgSO<sub>4</sub>, and concentrated in vacuo to give the desired (<i>R</i>)-ethyl 2-amino-5-methylcyclopent-1-enecarboxylate (136.2 g, 91% yield) as a brown oil. This material was used without further purification: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 5.5 (br s, 2H), 4.22–4.10 (m, 2H), 2.98–2.94 (m, 1H), 2.64–2.55 (m, 1H), 2.37–2.29 (m, 1H), 2.09–1.99 (m, 1H), 1.45–1.38 (m, 1H), 1.28 (t, <i>J</i> = 6.4 Hz, 3H), 1.96 (d, <i>J</i> = 6.4 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 170.1 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a 2 L three-necked magnetically stirred round-bottom reactor equipped with a condenser and thermocouple were added (<i>R</i>)-ethyl 2-amino-5-methylcyclopent-1-enecarboxylate (308.0 g, 1.8 mol), ammonium formate (172.0 g, 2.7 mol), and formamide (504 mL, 12.7 mol). The mixture was heated to an internal temperature of 150 °C for 24 h. <i>Note: Sublimed ammonium formate could build up in the condenser. Addition of 25 mL of a lower boiling solvent such as o-xylene helps keep the condenser clear</i>. The reaction mixture was cooled and transferred to 2 L single-neck flask, and the excess formamide was removed by distillation under vacuum. Once removal of the formamide was complete, the flask was cooled, and the resulting oil was dissolved in DCM (2.0 L) and washed with brine (3 × 200 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated by rotary evaporation. The resulting brown oil was dissolved in a small amount of DCM and slowly added to a stirring solution of ether (ca. 5× volume of ether vs DCM), resulting in a brown slurry. The slurry was filtered, and the resulting wet cake was rinsed with ether. The brown filtrate was concentrated by rotary evaporation and dried under high vacuum to give crude (<i>R</i>)-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-ol (180.1 g, 66% yield). This material was used without further purification: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 12.8 (br s, 1H), 8.07 (s, 1H), 3.35–3.29 (m, 1H), 2.98–2.91 (m, 1H), 2.85–2.78 (m, 1H), 2.36–2.26 (m, 1H), 1.71–1.64 (m, 1H), 1.31 (d, <i>J</i> = 6.4 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 151.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> General Procedure for the Incorporation of Boc-Protected Piperazine</h4><div id="sec5_4_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21"> (<i>R</i>)-<i>tert</i>-Butyl 4-(5-Methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (<b>7a</b>)</h5><div class="NLM_p">To a solution of (<i>R</i>)-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-ol (150.1 g, 998 mmol) in 1,2-dichloroethane (DCE; 500 mL) was added POCl<sub>3</sub> (233 mL, 2.5 mol) dropwise. The reaction mixture was heated to reflux for 6 h and concentrated by rotary evaporation. The crude oil was diluted with a small amount of DCM to give a suspension, which was added to a stirring solution of 6 M aqueous NaHCO<sub>3</sub> (more NaHCO<sub>3</sub> was added as needed to keep the solution basic). The organic layer was separated, and the aqueous layer was extracted with DCM (2 × 250 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The crude brown oil was purified by passing through a silica plug eluting with hexanes–EtOAc (4:1) to give the desired (<i>R</i>)-4-chloro-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidine (81.2 g, 48% yield) as a brown liquid: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.77 (s, 1H), 3.46–3.41 (m, 1H), 3.20–3.11 (m, 1H), 2.98 (ddd, <i>J</i> = 10.2, 6.4, 6.4, 1H), 2.42–2.32 (m, 1H), 1.86–1.78 (m, 1H), 1.34 (d, <i>J</i> = 6.4 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 169.3 (M + H)<sup>+</sup>.</div><div class="NLM_p last">A solution of (<i>R</i>)-4-chloro-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidine (73.3 g, 434.7 mmol), <i>tert</i>-butyl piperazine-1-carboxylate (85.0 g, 456.4 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (DIEA; 227.0 mL, 1.30 mol) in 1-BuOH (720 mL) was heated to refluxing under a nitrogen atmosphere for 16 h. The reaction mixture was concentrated by rotary evaporation, and the crude residue was purified by silica gel chromatography eluting with hexanes–EtOAc (2:1) to EtOAc to give a brown solid. The solid was recrystallized from heptane to give the desired pure (<i>R</i>)-<i>tert</i>-butyl 4-(5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (112.6 g, 81% yield) as an off-white solid: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.47 (s, 1H), 3.72–3.68 (m, 2H), 3.57–3.44 (m, 7H), 2.96–2.84 (m, 2H), 2.32–2.26 (m, 1H), 1.72–1.67 (m, 1H), 1.48 (s, 9H), 1.79 (d, <i>J</i> = 7.2 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 319.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_4_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22"> <i>tert</i>-Butyl 4-((5<i>R</i>)-7-Acetoxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (<b>9</b>)</h5><div class="NLM_p">To a 3 L three-necked round-bottom reactor equipped with a mechanical stirrer, nitrogen inlet, and thermocouple at 0 °C containing a mixture of <b>7a</b> (50.1 g, 157.0 mmol), solid NaHCO<sub>3</sub> (46.2 g, 550.4 mmol), and CHCl<sub>3</sub> (700 mL) was added <i>m</i>-chloroperoxybenzoic acid (<i>m</i>-CPBA; 45.0 g, 197.2 mmol, 75% by weight) in small portions. After the addition was complete, the reaction mixture was stirred at 0 °C for 10 min and then warmed to rt for 4.5 h. The reaction mixture was cooled to 0 °C, and a solution of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (49.7 g, 314 mmol) in water (70 mL) was added slowly. After complete addition, the reaction mixture was stirred at 0 °C for 10 min. The pH of the mixture was adjusted by the dropwise addition of Na<sub>2</sub>CO<sub>3</sub> (66.6 g, 628.0 mmol) as a solution in water (100 mL). The reaction mixture was stirred for 20 min and then warmed to rt for 10 min. The mixture was diluted with water (200 mL) and partitioned with CHCl<sub>3</sub> (200 mL). The organic layer was separated, and the aqueous layer was extracted with CHCl<sub>3</sub> (2 × 400 mL). The combined organics were washed with saturated Na<sub>2</sub>CO<sub>3</sub> (500 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through Celite, and concentrated in vacuo to give the crude (<i>R</i>)-4-(4-(<i>tert</i>-butoxycarbonyl)piperazin-1-yl)-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidine 1-oxide (52.5 g, 100% yield), which was used without purification in the next step: LC/MS APCI (+) <i>m</i>/<i>z</i> 335.1 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a round-bottom reactor containing the (<i>R</i>)-4-(4-(<i>tert</i>-butoxycarbonyl)piperazin-1-yl)-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidine 1-oxide (42.0 g, 126.0 mmol) was slowly added acetic anhydride (178 mL, 1.8 mol) (<i>note: mild exotherm</i>). After complete addition, the reaction mixture was heated to 100 °C and stirred under a nitrogen atmosphere for 2 h. The reaction mixture was cooled to rt and concentrated by rotary evaporation to remove excess acetic anhydride. The resulting residue was dissolved in DCM (1.0 L), and the solution was poured into ice and aqueous saturated Na<sub>2</sub>CO<sub>3</sub> (500 mL). The organic layer was separated, and the aqueous layer was extracted with DCM (2 × 200 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The crude material was passed through a plug of silica gel eluting with hexanes–EtOAc (1:1) to give the desired <i>tert</i>-butyl 4-((5<i>R</i>)-7-acetoxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (42.0 g, 89% yield) as a brown foam after rotary evaporation: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.60 (S, 1H), 6.04 (t, <i>J</i> = 7.2 Hz, 1H), 3.80–3.76 (m, 2H), 3.74–3.46 (m, 7H), 2.31–2.23 (m, 2H), 2.14 (s, 3H), 1.49 (s, 9H), 1.21 (d, <i>J</i> = 7.2 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 333.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_4_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> (<i>R</i>)-<i>tert</i>-Butyl 4-(5-Methyl-7-oxo-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (<b>10</b>)</h5><div class="NLM_p">To a solution of the <i>tert</i>-butyl 4-((5<i>R</i>)-7-acetoxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (16.5 g, 43.8 mmol) in THF (200 mL) was added 3 M LiOH (40 mL, 120 mmol). The reaction mixture was stirred at rt for 16 h and then neutralized with the addition of 2 N HCl (60 mL). The mixture was concentrated by rotary evaporation, and the residue was purified by silica gel chromatography eluting with DCM–MeOH (10:1) to give the desired <i>tert</i>-butyl 4-((5<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (14.5 g, 99% yield) as a clear oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.47 (s, 1H), 3.72–3.68 (m, 2H), 3.57–3.43 (m, 7H), 2.96–2.81 (m, 2H), 2.32–2.26 (m, 1H), 1.73–1.65 (m, 1H), 1.48 (s, 9H), 1.17 (d, <i>J</i> = 7.2 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 335.2 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a 1 L three-necked round-bottom reactor containing a solution of oxalyl chloride (21.2 mL, 243.4 mmol) in DCM (150 mL) at −78 °C was added a solution of dimethyl sulfoxide (DMSO; 34.5 mL, 486.7 mmol) in DCM (50 mL) dropwise. The reaction mixture was stirred for 30 min before a solution of the (<i>R</i>)-<i>tert</i>-butyl 4-(7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (58.1 g, 173.8 mmol) in DCM (80 mL) was added slowly. After complete addition, the reaction mixture was stirred for 1 h at −78 °C before triethylamine (TEA; 114 mL, 817.0 mmol) was added slowly. The reaction mixture was then allowed to warm to rt and stirred for 30 min before being quenched with water (200 mL). The organic layer was separated, and the aqueous layer was extracted with DCM (3 × 200 mL). The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with DCM–EtOAc (2:1 to 1:3) to give the desired (<i>R</i>)-<i>tert</i>-butyl 4-(5-methyl-7-oxo-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (41.0 g, 71% yield) as a brown foam: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.47 (s, 1H), 3.72–3.68 (m, 2H), 3.57–3.43 (m, 7H), 2.96–2.81 (m, 2H), 2.32–2.26 (m, 1H), 1.73–1.65 (m, 1H), 1.48 (s, 9H), 1.17 (d, <i>J</i> = 7.2 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 233.1 [M – C<sub>5</sub>H<sub>9</sub>O<sub>2</sub> + H].</div></div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> General Procedure for Asymmetric Hydrogenation</h4><div id="sec5_4_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> <i>tert</i>-Butyl 4-((5<i>R</i>,7<i>R</i>)-7-Hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (<b>12a</b>)</h5><div class="NLM_p">A round-bottom flask was charged with <b>10</b> (17.1 g, 51.4 mmol), DCM (400 mL), formic acid (2.4 mL, 63.3 mmol), and TEA (7.6 mL, 54.5 mmol) and flushed with nitrogen for 15 min. To this solution was added RuCl(<i>p</i>-cymene)[(<i>R</i>,<i>R</i>)-TsDPEN] (0.163 g, 0.257 mmol) in one portion, and the reaction mixture was stirred under a nitrogen atmosphere overnight. The reaction mixture was concentrated by rotary evaporation and purified directly by silica gel chromatography eluting with DCM–EtOAc (1:4) to DCM–MeOH (9:1) to give crude <i>tert</i>-butyl 4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (15.2 g, 88.2) as a tan foam. The material was dissolved in DCM (300 mL), cooled to 0 °C under nitrogen, and treated with TEA (18.9 mL, 136.2 mmol) and 4-nitrobenzoyl chloride (12.6 g, 68.1 mmol), respectively. The reaction was stirred, warming to rt for 3 h. The reaction was quenched with saturated aqueous NaHCO<sub>3</sub> and stirred for 5 min before separation of the organic layer. The aqueous layer was extracted with DCM (2 × 200 mL), and the combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The crude material was purified by silica gel chromatography eluting with hexanes–EtOAc (5:1) to EtOAc to provide the desired <i>tert</i>-butyl 4-((5<i>R</i>,7<i>R</i>)-5-methyl-7-((4-nitrobenzoyl)oxy)-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (19.2 g, 87% yield) as a tan foam: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.60 (s, 1H), 8.28–8.22 (ABq, 4H), 6.35 (t, <i>J</i> = 7.2 Hz, 1H), 3.83–3.78 (m, 2H), 3.78–3.49 (m, 7H), 2.40–2.36 (m, 2H), 1.49 (s, 9H), 1.27 (d, <i>J</i> = 7.2 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 484.1 (M + H)<sup>+</sup>.</div><div class="NLM_p last"><i>tert</i>-Butyl 4-((5<i>R</i>,7<i>R</i>)-5-methyl-7-((4-nitrobenzoyl)oxy)-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (19.2 g, 39.7 mmol) was dissolved in THF (150 mL) and water (75 mL). The reaction was cooled to 0 °C and treated with solid LiOH–H<sub>2</sub>O (4.2 g, 99.3 mmol). The mixture was stirred for 1 h and concentrated by rotary evaporation. The residue was partitioned between EtOAc (300 mL) and saturated aqueous NaHCO<sub>3</sub> (300 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (2 × 150 mL). The combined organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through Celite, and concentrated in vacuo to provide the desired <i>tert</i>-butyl 4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (11.5 g, 87% yield) as a tan powder: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.57 (s, 1H), 5.12 (t, <i>J</i> = 7.2 Hz, 1H), 4.04 (br s, 1H), 3.81–3.75 (m, 2H), 3.67–3.46 (m, 7H), 2.21–2.16 (m, 2H), 1.48 (s, 9H), 1.20 (d, <i>J</i> = 7.2 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 335.2 (M + H)<sup>+</sup>.</div></div><div id="sec5_4_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> <i>tert</i>-Butyl 4-((5<i>R</i>,7<i>S</i>)-7-Hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (<b>13a</b>)</h5><div class="NLM_p last">Compound <b>13a</b> was prepared from <b>10</b> by the same procedure as for compound <b>12a</b>, using RuCl(<i>p</i>-cymene)[(<i>S</i>,<i>S</i>)-TsDPEN]: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.56 (s, 1H), 5.04–5.00 (dd, 1H), 3.72–3.67 (m, 2H), 3.63–3.43 (m, 6H), 3.33–3.23 (m, 1H), 2.72 (dt, <i>J</i><sub>d</sub> = 13.5 Hz, <i>J</i><sub>t</sub> = 8.0 Hz, 1H), 1.66–1.58 (dt, 1H), 1.48 (s, 9H), 1.29 (d, <i>J</i> = 6.8 Hz, 3H); LC/MS (APCI) <i>m</i>/<i>z</i> 335.2 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> General Procedure for Preparation of Fluorinated Cores: <i>tert</i>-Butyl 4-((5<i>R</i>,7<i>S</i>)-7-Fluoro-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (<b>14a</b>)</h4><div class="NLM_p last">To a solution of <b>12a</b> (1.2 g, 3.6 mmol) in DCM (55 mL) at −20 °C was added DAST (1.4 mL, 10.7 mmol). After being stirred for 1 h at −20 °C, the reaction was quenched with ice and warmed to rt. The mixture was diluted with saturated aqueous NH<sub>4</sub>Cl, and the layers were separated. The aqueous phase was extracted with DCM (2 × 25 mL), and the combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography eluting with hexanes–EtOAc (2:1) to give the desired <i>tert</i>-butyl 4-((5<i>R</i>,7<i>S</i>)-7-fluoro-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazine-1-carboxylate (0.73 g, 61% yield) as a dark oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.62 (s, 1H), 5.80 (ddd, <i>J</i> = 560, 7.2, 3.2 Hz, 1H), 3.78–3.72 (m, 2H), 3.62–3.46 (m, 7H), 2.59–2.46 (m, 1H), 2.08–1.98 (m, 1H), 1.48 (s, 9H), 1.20 (d, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec5_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> General Procedure for Removal of the Boc Group on Piperazine</h4><div id="sec5_4_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> (5<i>R</i>,7<i>R</i>)-5-Methyl-4-(piperazin-1-yl)-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-7-ol Dihydrochloride (<b>12b</b>)</h5><div class="NLM_p last">To a solution of <b>12a</b> (11.5 g, 34.4 mmol) in dioxane (100 mL) and DCM (10 mL) was added 4 N HCl in dioxane (117 mL, 471 mmol) by addition funnel at 0 °C. The reaction mixture was warmed to rt and stirred under a nitrogen atmosphere overnight before concentration to dryness by rotary evaporation. The resulting solid was dissolved in a small amount of MeOH (60 mL) and added slowly to a stirring solution of ether (500 mL), resulting in a slurry. The slurry was stirred for 5 min before filtration under a nitrogen atmosphere (hygroscopic). The wet cake was dried under high vacuum to give the desired (5<i>R</i>,7<i>R</i>)-5-methyl-4-(piperazin-1-yl)-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-7-ol dihydrochloride (9.3 g, 89% yield) as a white solid: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.51 (s, 1H), 5.32 (t, <i>J</i> = 7.2 Hz, 1H), 4.27–4.23 (m, 2H), 4.09–4.06 (m, 2H), 3.58 (ddd, <i>J</i> = 7.2 Hz, 7.2 Hz, 7.2 Hz, 1H), 3.35–3.32 (m, 4H), 2.27–2.22 (m, 1H), 2.11–2.06 (m, 1H), 1.07 (d, <i>J</i> = 7.2 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 235.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_4_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> (<i>R</i>)<i>-</i>4-Benzyl-3-(2-(4-chlorophenyl)acetyl)oxazolidin-2-one (<b>17</b>)</h5><div class="NLM_p last">To a stirred solution of (<i>R</i>)-4-benzyloxazolidin-2-one (<b>16</b>) (48.7 g, 275.0 mmol) in THF (700 mL) at −78 °C was added 2.5 M <i>n</i>-BuLi in toluene (107 mL, 267.5 mmol) dropwise by syringe. After complete addition, the reaction was warmed to −20 °C for 1 h. The reaction mixture was cooled again to −78 °C, and 2-(4-chlorophenyl)acetyl chloride (47.2 g, 250 mmol) in THF (50 mL) was added slowly. After complete addition, the mixture was warmed to rt overnight. The reaction was quenched with 1 N HCl, and the partitioned organic layer was separated. The aqueous layer was extracted with EtOAc (2 × 250 mL), and the combined organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The crude material was purified by column chromatography eluting with hexanes–EtOAc (4:1) to give the desired (<i>R</i>)-4-benzyl-3-(2-(4-chlorophenyl)acetyl)oxazolidin-2-one (64.7 g, 79% yield) as a white solid: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.33–7.26 (m, 7H), 7.13 (d, <i>J</i> = 6.4 Hz, 2H), 4.69–4.66 (m,1H), 4.33–4.16 (m, 4H), 3.60 (dd, <i>J</i> = 10.2, 3.2 Hz), 1H), 2.76 (dd, <i>J</i> = 10.2, 9.6 Hz, 1H).</div></div></div><div id="sec5_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> General Procedure for the Asymmetric Mannich Reaction</h4><div id="sec5_4_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> <i>tert</i>-Butyl (<i>S</i>)-(3-((<i>R</i>)-4-Benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl)isopropylcarbamate (<b>19a</b>)</h5><div class="NLM_p last">To a −78 °C solution of (<i>R</i>)-4-benzyl-3-(2-(4-chlorophenyl)acetyl)oxazolidin-2-one (10.0 g, 30.3 mmol) in DCM (300 mL) was added 1 M TiCl<sub>4</sub> in toluene (31.8 mL, 31.8 mmol), resulting in an orange solution. Subsequent addition of DIEA (5.8 mL, 33.4 mmol) by syringe gave a dark purple reaction mixture. The reaction was stirred for 15 min before a solution of <i>tert</i>-butyl isopropyl(methoxymethyl)carbamate (8.0 g, 39.4 mmol) in DCM (20 mL) was added slowly by syringe. The reaction mixture was stirred for 15 min at −78 °C and then warmed to rt. The reaction was allowed to stir for 1.5 h before being quenched with saturated aqueous NH<sub>4</sub>Cl (50 mL). The organic layer was separated, and the aqueous layer was extracted with DCM (2 × 50 mL). The combined organics were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The crude material was purified by column chromatography eluting with hexanes–EtOAc (5:1) to give the desired <i>tert</i>-butyl (<i>S</i>)-(3-((<i>R</i>)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl)isopropylcarbamate (10.9 g, 72% yield) as a white foam: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.35–7.22 (m, 9H), 5.54 (br s, 1H), 4.62–4.58 (m, 1H), 4.13–3.95 (m, 4H), 3.41–3.36 (m, 2H), 2.76 (br s, 1H), 1.48 (s, 9H), 1.08 (d, <i>J</i> = 6.4 Hz, 3H), 0.90 (d, <i>J</i> = 6.4 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 359.0 [M – C<sub>5</sub>H<sub>9</sub>O<sub>2</sub> + H].</div></div><div id="sec5_4_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> (<i>S</i>)-3-((<i>tert</i>-Butoxycarbonyl)isopropylamino)-2-(4-chlorophenyl)propanoic Acid (<b>20a</b>)</h5><div class="NLM_p last">To a 0 °C solution of LiOH–H<sub>2</sub>O (3.1 g, 131.7 mmol) in THF (750 mL) and H<sub>2</sub>O (250 mL) was added 35 wt % aqueous hydrogen peroxide (19.2 mL, 197.6 mmol). This solution was stirred for 10 min before a solution of <i>tert</i>-butyl (<i>S</i>)-(3-((<i>R</i>)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl)isopropylcarbamate (33.0 g, 65.8 mmol) in THF (50 mL) was added. The reaction was warmed to rt overnight. The reaction was quenched by the addition of 10 wt % aqueous Na<sub>2</sub>SO<sub>3</sub> (10 mL) and saturated aqueous NaHCO<sub>3</sub> (10 mL). After being stirred for 10 min, the reaction was concentrated by rotary evaporation to remove THF before extraction of the remaining aqueous layer with ether (3 × 150 mL). The aqueous layer was partitioned with EtOAc (150 mL) and acidified to pH 1 with 1 N HCl. The organic layer was separated, and the aqueous layer was extracted with EtOAc (2 × 150 mL). The combined organic was dried over MgSO<sub>4</sub> and concentrated in vacuo to give the desired (<i>S</i>)-3-((<i>tert</i>-butoxycarbonyl)isopropylamino)-2-(4-chlorophenyl)propanoic acid (17.4 g, 77% yield), which was used without further purification: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.34 (ABq, 4H), 4.16–4.09 (m, 1H), 4.07 (br s, 1H), 3.75 (dd, <i>J</i> = 14.0, 7.2 Hz), 1H), 3.30 (dd, <i>J</i> = 14.0, 7.2 Hz, 1H), 1.45 (s, 9H), 1.04 (d, <i>J</i> = 6.8 Hz, 3H), 0.89 (d, <i>J</i> = 6.8 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 242.1 [M – C<sub>5</sub>H<sub>9</sub>O<sub>2</sub> + H].</div></div><div id="sec5_4_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> <i>tert</i>-Butyl (<i>S</i>)-(3-((<i>R</i>)-4-Benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl)(2,4-dimethoxybenzyl)carbamate (<b>19f</b>)</h5><div class="NLM_p last">To a −78 °C solution of (<i>R</i>)-4-benzyl-3-(2-(4-chlorophenyl)acetyl)oxazolidin-2-one (6.00 g, 18.2 mmol) in DCM (180 mL) was added 1 M TiCl<sub>4</sub> in toluene (22.7 mL, 22.7 mmol), followed by diisopropylethylamine (3.30 mL, 19.1 mmol), giving rise to a dark purple mixture. The reaction mixture was stirred for 20 min before a solution of <i>tert</i>-butyl (2,4-dimethoxybenzyl)(methoxymethyl)carbamate (6.80 g, 21.8 mmol) in DCM (30 mL) was added dropwise. After complete addition, the reaction mixture was stirred for 10 min at −78 °C and then warmed to −10 °C over 3 h. The reaction mixture was quenched with the addition of saturated NH<sub>4</sub>Cl solution (50 mL). The resulting mixture was separated, and the aqueous layer was extracted with DCM (3 × 100 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography eluting with hexanes–EtOAc (6:1 to 4:1) to provide the pure <i>tert</i>-butyl (<i>S</i>)-(3-((<i>R</i>)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl)(2,4-dimethoxybenzyl)carbamate (7.30 g, 66% yield) as a white foam: HPLC (method A) purity 95%; LC/MS APCI (+) <i>m</i>/<i>z</i> 509 (M – Boc + H).</div></div><div id="sec5_4_7_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> <i>tert</i>-Butyl (<i>S</i>)-(3-((<i>R</i>)-4-Benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl)carbamate (<b>19h</b>)</h5><div class="NLM_p last">To a solution of <b>19f</b> (5.30 g, 8.70 mmol) in DCM (80 mL) and H<sub>2</sub>O (5 mL) was added 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ; 2.57 g, 11.3 mmol). The reaction mixture was stirred vigorously at rt for 19 h. The mixture was quenched with saturated NaHCO<sub>3</sub> (10 mL), and the organic layer was washed with saturated NaHCO<sub>3</sub> (2 × 10 mL). The combined aqueous layer was extracted with DCM (2 × 50 mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude was purified by silica gel chromatography eluting with hexanes–EtOAc (9:1 to 5:1) to give the desired <i>tert</i>-butyl (<i>S</i>)-(3-((<i>R</i>)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl)carbamate (4.0 g, 100% yield) as a yellow oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 10.3 (s, 1H), 7.81 (d, <i>J</i> = 8.6 Hz, 1H), 7.38–7.19 (m, 6H), 6.58–6.53 (m, 1H), 6.47–6.43 (m, 1H), 5.19–5.11 (m, 1H), 4.84–4.77 (m, 1H), 4.67–4.58 (m, 1H), 4.11–4.03 (m, 1H), 3.76–3.65 (m, 1H), 3.58–3.47 (m, 1H), 3.36–3.26 (m, 1H), 2.90–2.78 (m, 1H), 1.43 (s, 9H); LC/MS APCI (+) <i>m</i>/<i>z</i> 359 (M – Boc + H).</div></div><div id="sec5_4_7_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> (<i>S</i>)-3-((<i>tert</i>-Butoxycarbonyl)amino)-2-(4-chlorophenyl)propanoic Acid (<b>20h</b>)</h5><div class="NLM_p">To a solution of LiOH–H<sub>2</sub>O (0.73 g, 17 mmol) in THF–H<sub>2</sub>O (2:1, 83 mL) was added 35 wt % aqueous H<sub>2</sub>O<sub>2</sub> (1.8 mL, 22 mmol). The reaction mixture was stirred for 30 min at rt before being cooled to 0 °C. A solution of <b>19h</b> (4.0 g, 8.7 mmol) in THF (40 mL) was added dropwise over a 25 min period, and the reaction mixture was warmed to rt for 12 h. The reaction mixture was cooled to 0 °C again and treated with 1 M Na<sub>2</sub>SO<sub>3</sub> (35 mL). The mixture was stirred for 15 min before concentration in vacuo. The mixture was diluted with water (40 mL) and washed twice with ether (2 × 25 mL). The aqueous layer was acidified with solid KHSO<sub>4</sub> and extracted with DCM (2 × 25 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give the desired (<i>S</i>)-3-(<i>ter</i>t-butoxycarbonyl)-2-(4-chlorophenyl)propanoic acid (2.8 g, 100% yield) as a crude pale yellow foam. This material was used without further purification: HPLC purity 80%; LC/MS APCI (+) <i>m</i>/<i>z</i> 200 (M – Boc + H).</div><div class="NLM_p">To a solution of (<i>S</i>)-3-(<i>tert</i>-butoxycarbonyl)-2-(4-chlorophenyl)propanoic acid (2.8 g, 9.4 mmol) in dioxane–DCM (2:1, 90 mL) was added slowly 4 N HCl in dioxane (70.8 mL, 283.1 mmol). The reaction mixture was stirred at rt for 17 h before concentration to dryness. The residue was dissolved in DCM (15 mL) and MeOH (5 mL). The resulting solution was added dropwise to a solution of vigorously stirring ether (300 mL), resulting in a slurry. The slurry was filtered under a nitrogen atmosphere, rinsed with ether (200 mL), and dried in vacuo to give (<i>S</i>)-3-amino-2-(4-chlorophenyl)propanoic acid hydrochloride (1.7 g, 79% yield) as a white solid: <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 7.42 (d, <i>J</i> = 8.6 Hz, 2H), 7.33 (d, <i>J</i> = 8.6 Hz, 2H), 3.97 (dd, 1H), 3.57–3.54 (m, 1H), 3.24–3.17 (m, 1H); HPLC (method A) purity 97%; LC/MS APCI (+) <i>m</i>/<i>z</i> 200 (M + H).</div><div class="NLM_p last">To a thin slurry of (<i>S</i>)-3-amino-2-(4-chlorophenyl)propanoic acid hydrochloride (1.7 g, 7.4 mmol) and tetramethylammonium hydroxide pentahydrate (3.4 g, 18.5 mmol) in 10:1 MeCN–H<sub>2</sub>O (80 mL) was added Boc<sub>2</sub>O (3.2 g, 14.8 mmol). The reaction mixture was stirred at rt for 8 h and concentrated by rotary evaporation. The mixture was diluted with 0.5 M NaOH (10 mL) and washed with ether (2 × 25 mL). The aqueous layer was acidified with solid KHSO<sub>4</sub> and extracted with DCM (2 × 50 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The resulting residue was concentrated from DCM–hexanes mixtures twice to give the desired (<i>S</i>)-3-((<i>tert</i>-butoxycarbonyl)amino)-2-(4-chlorophenyl)propanoic acid (2.07 g, 93% yield) as a white foam: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz, rotamers present) δ 7.32 (d, <i>J</i> = 8.4 Hz, 2H), 7.22 (d, <i>J</i> = 8.4 Hz, 2H), 3.96–3.85 (m, 0.2H), 3.82–3.73 (m, 0.8 H), 3.67–3.54 (m, 0.4H), 3.54–3.38 (m, 1.6H), 1.48 (s, 5.8H), 1.42 (s, 3.2H); HPLC (method B) purity 97%, >99% ee by chiral HPLC; LC/MS APCI (+) <i>m</i>/<i>z</i> 200 (M – Boc + H).</div></div></div><div id="sec5_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> General Procedure for Amide Coupling: <i>tert</i>-Butyl (<i>S</i>)-(2-(4-Chlorophenyl)-3-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropyl)isopropylcarbamate (<b>24a</b>)</h4><div class="NLM_p last">To a solution of <b>12b</b> (2.0 g, 6.5 mmol), <b>20a</b> (2.2 g, 6.5 mmol), and DIEA (3.6 mL, 20.8 mmol) in DCM (55 mL) at 0 °C was added <i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyl-<i>O</i>-(1<i>H</i>-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU; 2.4 g, 6.5 mmol). The reaction mixture was warmed to rt over a 4 h period. The reaction was quenched by the addition of 2 M Na<sub>2</sub>CO<sub>3</sub> (5 mL), and the organic layer was separated. The aqueous layer was extracted with DCM (2 × 25 mL), and the combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude material was purified by silica gel chromatography eluting with DCM–EtOAc (1:1 to 1:9) and then DCM–MeOH (30:1). The crude product was dissolved in DCM (10 mL) and hexanes (100 mL). The resulting slurry was cooled to 0 °C and filtered to give the desired <i>tert</i>-butyl (<i>S</i>)-(2-(4-chlorophenyl)-3-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-oxopropyl)isopropylcarbamate (3.2 g, 87% yield) as a white powder: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.49 (s, 1H), 7.34 (d, <i>J</i> = 8.4 Hz, 2H), 7.29 (d, <i>J</i> = 8.4 Hz, 2H), 5.09 (t, <i>J</i> = 7.2 Hz, 1H), 3.78–3.31 (m, 15H), 2.18–2.14 (m, 2H), 1.47 (s, 9H), 1.13 (d, <i>J</i> = 7.2 Hz, 3H), 0.97–0.95 (m, 3H), 0.68–0.67 (m, 2H); LC/MS APCI (+) <i>m</i>/<i>z</i> 458.2 [M – C<sub>5</sub>H<sub>9</sub>O<sub>2</sub> + H].</div></div><div id="sec5_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> General Procedure for Boc Deprotection</h4><div id="sec5_4_9_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one Dihydrochloride Salt (<b>28</b>)</h5><div class="NLM_p last">To a solution of <b>24a</b> (2.5 g, 4.5 mmol) in dioxane (25 mL) was added 4 M HCl in dioxane (22.4 mL, 89.6 mmol). The resulting solution was stirred overnight at rt before concentration by rotary evaporation to a gel. This gel was dissolved in a small amount of MeOH (10 mL) followed by addition to ether (300 mL) to give a white slurry. The resulting slurry was filtered under a nitrogen atmosphere and subsequently dried under a nitrogen flow to give the desired (<i>S</i>)-2-(4-chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one dihydrochloride salt (2.1 g, 90% yield) as a light yellow solid: <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 8.58 (s, 1H), 7.45 (d, <i>J</i> = 8.4 Hz, 2H), 7.40 (d, <i>J</i> = 8.4 Hz, 2H), 5.31 (appt, <i>J</i> = 8.0 Hz, 1H), 4.58 (dd, <i>J</i> = 9.6, 4.0 Hz, 1H), 4.19 (m, 1H), 4.05–3.89 (m, 3H), 3.82–3.65 (m, 5H), 3.48–3.41 (m, 2H), 3.17 (dd, <i>J</i> = 12.4, 3.6 Hz, 1H), 2.30 (dd, <i>J</i> = 12.8, 7.6 Hz, 1H), 2.19 (ddd, <i>J</i> = 16.4, 12.8, 8.0 Hz, 1H), 1.37 (d, <i>J</i> = 6.4 Hz, 6H), 1.19 (d, <i>J</i> = 6.8 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 458 (M + H)<sup>+</sup>; HPLC (method B) >99% purity, <i>t</i><sub>R</sub> = 1.83 min.</div></div><div id="sec5_4_9_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> (<i>S</i>)-2-(4-Chlorophenyl)-3-(isopropylamino)-1-(4-((<i>R</i>)-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)propan-1-one Dihydrochloride Salt (<b>3</b>)</h5><div class="NLM_p last">Compound <b>3</b> was prepared from <b>8a</b> and <b>20a</b> by the same procedure as described for <b>28</b>: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.30 (s, 1H), 7.36 (d, <i>J</i> = 8.6 Hz, 2H), 7.22 (d, <i>J</i> = 8.6 Hz, 2H), 4.31 (dd, <i>J</i> = 8.2, 4.7 Hz, 1H), 4.16–4.04 (m, 1H), 3.92–3.82 (m, 1H), 3.80–3.70 (m, 1H), 3.70–3.58 (m, 1H), 3.58–3.40 (m, 6H), 3.35 (d, <i>J</i> = 6.5 Hz, 1H), 3.21 (dd, <i>J</i> = 12.9, 4.7 Hz, 1H), 2.97 (d, <i>J</i> = 9.0 Hz, 1H), 2.82 (ddd, <i>J</i> = 18.3, 9.8, 2.7 Hz, 1H), 2.30–2.16 (m, 1H), 1.78–1.68 (m, 1H), 1.20 (d, <i>J</i> = 4.4 Hz, 3H), 1.19 (d, <i>J</i> = 4.0 Hz, 3H), 0.94 (d, <i>J</i> = 6.6 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 442 (M + H)<sup>+</sup>; HPLC (method A) >99% purity, <i>t</i><sub>R</sub> = 1.86 min.</div></div><div id="sec5_4_9_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-(5,5-dimethyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one Bis(trifluoroacetate) Salt (<b>25</b>)</h5><div class="NLM_p last">Compound <b>25</b> was prepared from <b>8b</b> and <b>20a</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 8.45 (s, 1H), 7.36 (dd, <i>J</i> = 20.9, 8.5 Hz, 4H), 4.17 (dd, <i>J</i> = 8.2, 5.6 Hz, 1H), 3.74–3.55 (m, 3H), 3.51–3.38 (m, 1H), 3.27–3.04 (m, 4H), 2.95–2.57 (m, 6H), 1.81 (t, <i>J</i> = 7.2 Hz, 2H), 1.32 (d, <i>J</i> = 4.9 Hz, 6H), 0.93 (dd, <i>J</i> = 7.4, 6.4 Hz, 6H); LC/MS <i>m</i>/<i>z</i> 456 (M + H)<sup>+</sup>; HPLC (method E) 97.9% purity, <i>t</i><sub>R</sub> = 3.38 min.</div></div><div id="sec5_4_9_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> (<i>S</i>)-2-(4-Chlorophenyl)-3-(isopropylamino)-1-(4-((<i>S</i>)-5-vinyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)propan-1-one (<b>26</b>)</h5><div class="NLM_p last">Compound <b>26</b> was prepared from <b>8c</b> and <b>20a</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 8.35 (s, 1H), 7.36 (dd, <i>J</i> = 8.0, 8.5 Hz, 4H), 5.85 (ddd, <i>J</i> = 17.2, 10.2, 7.0 Hz, 1H), 4.99 (d, <i>J</i> = 10.2 Hz, 1H), 4.81 (d, <i>J</i> = 17.2 Hz, 1H), 4.18 (dd, <i>J</i> = 8.4, 5.6 Hz, 1H), 4.04 (m, 1H), 3.45–3.70 (m, 7H), 3.13 (dd, <i>J</i> = 11.6, 8.6 Hz, 2H), 3.06 (d, <i>J</i> = 10.0 Hz, 1H), 2.80–2.61 (m, 4H), 2.21 (m, 1H), 1.74 (m, 1H), 0.95 (t, <i>J</i> = 6.6 Hz, 6H); LC/MS APCI (+) <i>m</i>/<i>z</i> 454.2 (M + 1); HPLC (method D) 98% purity, <i>t</i><sub>R</sub> = 3.88 min.</div></div><div id="sec5_4_9_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((<i>R</i>)-5-(hydroxymethyl)-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one (<b>27</b>)</h5><div class="NLM_p last">Compound <b>27</b> was prepared from <b>8d</b> and <b>20a</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (CD<sub>3</sub>OD, 500 MHz) δ 8.39 (s, 1H), 7.40 (d, <i>J</i> = 8.4 Hz, 2H), 7.23 (d, <i>J</i> = 8.4 Hz, 2H), 4.18 (m, 1H), 4.08 (m, 1H), 3.90 (m, 1H), 3.75 (m, 1H), 3.69–3.48 (m, 7H), 3.42 (m, 3H), 3.27 (m, 1H), 3.07–2.82 (m, 2H), 2.25 (m, 1H), 2.04 (m, 1H), 1.25 (t, <i>J</i> = 6.6 Hz, 6H); LC/MS APCI (+) <i>m</i>/<i>z</i> 458.2 (M + 1); HPLC (method E) 100% purity, <i>t</i><sub>R</sub> = 6.47 min.</div></div><div id="sec5_4_9_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((5<i>R</i>,7<i>S</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one Dihydrochloride Salt (<b>29</b>)</h5><div class="NLM_p last">Compound <b>29</b> was prepared from <b>13b</b> and <b>20a</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.39 (s, 1H), 7.36 (d, <i>J</i> = 8.4 Hz, 2H), 7.21 (d, <i>J</i> = 8.4 Hz, 2H), 5.08 (dd, <i>J</i> = 8.4, 4.8 Hz, 1H), 4.30 (dd, <i>J</i> = 8.0, 4.8 Hz, 1H), 4.15 (m, 1H), 3.84 (m, 1H), 3.69 (m, 1H), 3.56–3.43 (m, 5H), 3.41–3.32 (m, 2H), 3.22 (dd, <i>J</i> = 12.8, 4.8 Hz, 1H), 2.67 (ddd, <i>J</i> = 14.4, 8.0, 4.0 Hz, 1H), 1.51 (ddd, <i>J</i> = 14.0, 10.0, 4.0 Hz, 1H), 1.38 (d, <i>J</i> = 7.2 Hz, 1H), 1.19 (dd, <i>J</i> = 6.4, 4.4 Hz, 6H), 1.04 (d, <i>J</i> = 7.2 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 458 (M + H)<sup>+</sup>; HPLC (method A) >95% purity, <i>t</i><sub>R</sub> = 1.82 min.</div></div><div id="sec5_4_9_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-fluoro-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one Bis(trifluoroacetate) Salt (<b>30</b>)</h5><div class="NLM_p last">Compound <b>30</b> was prepared from <b>15b</b> and <b>20a</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.52 (s, 1H), 7.50 (d, <i>J</i> = 8.0 Hz, 2H), 7.37 (d, <i>J</i> = 8.0 Hz, 2H), 5.71 (td, <i>J</i> = 56.0, 8.0 Hz, 1H), 4.42 (m, 2H), 3.93–3.83 (m, 1H), 3.78–3.68 (m, 1H), 3.60–3.30 (m, 7H), 3.20–3.00 (m, 2H), 2.65–2.50 (m, 1H), 1.77 (dd, <i>J</i> = 28, 8 Hz, 1H), 1.23 (m, 6H), 1.14 (d, <i>J</i> = 8.0 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 460 (M + H)<sup>+</sup>; HPLC (method C) 99% purity, <i>t</i><sub>R</sub> = 3.84 min.</div></div><div id="sec5_4_9_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((5<i>R</i>,7<i>S</i>)-7-fluoro-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one Bis(trifluoroacetate) Salt (<b>31</b>)</h5><div class="NLM_p last">Compound <b>31</b> was prepared from <b>14b</b> and <b>20a</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.54 (s, 1H), 7.50 (d, <i>J</i> = 8.0 Hz, 2H), 7.37 (d, <i>J</i> = 8.0 Hz, 2H), 5.86 (dt, <i>J</i> = 56.0, 4.0 Hz, 1H), 4.47 (m, 2H), 3.90–3.78 (m, 3H), 3.83 (m, 1H), 3.70 (m, 1H), 3.62–3.50 (m, 5H), 3.18–3.00 (m, 2H), 2.45–2.30 (m, 1H), 2.12–1.98 (m, 1H), 1.23 (m, 6H), 1.06 (d, <i>J</i> = 8.0 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 460 (M + H)<sup>+</sup>; HPLC (method C) >99% purity, <i>t</i><sub>R</sub> = 3.92 min.</div></div><div id="sec5_4_9_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((<i>R</i>)-7,7-difluoro-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one Dihydrochloride Salt (<b>32</b>)</h5><div class="NLM_p last">Compound <b>32</b> was prepared from <b>11b</b> and <b>20a</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.28 (s, 1H), 7.32 (d, <i>J</i> = 8.6 Hz, 2H), 7.18 (d, <i>J</i> = 8.6 Hz, 2H), 4.28 (dd, <i>J</i> = 8.4, 4.9 Hz, 1H), 3.94–3.80 (m, 2H), 3.58–3.38 (m, 7H), 3.33 (d, <i>J</i> = 6.6 Hz, 1H), 3.19 (dd, <i>J</i> = 12.8, 4.8 Hz, 1H), 3.12–3.02 (m, 1H), 2.76–2.56 (m, 1H), 2.20–2.04 (m, 1H), 1.19 (d, <i>J</i> = 4.0 Hz, 3H), 1.17 (d, <i>J</i> = 4.0 Hz, 3H), 0.98 (d, <i>J</i> = 7.0 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 478 (M + H)<sup>+</sup>; HPLC (method B) >99% purity, <i>t</i><sub>R</sub> = 2.27 min.</div></div><div id="sec5_4_9_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((<i>R</i>)-5-(fluoromethyl)-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one (<b>33</b>)</h5><div class="NLM_p last">Compound <b>33</b> was prepared from <b>8e</b> and <b>20a</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 8.59 (s, 1H), 7.41 (m, 4H), 4.20 (m, 1H), 4.07 (m, 1H), 3.98–3.84 (m, 3H), 3.62–3.80 (m, 5H), 3.60–3.40 (m, 4H), 3.27–2.92 (m, 4H), 2.40 (m, 1H), 2.15 (m, 1H), 1.37 (m, 6H); LC/MS APCI (+) <i>m</i>/<i>z</i> 460.2 (M + 1); HPLC (method C) 88% purity, <i>t</i><sub>R</sub> = 3.48 min.</div></div><div id="sec5_4_9_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (<i>S</i>)-3-Amino-2-(4-chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)propan-1-one Dihydrochloride Salt (<b>34</b>)</h5><div class="NLM_p last">Compound <b>34</b> was prepared from <b>12b</b> and <b>20f</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.39 (s, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.22 (d, <i>J</i> = 8.4 Hz, 2H), 5.27 (appt, <i>J</i> = 7.6 Hz, 1H), 4.30 (dd, <i>J</i> = 6.4 Hz, 1H), 4.11 (m, 1H), 3.88–3.80 (m, 2H), 3.70 (dd, <i>J</i> = 6.4, 4.4 Hz, 1H), 3.69–3.65 (m, 1H), 3.63–3.60 (m, 2H), 3.56–3.53 (m, 2H), 3.26 (dd, <i>J</i> = 13.2, 5.6 Hz, 1H), 2.20 (dd, <i>J</i> = 13.2, 8.0 Hz, 1H), 2.03 (ddd, <i>J</i> = 16.0, 12.8, 8.0 Hz, 1H), 1.21 (d, <i>J</i> = 6.4 Hz, 1H), 0.97 (d, <i>J</i> = 6.4 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 416 (M + H)<sup>+</sup>; HPLC (method B) 98.5% purity, <i>t</i><sub>R</sub> = 1.72 min.</div></div><div id="sec5_4_9_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> (<i>S</i>)-2-(4-Chlorophenyl)-3-((cyclopropylmethyl)amino)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)propan-1-one Dihydrochloride Salt (<b>35</b>)</h5><div class="NLM_p last">Compound <b>35</b> was prepared from <b>12b</b> and <b>20b</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 0.38 (2H, d, <i>J</i> = 5.3 Hz), 0.71 (2H, d, <i>J</i> = 7.2 Hz), 1.18 (3H, t, <i>J</i> = 6.9 Hz), 2.19 (1H, dd, <i>J</i> = 8.0, 14.6 Hz), 2.36 (1H, dd, <i>J</i> = 7.7, 13.0 Hz), 3.01 (2H, d, <i>J</i> = 7.2 Hz), 3.30 (1H, m), 3.49 (1H, dd, <i>J</i> = 5.1, 12.9 Hz), 3.57–3.75 (m, 8H), 3.92 (1H, m), 4.07–4.19 (3H, m), 4.52 (1H, dd, <i>J</i> = 5.5, 7.8 Hz), 5.43 (1H, t, <i>J</i> = 7.9 Hz), 7.39 (2H, d, <i>J</i> = 8.4 Hz), 7.53 (2H, d, <i>J</i> = 8.4 Hz), 8.55 (1H, s); LC/MS APCI (+) <i>m</i>/<i>z</i> 470 [M + H]<sup>+</sup>; HPLC (method B), 97% purity, <i>t</i><sub>R</sub> = 1.86 min</div></div><div id="sec5_4_9_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> (<i>S</i>)-2-(4-Chlorophenyl)-3-((2-fluoroethyl)amino)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)propan-1-one (<b>36</b>)</h5><div class="NLM_p last">Compound <b>36</b> was prepared from <b>12b</b> and <b>20c</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 8.58 (s, 1H), 7.46 (d, <i>J</i> = 8.4 Hz, 2H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 5.31 (t, <i>J</i> = 8.0 Hz, 1H), 4.72 (t, <i>J</i> = 4.4 Hz, 1H), 4.61 (dd, <i>J</i> = 8.4, 4.4 Hz, 1H), 4.01–3.66 (m, 8H), 3.51–3.41 (m, 4H), 2.32–2.27 (m, 1H), 2.22–2.17 (m, 1H), 1.39–1.35 (m, 3H), 1.18 (d, <i>J</i> = 6.8 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 462.2 (M + H)<sup>+</sup>; HPLC (method B) 99% purity, <i>t</i><sub>R</sub> = 2.24 min.</div></div><div id="sec5_4_9_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-((2-methoxyethyl)amino)propan-1-one Dihydrochloride Salt (<b>38</b>)</h5><div class="NLM_p last">Compound <b>38</b> was prepared from <b>12b</b> and <b>20d</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 8.58 (s, 1H), 7.46 (d, <i>J</i> = 8.4 Hz, 2H), 7.38 (d, <i>J</i> = 8.4 Hz, 2H), 5.32 (appt, <i>J</i> = 8.0 Hz, 1H), 4.56 (dd, <i>J</i> = 9.6, 4.0 Hz, 1H), 4.25–4.18 (m, 1H), 4.01–3.91 (m, 2H), 3.84–3.82 (m, 1H), 3.75–3.65 (m, 8H), 3.48 (q, <i>J</i> = 6.8 Hz, 2H), 3.41 (s, 3H), 3.31–3.26 (m, 2H), 2.30 (dd, <i>J</i> = 13.2, 7.6 Hz, 1H), 2.19 (ddd, <i>J</i> = 13.2, 8.4, 3.6 Hz, 1H), 1.18 (d, <i>J</i> = 6.8 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 474.1 (M + H)<sup>+</sup>; HPLC (method B) >99% purity, <i>t</i><sub>R</sub> = 1.81 min.</div></div><div id="sec5_4_9_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> (<i>S</i>)-2-(3-Fluoro-4-(trifluoromethyl)phenyl)-3-((1-hydroxy-2-methylprop-2-yl)amino)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)propan-1-one Bis(trifluoroacetate) Salt (<b>39</b>)</h5><div class="NLM_p last">Compound <b>39</b> was prepared from <b>12b</b> and <b>20e</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.58 (s, 1H), 7.86 (dd, <i>J</i> = 8.0, 5.6 Hz, 1H), 7.49 (d, <i>J</i> = 8.0 Hz, 1H), 7.36 (d, <i>J</i> = 5.6 Hz, 1H), 5.07 (m, 1H), 4.50 (m, 1H), 3.91 (m, 2H), 3.80–3.60 (m, 4H), 3.40–3.22 (m, 5H), 3.04 (m, 2H), 2.02 (m, 2H), 1.22 (m, 6H), 1.04 (d, <i>J</i> = 8.0 Hz, 6H); LC/MS APCI (+) <i>m</i>/<i>z</i> 540 (M + H)<sup>+</sup>; HPLC (method C) 98.3% purity, <i>t</i><sub>R</sub> = 3.90 min.</div></div><div id="sec5_4_9_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> (<i>S</i>)-2-(4-Chlorophenyl)-3-(cyclohexylamino)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)propan-1-one Dihydrochloride Salt (<b>41</b>)</h5><div class="NLM_p last">Compound <b>41</b> was prepared from <b>12b</b> and <b>20e</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.37 (s, 1H), 7.28 (ABq, 4H), 5.29 (t, <i>J</i> = 7.2 Hz, 1H), 4.32–4.27 (m, 1H), 4.18–4.10 (m, 1H), 3.88–3.78 (m, 2H), 3.71–3.62 (m, 1H), 3.56–3.44 (m, 5H), 3.28–3.20 (m, 2H), 3.04–2.98 (m, 1H), 2.21–2.16 (m, 1H), 2.05–1.99 (m, 1H), 1.94–1.88 (m, 2H), 1.70–1.68 (m, 2H), 1.53–1.50 (m, 1H), 1.24–1.56 (m, 4H), 1.06–1.03 (m, 1H), 0.96 (d, <i>J</i> = 7.2 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 498.3 (M + H)<sup>+</sup>; HPLC (method B) >99% purity, <i>t</i><sub>R</sub> = 2.01 min.</div></div><div id="sec5_4_9_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylmethylamino)propan-1-one Dihydrochloride Salt (<b>42</b>)</h5><div class="NLM_p last">A solution of <b>28</b> (0.040 g, 0.075 mmol), DIEA (0.039 mL, 0.23 mmol), and 37% formaldehyde (0.056 mL, 0.75 mmol) in 1:1 DCE–THF (0.8 mL) was stirred for 10 min. NaBH(OAc)<sub>3</sub> (0.024 g, 0.11 mmol) was added. The reaction mixture was stirred at rt for 6 h. Saturated NaHCO<sub>3</sub> was added, and the mixture was extracted with DCM. The combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude was purified by flash column chromatography with silica gel (6:1 DCM–MeOH) to give the free base, which was converted to (<i>S</i>)-2-(4-chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylmethylamino)propan-1-one dihydrochloride (0.031 g, 76% yield) by treatment with 2 M HCl in diethyl ether: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz, note that rotamers were observed) δ 8.37 (s, 1H), 7.38 (d, <i>J</i> = 8.6 Hz, 0.4H), 7.35 (d, <i>J</i> = 8.6 Hz, 1.6H), 7.27 (d, <i>J</i> = 8.6 Hz, 0.4H), 7.21 (d, <i>J</i> = 8.6 Hz, 1.6H), 5.26 (t, <i>J</i> = 8.0 Hz, 1H), 4.47 (dd, <i>J</i> = 11.0, 3.5 Hz, 1H), 4.18–4.06 (m, 1H), 3.92–3.42 (m, 9H), 3.34–3.20 (m, 1H), 3.00 (dd, <i>J</i> = 12.9, 3.5 Hz, 1H), 2.74 (s, 2.3H), 2.68 (s, 0.7H), 2.19 (dd, <i>J</i> = 13.1, 7.6 Hz, 1H), 2.08–1.98 (m, 1H), 1.26 (d, <i>J</i> = 6.7 Hz, 2.3H), 1.20 (d, <i>J</i> = 6.7 Hz, 0.7H), 1.18 (d, <i>J</i> = 6.7 Hz, 2.3H), 1.15 (d, <i>J</i> = 6.7 Hz, 0.7H), 0.97 (d, <i>J</i> = 7.0 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 472 (M + H)<sup>+</sup>; HPLC (method B) 99% purity, <i>t</i><sub>R</sub> = 1.89 min.</div></div><div id="sec5_4_9_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-2-((<i>S</i>)-pyrrolidin-2-yl)ethanone Dihydrochloride Salt (<b>43</b>)</h5><div class="NLM_p last">Compound <b>43</b> was prepared from <b>12b</b> and <b>23i</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 8.57 (s, 1H), 7.45 (d, <i>J</i> = 8.6, 2H), 7.41 (d, <i>J</i> = 8.6, 2H), 5.31 (t, <i>J</i> = 8.0, 1H), 4.51–4.45 (m, 1H), 4.23–3.28 (mm, 11H), 2.33–2.26 (m, 1H), 2.23–2.16 (m, 1H), 2.16–2.06 (m, 1H), 1.98–1.84 (m, 1H), 1.84–1.72 (m, 1H), 1.40–1.34 (m, 2H), 1.18 (d, <i>J</i> = 7.0, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 456.1, 458.1 (M + H)<sup>+</sup>; HPLC (method A) >97% purity, <i>t</i><sub>R</sub> = 2.56 min.</div></div></div><div id="sec5_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> General Procedure for Reductive Amination</h4><div id="sec5_4_10_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)propan-1-one Dihydrochloride Salt (<b>44</b>)</h5><div class="NLM_p last">A solution of <b>34</b> (0.075 g, 0.15 mmol) in 2 M Na<sub>2</sub>CO<sub>3</sub> (20 mL) was saturated with NaCl and extracted three times with DCM. The combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The resulting residue was dissolved in DCE (2.5 mL). Tetrahydropyran-4-one (0.021 mL, 0.23 mmol) was added, and the solution was stirred at rt for 5 min. NaBH(OAc)<sub>3</sub> (0.065 g, 0.31 mmol) was then added, and the reaction mixture was stirred at rt for 13 h. Saturated NaHCO<sub>3</sub> was added, and the mixture was extracted with DCM. The combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude material was purified by flash column chromatography with silica gel (6:1 DCM–MeOH) to give the free base, which was converted to (<i>S</i>)-2-(4-chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)propan-1-one dihydrochloride (0.041 g, 47% yield) by treatment with 2 M HCl in diethyl ether: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.36 (s, 1H), 7.35 (d, <i>J</i> = 8.6 Hz, 2H), 7.21 (d, <i>J</i> = 8.6 Hz, 2H), 5.24 (t, <i>J</i> = 7.8 Hz, 1H), 4.31 (dd, <i>J</i> = 8.4, 4.9 Hz, 1H), 4.14–4.04 (m, 1H), 3.93 (d, <i>J</i> = 11.7 Hz, 2H), 3.90–3.82 (m, 1H), 3.82–3.72 (m, 1H), 3.70–3.60 (m, 1H), 3.60–3.40 (m, 5H), 3.40–3.30 (m, 3H), 3.30–3.20 (m, 2H), 2.18 (dd, <i>J</i> = 13.3, 7.4 Hz, 1H), 2.08–1.99 (m, 1H), 1.99–1.87 (m, 2H), 1.59 (dd, <i>J</i> = 12.1, 4.7 Hz, 2H), 0.96 (d, <i>J</i> = 7.0 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 500 (M + H)<sup>+</sup>; HPLC (method B) 99% purity, <i>t</i><sub>R</sub> = 1.86 min.</div></div><div id="sec5_4_10_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-(((1<i>R</i>,4<i>S</i>)-4-methoxycyclohexyl)amino)propan-1-one (<b>45</b>)</h5><div class="NLM_p last">Compound <b>45</b> was prepared from <b>12b</b> and <b>20g</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 11.11 (br s, 1H), 8.45 (s, 1H), 7.20 (ABq, 4H), 6.62 (br s, 1H), 5.44–5.42 (m, 1H), 4.78–4.67 (m, 1H), 4.14–3.48 (m, 9H), 3.34 (s, 3H), 3.21–3.06 (m, 4H), 2.27–2.18 (m, 6H), 1.60–1.56 (m, 2H), 1.34–1.28 (m, 2H), 1.16 (t, <i>J</i> = 6.0 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 528 (M + H)<sup>+</sup>; HPLC (method B) 98% purity, <i>t</i><sub>R</sub> = 1.95 min.</div></div><div id="sec5_4_10_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-(((tetrahydro-2<i>H</i>-pyran-4-yl)methyl)amino)propan-1-one (<b>46</b>)</h5><div class="NLM_p last">Compound <b>46</b> was prepared from <b>34</b> and tetrahydro-2<i>H</i>-pyran-4-carbaldehyde by the same procedure described for <b>44</b>: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.34 (s, 1H), 7.28 (ABq, 4H), 5.21 (t, <i>J</i> = 7.2 Hz, 1H), 4.30 (dd, <i>J</i> = 5.2, 5.2 Hz, 1H), 4.11–4.05 (m, 1H), 3.87–3.83 (m, 3H), 3.76–3.73 (m, 1H), 3.66–3.62 (m, 1H), 3.52–3.42 (m, 5H), 3.37–3.24 (m, 4H), 2.93–2.82 (m, 2H), 2.19–2.13 (m, 1H), 2.05–1.92 (m, 2H), 1.58–1.55 (m, 2H), 1.27–1.16 (m, 2H), 0.95 (d, <i>J</i> = 7.2 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 514.3 (M + H)<sup>+</sup>; HPLC (method B) >99% purity, <i>t</i><sub>R</sub> = 1.88 min.</div></div><div id="sec5_4_10_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-2-((<i>S</i>)-piperidin-2-yl)ethanone Dihydrochloride Salt (<b>47</b>)</h5><div class="NLM_p last">Compound <b>47</b> was prepared from <b>12b</b> and <b>23j</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.36 (s, 1H), 7.35 (d, <i>J</i> = 8.6 Hz, 2H), 7.20 (d, <i>J</i> = 8.6 Hz, 2H), 5.26 (t, <i>J</i> = 7.8 Hz, 1H), 4.16–4.06 (m, 2H), 3.92–3.84 (m, 1H), 3.84–3.75 (m, 1H), 3.70–3.61 (m, 1H), 3.61–3.45 (m, 4H), 3.36–3.18 (m, 2H), 2.87 (t, <i>J</i> = 13.1 Hz, 1H), 2.19 (dd, <i>J</i> = 13.3, 7.8 Hz, 1H), 2.08–1.97 (m, 1H), 1.73 (app. t, <i>J</i> = 16.8 Hz, 2H), 1.54 (app. t, <i>J</i> = 16.4 Hz, 2H), 1.48–1.25 (m, 3H), 0.96 (d, <i>J</i> = 6.6 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 470 (M + H)<sup>+</sup>; HPLC (method B) 99% purity, <i>t</i><sub>R</sub> = 1.87 min.</div></div><div id="sec5_4_10_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-2-((<i>R</i>)-morpholin-3-yl)ethanone Hydrochloride Salt (<b>48</b>)</h5><div class="NLM_p last">Compound <b>48</b> was prepared from <b>12b</b> and <b>23k</b> by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 8.57 (s, 1H), 7.48 (d, <i>J</i> = 8.6 Hz, 2H), 7.40 (d, <i>J</i> = 8.6 Hz, 2H), 5.28 (t, <i>J</i> = 7.8, 1H), 4.51 (d, <i>J</i> = 9.0 Hz, 1H), 4.17–4.10 (m, 1H), 4.02–3.19 (m, 15H), 2.32–2.24 (m, 1H), 2.22–2.13 (m, 1H), 1.17 (d, <i>J</i> = 7.0 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 472.1, 474.1 (M + H)<sup>+</sup>; HPLC (method A) >95% purity, <i>t</i><sub>R</sub> = 2.40 min.</div></div><div id="sec5_4_10_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> Potassium 2-(4-Chlorophenyl)-3-((2,2,2-trifluoroethyl)amino)propanoate (<b>58a</b>)</h5><div class="NLM_p">A solution of methyl 3-amino-2-(4-chlorophenyl)propanoate hydrochloride (215 mg, 0.860 mmol) in 1:1 THF–DMF (3.0 mL) was treated with DIEA (389 μL, 2,23 mmol) at rt. Trifluoroethyl triflate (299 mg, 1.29 mmol) was added to the mixture, and the reaction mixture was stirred for 20 h. The mixture was partitioned between ethyl acetate and diluted NaHCO<sub>3</sub> solution. The aqueous portion was extracted twice, and the combined organics were washed with water (3×). The organic portion was washed with brine, separated, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (4:1 hexanes–EtOAc) to afford methyl 2-(4-chlorophenyl)-3-((2,2,2-trifluoroethyl)amino)propanoate (235 mg, 93% yield) as a colorless oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.33–7.29 (m, 2H), 7.24–7.20 (m, 2H), 3.76–3.71 (dd, 1H), 3.69 (s, 3H), 3.38–3.30 (m, 1H), 3.24–3.12 (m, 2H), 3.05–2.97 (m, 1H); LC/MS APCI (+) <i>m</i>/<i>z</i> 296 (M + H)<sup>+</sup>.</div><div class="NLM_p last">A solution of methyl 2-(4-chlorophenyl)-3-((2,2,2-trifluoroethyl)amino)propanoate (235 mg, 0.795 mmol) in THF (3.0 mL) was treated with KO(TMS) (153 mg, 1.19 mmol) at rt. The reaction mixture was stirred for 18 h before the mixture was diluted with diethyl ether. The resulting precipitate was isolated by filtration and dried in vacuo to give potassium 2-(4-chlorophenyl)-3-((2,2,2-trifluoroethyl)amino)propanoate (299 mg, 100% yield) as a white solid: <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 7.33 (d, <i>J</i> = 8.4 Hz, 2H), 7.25 (d, <i>J</i> = 8.4 Hz, 2H), 3.65–3.60 (m, 1H), 3.27–3.18 (m, 3H), 2.86–2.80 (m, 1H); LC/MS APCI (+) <i>m</i>/<i>z</i> 282 (M + H)<sup>+</sup>.</div></div><div id="sec5_4_10_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> (<i>S</i>)-2-(4-Chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-((2,2,2-trifluoroethyl)amino)propan-1-one Dihydrochloride Salt (<b>37</b>)</h5><div class="NLM_p last">To a solution of <b>12a</b> (0.163 g, 0.531 mmol), <b>58a</b> (0.170 g, 0.531 mmol), and DIEA (0.323 mL, 1.86 mmol) in 1:1 DCM–DMF (5 mL) was added HBTU (0.201 g, 0.531 mmol). The reaction mixture was stirred at rt for 1 h, after which 2 M Na<sub>2</sub>CO<sub>3</sub> was added. The mixture was extracted with DCM, and the combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude was purified by silica gel column chromatography (9:1 DCM–MeOH) to give the 1:1 mixture of diastereomers, which was separated by chiral HPLC to give (<i>S</i>)-2-(4-chlorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-((2,2,2-trifluoroethyl)amino)propan-1-one dihydrochloride (0.062 g, 20% yield): <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.36 (s, 1H), 7.35 (d, <i>J</i> = 8.6 Hz, 2H), 7.21 (d, <i>J</i> = 8.6 Hz, 2H), 5.25 (t, <i>J</i> = 8.0 Hz, 1H), 4.34 (dd, <i>J</i> = 8.2, 5.2 Hz, 1H), 4.16–4.04 (m, 1H), 3.90–3.40 (m, 10H), 3.32 (dd, <i>J</i> = 12.8, 5.4 Hz, 2H), 2.18 (dd, <i>J</i> = 12.8, 8.0 Hz, 1H), 2.08–1.96 (m, 1H), 0.96 (d, <i>J</i> = 7.0 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 478.2 (M + H)<sup>+</sup>; HPLC (method B) 98% purity, <i>t</i><sub>R</sub> = 2.21 min.</div></div></div><div id="sec5_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> General Procedure for Preparation of Compounds with Cyclic Tertiary Amines and <i>tert</i>-Butylamines</h4><div id="sec5_4_11_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> (<i>S</i>)-2-(4-Chlorophenyl)-3-(4-fluoropiperidin-1-yl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)propan-1-one (<b>40</b>)</h5><div class="NLM_p">A solution of 4-fluoropiperidine hydrochloride (1.065 g, 7.629 mmol) in THF (10 mL) was treated with TEA (1.134 mL, 8.137 mmol) followed by the addition of methyl 2-(4-chlorophenyl)acrylate (<b>57a</b>; 1.000 g, 5.086 mmol). The reaction mixture was stirred at rt for 48 h. The reaction was diluted with EtOAc, washed with NaHCO<sub>3</sub> and brine, dried over MgSO<sub>4</sub>, filtered, and concentrated to give methyl 2-(4-chlorophenyl)-3-(4-fluoropiperidin-1-yl)propanoate (1.521 g, 100% yield): <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.31–7.23 (m, 4H), 4.73–4.66 (m, 0.5H), 4.60–4.54 (m, 0.5H), 3.83–3.77 (dd, 1H), 3.68 (s, 3H), 3.15–3.07 (dd, 1H), 2.73–2.64 (m, 1H), 2.62–2.43 (m, 3H), 2.40–2.32 (m, 1H), 1.92–1.75 (m, 4H); LC/MS APCI (+) <i>m</i>/<i>z</i> 300.1 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of methyl 2-(4-chlorophenyl)-3-(4-fluoropiperidin-1-yl)propanoate (0.380 g, 1.27 mmol) in THF (10 mL) was added KO(TMS) (0.199 g, 1.39 mmol). The reaction mixture was stirred at rt overnight. Additional KO(TMS) (20 mg) was added. The reaction was concentrated, and the crude product (0.232 g, 0.716 mmol) was added to a solution of <b>12b</b> (0.200 g, 0.651 mmol) in DCM (4 mL). DIEA (0.363 mL, 2.08 mmol) and HBTU (0.272 g, 0.716 mmol) were added to the reaction mixture. The reaction was stirred at rt overnight and then partitioned between DCM and saturated NaHCO<sub>3</sub>. The aqueous layer was extracted with DCM. The combined extracts were washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel column chromatography (12:1 DCM–MeOH) to give the 1:1 mixture of diastereomers, which was separated by chiral SFC to give (<i>S</i>)-2-(4-chlorophenyl)-3-(4-fluoropiperidin-1-yl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)propan-1-one (0.032 g, 10% yield): <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 8.44 (s, 1H), 7.39 (d, <i>J</i> = 9.2 Hz, 2H), 7.36 (d, <i>J</i> = 9.2 Hz, 2H), 5.41 (d, <i>J</i> = 5.6 Hz, 1H), 4.84 (dd, <i>J</i> = 12.0, 6.4 Hz, 1H), 4.62 (dd, <i>J</i> = 49.2, 3.2 Hz, 1H), 4.31 (dd, <i>J</i> = 12.0, 6.4 Hz, 1H), 3.74–3.72 (m, 1H), 3.64–3.60 (m, 2H), 3.54–3.28 (m, 5H), 3.02 (dd, <i>J</i> = 12.4, 8.0 Hz, 1H), 2.59–2.54 (m, 2H), 2.44 (dd, <i>J</i> = 12.8, 6.0 Hz, 1H), 2.36–2.34 (m, 2H), 1.95 (ddd, <i>J</i> = 27.6, 13.2, 6.4 Hz, 1H), 1.92 (ddd, <i>J</i> = 20.4, 13.2, 3.2 Hz, 1H), 1.79–1.76 (m, 1H), 1.73–1.70 (m, 1H), 1.13 (d, <i>J</i> = 6.4, 1H), 1.05 (d, <i>J</i> = 6.8 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 502 (M + H)<sup>+</sup>; HPLC (method B) >99% purity, <i>t</i><sub>R</sub> = 1.89 min.</div></div><div id="sec5_4_11_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> (<i>S</i>)-2-(4-Chlorophenyl)-3-((1-hydroxy-2-methylpropan-2-yl)amino)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)propan-1-one Bis(trifluoroacetate) Salt (<b>39</b>)</h5><div class="NLM_p last">Compound <b>39</b> was prepared from <b>57a</b> and 2-amino-2-methylpropan-1-ol by the same procedure described for <b>40</b>: <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 8.40 (s, 1H), 7.39 (d, <i>J</i> = 8.0 Hz, 2H), 7.32 (d, <i>J</i> = 8.0 Hz, 2H), 5.36 (d, <i>J</i> = 6.2 Hz, 1H), 4.84–4.79 (m, 1H), 4.39–4.36 (m, 1H), 4.30 (d, <i>J</i> = 4.5 Hz, 2H), 4.09–4.05 (m, 1H), 3.70–3.55 (m, 4H), 3.50–3.43 (m, 3H), 3.20–3.00 (m, 4H), 2.60–2.57 (m, 1H), 2.06–1.94 (m, 2H), 1.09–1.04 (m, 3H), 0.89 (d, <i>J</i> = 8.0 Hz, 6H); LC/MS APCI (+) <i>m</i>/<i>z</i> 488 (M + H)<sup>+</sup>; HPLC (method C) >99% purity, <i>t</i><sub>R</sub> = 3.42 min.</div></div><div id="sec5_4_11_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> (<i>S</i>)-3-Amino-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-2-(4-(trifluoromethyl)phenyl)propan-1-one Bis(trifluoroacetate) Salt (<b>49</b>)</h5><div class="NLM_p last">Compound <b>49</b> was prepared from 2-(4-trifluoromethyl)acetyl chloride by the same procedure described for <b>34</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 8.80 (s, 1H), 7.92 (d, <i>J</i> = 8.0 Hz, 2H), 7.61 (d, <i>J</i> = 8.0 Hz, 2H), 5.08 (m, 1H), 4.44–4.40 (m, 1H), 3.89–3.84 (m, 2H), 3.76–3.30 (m, 8H), 3.12 (m, 2H), 2.08 (m, 2H), 1.07 (d, <i>J</i> = 8.0 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 450 (M + H)<sup>+</sup>; HPLC (method C) >99% purity, <i>t</i><sub>R</sub> = 3.30 min.</div></div><div id="sec5_4_11_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> (<i>S</i>)-2-(4-Chloro-3-fluorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one Dihydrochloride Salt (<b>50</b>)</h5><div class="NLM_p last">Compound <b>50</b> was prepared from <b>12b</b> and (<i>S</i>)-2-(4-chloro-3-fluorophenyl)-3-(isopropylamino)propanoic acid by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.35 (s, 1H), 7.44 (t, <i>J</i> = 7.2 Hz, 1H), 7.14 (d, <i>J</i> = 9.2 Hz, 1H), 7.04 (d, <i>J</i> = 7.2 Hz, 1H), 5.28–5.16 (m, 1H), 4.38–4.28 (m, 1H), 4.10–3.98 (m, 1H), 3.88–3.72 (m, 2H), 3.72–3.16 (m, 9H), 2.22–2.12 (m, 1H), 2.10–1.96 (m, 1H), 1.32–1.08 (m, 6H), 0.96 (d, <i>J</i> = 5.6 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 476 (M + H)<sup>+</sup>; HPLC (method A) 98% purity, <i>t</i><sub>R</sub> = 2.38 min.</div></div><div id="sec5_4_11_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> (<i>S</i>)-3-(<i>tert</i>-Butyl)-2-(3-fluoro-4-(trifluoromethyl)phenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)propan-1-one Bis(trifluoroacetate) Salt (<b>51</b>)</h5><div class="NLM_p last">Compound <b>51</b> was prepared from <b>57b</b> and <i>tert</i>-butylamine by the same procedure described for <b>40</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 8.80 (s, 1H), 7.92 (d, <i>J</i> = 8.0 Hz, 2H), 7.61 (d, <i>J</i> = 8.0 Hz, 2H), 5.08 (m, 1H), 4.44–4.40 (m, 1H), 3.89–3.85 (m, 2H), 3.76–3.30 (m, 8H), 3.12 (m, 2H), 2.08 (m, 2H), 1.07 (d, <i>J</i> = 8.0 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 524 (M + H)<sup>+</sup>; HPLC (method C) 95.3% purity, <i>t</i><sub>R</sub> = 3.95 min.</div></div><div id="sec5_4_11_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> (<i>S</i>)-2-(3-Fluoro-4-(trifluoromethyl)phenyl)-3-((1-hydroxy-2-methylpropan-2-yl)amino)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)propan-1-one Bis(trifluoroacetate Salt (<b>52</b>)</h5><div class="NLM_p last">Compound <b>52</b> was prepared from <b>57b</b> and 2-amino-2-methylpropan-1-ol by the same procedure described for <b>40</b>: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.58 (s, 1H), 7.86 (dd, <i>J</i> = 8.0, 5.6 Hz, 1H), 7.49 (d, <i>J</i> = 8.0 Hz, 1H), 7.36 (d, <i>J</i> = 5.6 Hz, 1H), 5.07 (m, 1H), 4.50 (m, 1H), 3.91 (m, 2H), 3.80–3.60 (m, 4H), 3.40–3.22 (m, 5H), 3.04 (m, 2H), 2.02 (m, 2H), 1.22 (m, 6H), 1.04 (d, <i>J</i> = 8.0 Hz, 6H); LC/MS APCI (+) <i>m</i>/<i>z</i> 540 (M + H)<sup>+</sup>; HPLC (method C) 98.3% purity, <i>t</i><sub>R</sub> = 3.90 min.</div></div><div id="sec5_4_11_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> (<i>S</i>)-3-((Cyclopropylmethyl)amino)-2-(3-fluoro-4-(trifluoromethyl)phenyl)-1-(4-(5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)propan-1-one Bis(trifluoroacetate) Salt (<b>53</b>)</h5><div class="NLM_p last">Compound <b>53</b> was prepared from <b>12b</b> and (<i>S</i>)-3-((cyclopropylmethyl)amino)-2-(3-fluoro-4-(trifluoromethyl)phenyl)propanoic acid by the same procedure described for <b>28</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 8.32 (s, 1H), 7.78 (dd, <i>J</i> = 8.0, 6.2 Hz, 1H), 7.53 (d, <i>J</i> = 8.0 Hz, 1H), 7.39 (d, <i>J</i> = 6.2 Hz, 1H), 5.10–5.08 (m, 1H), 4.62–4.60 (m, 1H), 3.90–3.20 (m, 8H), 2.86 (m, 2H), 2.06–2.02 (m, 2H), 1.18–1.15 (m, 1H), 1.09 (d, <i>J</i> = 8.0 Hz, 3H), 0.59–0.54 (m, 2H), 0.33–0.29 (m, 2H); LC/MS APCI (+) <i>m</i>/<i>z</i> 522 (M + H)<sup>+</sup>; HPLC (method C) >99% purity, <i>t</i><sub>R</sub> = 4.08 min.</div></div><div id="sec5_4_11_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> (<i>S</i>)-2-(4-Chloro-3-fluorophenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)-3-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)propan-1-one Dihydrochloride Salt (<b>54</b>)</h5><div class="NLM_p last">Compound <b>54</b> was prepared from (<i>S</i>)-3-amino-2-(3-fluoro-4-(trifluoromethyl)phenyl)-1-(4-((5<i>R</i>,7<i>R</i>)-7-hydroxy-5-methyl-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidin-4-yl)piperazin-1-yl)propan-1-one and tetrahydro-2<i>H</i>-pyran-4-carbaldehyde by the same procedure described for <b>44</b>: <sup>1</sup>H NMR (D<sub>2</sub>O, 400 MHz) δ 8.37 (s, 1H), 7.44 (t, <i>J</i> = 7.6 Hz, 1H), 7.15 (d, <i>J</i> = 9.6 Hz, 1H), 7.05 (d, <i>J</i> = 7.6 Hz, 1H), 5.24 (t, <i>J</i> = 7.8 Hz, 1H), 4.38–4.30 (m, 1H), 4.12–4.04 (m, 1H), 4.00–3.88 (m, 2H), 3.88–3.75 (m, 2H), 3.75–3.64 (m, 1H), 3.64–3.42 (m, 5H), 3.42–3.18 (m, 5H), 2.22–2.18 (m, 1H), 2.08–1.86 (m, 3H), 1.68–1.52 (m, 2H), 0.97 (d, <i>J</i> = 6.4 Hz, 3H); LC/MS APCI (+) <i>m</i>/<i>z</i> 518 (M + H)<sup>+</sup>; HPLC (method A) 98% purity, <i>t</i><sub>R</sub> = 2.37 min.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74"><a href="/doi/suppl/10.1021/jm301024w">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75266" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75266" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Enzyme inhibition results (expressed as a percentage of the control) for compounds <b>2</b>, <b>3</b>, and <b>28</b> tested against a panel of 226, 225, and 230 kinases, respectively, performed at Upstate, Charlottesville, VA.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301024w/suppl_file/jm301024w_si_001.pdf">jm301024w_si_001.pdf (150.98 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm301024w" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James F. Blake</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc., 3200 Walnut Street, Boulder, Colorado 80301, United
States </span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2c464e404d47496c4d5e5e4d554e45435c444d5e414d024f4341"><span class="__cf_email__" data-cfemail="573d353b363c3217362525362e353e38273f36253a367934383a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rui Xu</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc., 3200 Walnut Street, Boulder, Colorado 80301, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Josef R. Bencsik</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc., 3200 Walnut Street, Boulder, Colorado 80301, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dengming Xiao</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc., 3200 Walnut Street, Boulder, Colorado 80301, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicholas C. Kallan</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc., 3200 Walnut Street, Boulder, Colorado 80301, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Schlachter</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc., 3200 Walnut Street, Boulder, Colorado 80301, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ian S. Mitchell</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc., 3200 Walnut Street, Boulder, Colorado 80301, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keith L. Spencer</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc., 3200 Walnut Street, Boulder, Colorado 80301, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna L. Banka</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc., 3200 Walnut Street, Boulder, Colorado 80301, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eli M. Wallace</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc., 3200 Walnut Street, Boulder, Colorado 80301, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan L. Gloor</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc., 3200 Walnut Street, Boulder, Colorado 80301, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew Martinson</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc., 3200 Walnut Street, Boulder, Colorado 80301, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard D. Woessner</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc., 3200 Walnut Street, Boulder, Colorado 80301, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guy P.A. Vigers</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc., 3200 Walnut Street, Boulder, Colorado 80301, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbara J. Brandhuber</span> - <span class="hlFld-Affiliation affiliation">Array BioPharma
Inc., 3200 Walnut Street, Boulder, Colorado 80301, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun Liang</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080-4990,
United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian S. Safina</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080-4990,
United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun Li</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080-4990,
United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Birong Zhang</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080-4990,
United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine Chabot</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080-4990,
United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven Do</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080-4990,
United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leslie Lee</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080-4990,
United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Oeh</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080-4990,
United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deepak Sampath</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080-4990,
United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian B. Lee</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080-4990,
United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kui Lin</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080-4990,
United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bianca M. Liederer</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080-4990,
United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicholas J. Skelton</span> - <span class="hlFld-Affiliation affiliation">Genentech
Inc., 1 DNA Way, South San Francisco, California 94080-4990,
United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i75" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i75"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i76" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i76"> Abbreviations Used</h2><tr><td class="NLM_term">AGC</td><td class="NLM_def"><p class="first last">cAMP-dependent protein kinase/protein kinase G/protein kinase C extended family</p></td></tr><tr><td class="NLM_term">DAST</td><td class="NLM_def"><p class="first last">diethylaminosulfur trifluoride</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth ractor receptor 2</p></td></tr><tr><td class="NLM_term">LNCaP</td><td class="NLM_def"><p class="first last">lymph node carcinoma of the prostate</p></td></tr><tr><td class="NLM_term">MCF7</td><td class="NLM_def"><p class="first last">Michigan Cancer Foundation-7</p></td></tr><tr><td class="NLM_term">MCT</td><td class="NLM_def"><p class="first last">methylcellulose with 0.2% Tween-80</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">p70S6K</td><td class="NLM_def"><p class="first last">phosphoprotein 70 ribosomal protein S6 kinase</p></td></tr><tr><td class="NLM_term">PBSF</td><td class="NLM_def"><p class="first last"><i>n</i>-perfluorobutanesulfonyl fluoride</p></td></tr><tr><td class="NLM_term">PC3</td><td class="NLM_def"><p class="first last">prostate cancer cell line</p></td></tr><tr><td class="NLM_term">PRAS40</td><td class="NLM_def"><p class="first last">proline-rich Akt substrate</p></td></tr><tr><td class="NLM_term">PRKG</td><td class="NLM_def"><p class="first last">cyclic GMP-dependent protein kinase</p></td></tr><tr><td class="NLM_term">PTEN</td><td class="NLM_def"><p class="first last">phosphatase and tensin homologue</p></td></tr><tr><td class="NLM_term">ROCK1</td><td class="NLM_def"><p class="first last">ρ-associated coiled coil containing protein kinase 1</p></td></tr><tr><td class="NLM_term">RPS6</td><td class="NLM_def"><p class="first last">ribosomal protein S6</p></td></tr><tr><td class="NLM_term">shRNA</td><td class="NLM_def"><p class="first last">short hairpin RNA</p></td></tr><tr><td class="NLM_term">TsDPEN</td><td class="NLM_def"><p class="first last">tosyl-1,2-diphenylethylene</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77252" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77252" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 23 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cheng, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, G. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicosia, S. V.</span><span> </span><span class="NLM_article-title">The Akt/PKB pathway: molecular target for cancer drug discovery</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">7482</span><span class="NLM_x">–</span> <span class="NLM_lpage">7492</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=7482-7492&author=J.+Q.+Chengauthor=C.+W.+Lindsleyauthor=G.+Z.+Chengauthor=H.+Yangauthor=S.+V.+Nicosia&title=The+Akt%2FPKB+pathway%3A+molecular+target+for+cancer+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%2BQ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DCheng%26aufirst%3DG.%2BZ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DNicosia%26aufirst%3DS.%2BV.%26atitle%3DThe%2520Akt%252FPKB%2520pathway%253A%2520molecular%2520target%2520for%2520cancer%2520drug%2520discovery%26jtitle%3DOncogene%26date%3D2005%26volume%3D24%26spage%3D7482%26epage%3D7492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Manning, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">AKT/PKB signaling: navigating downstream</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">1261</span><span class="NLM_x">–</span> <span class="NLM_lpage">1274</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2007&pages=1261-1274&author=B.+D.+Manningauthor=L.+C.+Cantley&title=AKT%2FPKB+signaling%3A+navigating+downstream"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DB.%2BD.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DAKT%252FPKB%2520signaling%253A%2520navigating%2520downstream%26jtitle%3DCell%26date%3D2007%26volume%3D129%26spage%3D1261%26epage%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Altomare, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testa, J. R.</span><span> </span><span class="NLM_article-title">Perturbations of the AKT signaling pathway in human cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">7455</span><span class="NLM_x">–</span> <span class="NLM_lpage">7464</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=7455-7464&author=D.+A.+Altomareauthor=J.+R.+Testa&title=Perturbations+of+the+AKT+signaling+pathway+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAltomare%26aufirst%3DD.%2BA.%26aulast%3DTesta%26aufirst%3DJ.%2BR.%26atitle%3DPerturbations%2520of%2520the%2520AKT%2520signaling%2520pathway%2520in%2520human%2520cancer%26jtitle%3DOncogene%26date%3D2005%26volume%3D24%26spage%3D7455%26epage%3D7464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Vivanco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">The phosphatidylinositol 3-kinase AKT pathway in human cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.1038%2Fnrc839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=12094235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=489-501&author=I.+Vivancoauthor=C.+L.+Sawyers&title=The+phosphatidylinositol+3-kinase+AKT+pathway+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol 3-Kinase-AKT pathway in human cancer</span></div><div class="casAuthors">Vivanco, Igor; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One signal that is overactivated in a wide range of tumor types is the prodn. of a phospholipid, phosphatidylinositol (3,4,5) trisphosphate, by phosphatidylinositol 3-kinase (PI3K).  This lipid and the protein kinase that is activated by it, AKT, trigger a cascade of responses, from cell growth and proliferation to survival and motility, that drive tumor progression.  Small-mol. therapeutics that block PI3K signaling might deal a severe blow to cancer cells by blocking many aspects of the tumor-cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAQ-0qeD7pLVg90H21EOLACvtfcHk0ljm1cMtvpxStQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D&md5=c6762d32f9f1281632f4ccdbcd29268c</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fnrc839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc839%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DThe%2520phosphatidylinositol%25203-kinase%2520AKT%2520pathway%2520in%2520human%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D489%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cristofano, A.</span><span> </span><span class="NLM_article-title">Class reunion: PTEN joins the nuclear crew</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">7394</span><span class="NLM_x">–</span> <span class="NLM_lpage">7400</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=7394-7400&author=Z.+Lianauthor=A.+Di+Cristofano&title=Class+reunion%3A+PTEN+joins+the+nuclear+crew"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLian%26aufirst%3DZ.%26aulast%3DDi%2BCristofano%26aufirst%3DA.%26atitle%3DClass%2520reunion%253A%2520PTEN%2520joins%2520the%2520nuclear%2520crew%26jtitle%3DOncogene%26date%3D2005%26volume%3D24%26spage%3D7394%26epage%3D7400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Degtyarev, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Mazière, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tien, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dijk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klumperman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span> </span><span class="NLM_article-title">Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2008&pages=101-16&author=M.+Degtyarevauthor=A.+De+Mazi%C3%A8reauthor=C.+Orrauthor=J.+Linauthor=B.+B.+Leeauthor=J.+Y.+Tienauthor=W.+W.+Priorauthor=S.+van+Dijkauthor=H.+Wuauthor=D.+C.+Grayauthor=D.+P.+Davisauthor=H.+M.+Sternauthor=L.+J.+Murrayauthor=K.+P.+Hoeflichauthor=J.+Klumpermanauthor=L.+S.+Friedmanauthor=K.+Lin&title=Akt+inhibition+promotes+autophagy+and+sensitizes+PTEN-null+tumors+to+lysosomotropic+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDegtyarev%26aufirst%3DM.%26aulast%3DDe%2BMazi%25C3%25A8re%26aufirst%3DA.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DB.%2BB.%26aulast%3DTien%26aufirst%3DJ.%2BY.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3Dvan%2BDijk%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DGray%26aufirst%3DD.%2BC.%26aulast%3DDavis%26aufirst%3DD.%2BP.%26aulast%3DStern%26aufirst%3DH.%2BM.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DKlumperman%26aufirst%3DJ.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DLin%26aufirst%3DK.%26atitle%3DAkt%2520inhibition%2520promotes%2520autophagy%2520and%2520sensitizes%2520PTEN-null%2520tumors%2520to%2520lysosomotropic%2520agents%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2008%26volume%3D183%26spage%3D101%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chen, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, P. -Y</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, H. H.</span><span> </span><span class="NLM_article-title">Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy</span> <span class="citation_source-journal">Curr. Med. Chem. Anticancer Agents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">589</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.2174%2F156801105774574649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=16305480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A280%3ADC%252BD2Mnitlymtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=575-589&author=Y.+L.+Chenauthor=P.+-Y+Lawauthor=H.+H.+Loh&title=Inhibition+of+PI3K%2FAkt+signaling%3A+an+emerging+paradigm+for+targeted+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy</span></div><div class="casAuthors">Chen Yulong L; Law Ping-Y; Loh Horace H</div><div class="citationInfo"><span class="NLM_cas:title">Current medicinal chemistry. Anti-cancer agents</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">575-89</span>
        ISSN:<span class="NLM_cas:issn">1568-0118</span>.
    </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B, PKB) signaling pathway plays a critical role in cell growth and survival.  Dysregulation of this pathway has been found in a variety of cancer cells.  Recently, constitutively active PI3K/Akt signaling has been firmly established as a major determinant for cell growth and survival in an array of cancers.  Blocking the constitutively active PI3K/AKT signaling pathway provides a new strategy for targeted cancer therapy.  Thus, inhibitors of this signaling pathway would be potential anticancer agents, particularly for cancer cells whose survival and growth are dominated by constitutively active PI3K/Akt signaling.  This review describes the current understanding of small molecule drugs targeting this pathway both in vitro and in vivo.  Inhibitors and functions of the upstream and downstream molecular targets of the PI3K/Akt pathway are discussed in the context of using the inhibitors to block this pathway for targeted cancer therapy.  Special emphasis is placed on the following targets: receptor tyrosine kinases, PI3K, Akt, and the mammalian target of rapamycin.  While the molecular therapeutic strategy holds great promise for the treatment of a variety of cancers, few small molecule inhibitors with potential high therapeutic indexes are available.  Thus, new inhibitors with high selectivity, bioavailability, and potency are greatly needed.  Novel approaches toward the development of PI3K/Akt pathway inhibitors as anticancer therapeutics are discussed in detail, with emphasis on chemical genetics-based and structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQoT7lhSKHCPe_Q9URG6Dx8fW6udTcc2eZEV-ifo9KL67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mnitlymtg%253D%253D&md5=d9d6980724d20abbc1e71b9d1bde1279</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.2174%2F156801105774574649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156801105774574649%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DLaw%26aufirst%3DP.%2B-Y%26aulast%3DLoh%26aufirst%3DH.%2BH.%26atitle%3DInhibition%2520of%2520PI3K%252FAkt%2520signaling%253A%2520an%2520emerging%2520paradigm%2520for%2520targeted%2520cancer%2520therapy%26jtitle%3DCurr.%2520Med.%2520Chem.%2520Anticancer%2520Agents%26date%3D2005%26volume%3D5%26spage%3D575%26epage%3D589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span> </span><span class="NLM_article-title">Targeting PI3K-AKT pathway for cancer therapy</span> <span class="citation_source-journal">Rev. Clin. Exp. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">228</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=14763163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSqsLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2003&pages=205-228&author=Y.+Luauthor=H.+Wangauthor=G.+B.+Mills&title=Targeting+PI3K-AKT+pathway+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K-AKT pathway for cancer therapy</span></div><div class="casAuthors">Lu, Yiling; Wang, Hongwei; Mills, Gordon B.</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in Clinical and Experimental Hematology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-228</span>CODEN:
                <span class="NLM_cas:coden">RCEHFB</span>;
        ISSN:<span class="NLM_cas:issn">1127-0020</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The phosphatydilinositol 3-kinase/protein kinase 8 (PI3K-AKT) pathway presents an exciting new target for mol. therapeutics.  While exhibiting great promise, addnl. preclin. and clin. studies will be required to det. how best to target this pathway to improve patient outcome.  A no. of questions need to be answered prior to the implementation into patient care practices.  As described below, the PI3K-AKT pathway regulates a broad spectrum of cellular processes, some of which are necessary to maintain normal physiol. functions, which potentially contribute to the toxicity of the drugs targeting the pathway.  Elucidation of the precise function of the PI3K-AKT isoforms, could promote the development of isoform specific approaches to provide a selective action on tumor cells.  However, whether this will be possible due to conservation of structural domains is not yet clear.  Inhibition of the PI3K-AKT pathway at multiple sites or a combination with inhibitors of different signaling pathways may allow the development of an acceptable therapeutic index for cancer management.  Further, inhibition of the PI3K-AKT pathway combined with conventional chemotherapy or radiation therapy may provide a more effective strategy to improve patient outcome.  As mol. therapeutics target the underlying defects in patient tumors, mol. diagnostics are required to identify patients with particular genetic aberrations in the pathway.  It will be crit. to provide adequate therapeutic strategies tailored to each patient.  In addn., patients with different genetic backgrounds or in different health conditions could respond adversely to particular therapeutics.  Therefore, identification of patients for particular drugs based on the underlying genetic defects in the tumor as well as the characteristics of the host would be of benefit for improving patient outcome.  Linking the targeted therapeutics to mol. imaging approaches will det. appropriate biol. relevant dose for patients.  It will also define expected tumor responsiveness and eventually will improve efficacy and decrease toxicity.  In this regard, personalized mol. medicine is likely to soon provide effective cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNhTtR9V2YCbVg90H21EOLACvtfcHk0lgW1T8ABG-hzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSqsLvO&md5=80c1accfd7e1bf4b1ab8df10c5452ca3</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMills%26aufirst%3DG.%2BB.%26atitle%3DTargeting%2520PI3K-AKT%2520pathway%2520for%2520cancer%2520therapy%26jtitle%3DRev.%2520Clin.%2520Exp.%2520Hematol.%26date%3D2003%26volume%3D7%26spage%3D205%26epage%3D228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Mitsiades, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koutsilieris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgatti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capitani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brazil, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemmings, B. A.</span><span> </span><span class="NLM_article-title">The Akt pathway: molecular targets for anti-cancer drug development</span> <span class="citation_source-journal">Curr. Cancer Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.2174%2F1568009043333032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=15134532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1Gnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=235-256&author=C.+S.+Mitsiadesauthor=N.+Mitsiadesauthor=M.+Koutsilierisauthor=K.+M.+Nicholsonauthor=N.+G.+Andersonauthor=L.+M.+Neriauthor=P.+Borgattiauthor=S.+Capitaniauthor=M.+Martelliauthor=D.+P.+Brazilauthor=B.+A.+Hemmings&title=The+Akt+pathway%3A+molecular+targets+for+anti-cancer+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">The Akt pathway: Molecular targets for anti-cancer drug development</span></div><div class="casAuthors">Mitsiades, Constantine S.; Mitsiades, Nicholas; Koutsilieris, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-256</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The serine/threonine kinase Akt functions intracellularly as a cardinal nodal point for a constellation of converging upstream signaling pathways, which involve stimulation of receptor tyrosine kinases such as IGR-1R, HER2/Neu, VEGF-R, PDGF-R, and an assembly of membrane-localized complexes of receptor-PI-3K and activation of Akt through the second messenger PIP3.  The integration of these intracellular signals at the level of Akt and its kinase activity, regulates the phosphorylation of its several downstream effectors, such as NF-κB, mTOR, Forkhead, Bad, GSK-3 and MDM-2.  These phosphorylation events in turn mediate the effects of Akt on cell growth, proliferation, protection from pro-apoptotic stimuli, and stimulation of neoangiogenesis.  Because Akt and its upstream regulators are deregulated in a wide range of solid tumors and hematol. malignancies, and in view of the aforementioned biol. sequelae of this pathway, the Akt pathway is considered a key determinant of biol. aggressiveness of these tumors, and a major potential target for novel anti-cancer therapies.  This review focuses on ongoing translational efforts to therapeutically target Akt and its biol. sequelae, either at the level of Akt itself or at the levels of its upstream regulators and downstream effectors.  Because Akt is also important for proliferative and anti-apoptotic signaling pathways crit. for normal cells, particular emphasis is placed on the fine-tuning the targeting of individual components of this pathway to maximize the therapeutic index of anti-cancer strategies based on the PI-3K/Akt pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGZbuqTPNYgLVg90H21EOLACvtfcHk0lgW1T8ABG-hzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1Gnu78%253D&md5=299909de4babdbbf0e242bd1a7abdab1</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.2174%2F1568009043333032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009043333032%26sid%3Dliteratum%253Aachs%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DMitsiades%26aufirst%3DN.%26aulast%3DKoutsilieris%26aufirst%3DM.%26aulast%3DNicholson%26aufirst%3DK.%2BM.%26aulast%3DAnderson%26aufirst%3DN.%2BG.%26aulast%3DNeri%26aufirst%3DL.%2BM.%26aulast%3DBorgatti%26aufirst%3DP.%26aulast%3DCapitani%26aufirst%3DS.%26aulast%3DMartelli%26aufirst%3DM.%26aulast%3DBrazil%26aufirst%3DD.%2BP.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DThe%2520Akt%2520pathway%253A%2520molecular%2520targets%2520for%2520anti-cancer%2520drug%2520development%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2004%26volume%3D4%26spage%3D235%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Pal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reckamp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figlin, R. A.</span><span> </span><span class="NLM_article-title">Akt inhibitors in clinical development for the treatment of cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1366</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=1355-1366&author=S.+K.+Palauthor=K.+Reckampauthor=H.+Yuauthor=R.+A.+Figlin&title=Akt+inhibitors+in+clinical+development+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPal%26aufirst%3DS.%2BK.%26aulast%3DReckamp%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26atitle%3DAkt%2520inhibitors%2520in%2520clinical%2520development%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D19%26spage%3D1355%26epage%3D1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bencsik, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woessner, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G. P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span> </span><span class="NLM_article-title">Discovery of pyrrolopyrimidine inhibitors of Akt</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5607</span><span class="NLM_x">–</span> <span class="NLM_lpage">5612</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5607-5612&author=J.+F.+Blakeauthor=N.+C.+Kallanauthor=D.+Xiaoauthor=R.+Xuauthor=J.+R.+Bencsikauthor=N.+J.+Skeltonauthor=K.+L.+Spencerauthor=I.+S.+Mitchellauthor=R.+D.+Woessnerauthor=S.+L.+Gloorauthor=T.+Risomauthor=S.+D.+Grossauthor=M.+Martinsonauthor=T.+H.+Moralesauthor=G.+P.+A.+Vigersauthor=B.+J.+Brandhuber&title=Discovery+of+pyrrolopyrimidine+inhibitors+of+Akt"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKallan%26aufirst%3DN.%2BC.%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DBencsik%26aufirst%3DJ.%2BR.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DSpencer%26aufirst%3DK.%2BL.%26aulast%3DMitchell%26aufirst%3DI.%2BS.%26aulast%3DWoessner%26aufirst%3DR.%2BD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DGross%26aufirst%3DS.%2BD.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DMorales%26aufirst%3DT.%2BH.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26atitle%3DDiscovery%2520of%2520pyrrolopyrimidine%2520inhibitors%2520of%2520Akt%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5607%26epage%3D5612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Bencsik, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woessner, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dizon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G. P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span> </span><span class="NLM_article-title">Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">7037</span><span class="NLM_x">–</span> <span class="NLM_lpage">7041</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.1016%2Fj.bmcl.2010.09.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=20971641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7037-7041&author=J.+R.+Bencsikauthor=D.+Xiaoauthor=J.+F.+Blakeauthor=N.+C.+Kallanauthor=I.+S.+Mitchellauthor=K.+L.+Spencerauthor=R.+Xuauthor=S.+L.+Gloorauthor=M.+Martinsonauthor=T.+Risomauthor=R.+D.+Woessnerauthor=F.+Dizonauthor=W.-I.+Wuauthor=G.+P.+A.+Vigersauthor=B.+J.+Brandhuberauthor=N.+J.+Skeltonauthor=W.+W.+Priorauthor=L.+J.+Murray&title=Discovery+of+dihydrothieno-+and+dihydrofuropyrimidines+as+potent+pan+Akt+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors</span></div><div class="casAuthors">Bencsik, Josef R.; Xiao, Dengming; Blake, James F.; Kallan, Nicholas C.; Mitchell, Ian S.; Spencer, Keith L.; Xu, Rui; Gloor, Susan L.; Martinson, Matthew; Risom, Tyler; Woessner, Richard D.; Dizon, Faith; Wu, Wen-I.; Vigers, Guy P. A.; Brandhuber, Barbara J.; Skelton, Nicholas J.; Prior, Wei Wei; Murray, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7037-7041</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis of a novel series of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors is reported.  Inhibitors displaying increased PKA and general kinase selectivity with improved tolerability compared to the progenitor pyrrolopyrimidine were developed using previous SAR and anal. of the amino acid sequences in the binding site.  Dihydrothieno compd. I was advanced into a PC3-NCI prostate mouse tumor model in which it demonstrated a dose-dependent redn. in tumor growth and stasis when dosed orally daily at 200 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8-bp6rwVWNrVg90H21EOLACvtfcHk0lifocVK2pT2rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtLnJ&md5=d6aed3020c07ed85e83379c40d53394e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.09.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.09.112%26sid%3Dliteratum%253Aachs%26aulast%3DBencsik%26aufirst%3DJ.%2BR.%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKallan%26aufirst%3DN.%2BC.%26aulast%3DMitchell%26aufirst%3DI.%2BS.%26aulast%3DSpencer%26aufirst%3DK.%2BL.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DWoessner%26aufirst%3DR.%2BD.%26aulast%3DDizon%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DW.-I.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26atitle%3DDiscovery%2520of%2520dihydrothieno-%2520and%2520dihydrofuropyrimidines%2520as%2520potent%2520pan%2520Akt%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7037%26epage%3D7041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Taber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petty, E. H.</span><span> </span><span class="NLM_article-title">General route to highly functionalized cyclopentane derivatives by intermolecular C–H insertion</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4808</span><span class="NLM_x">–</span> <span class="NLM_lpage">4809</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00145a050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1982&pages=4808-4809&author=D.+F.+Taberauthor=E.+H.+Petty&title=General+route+to+highly+functionalized+cyclopentane+derivatives+by+intermolecular+C%E2%80%93H+insertion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjo00145a050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00145a050%26sid%3Dliteratum%253Aachs%26aulast%3DTaber%26aufirst%3DD.%2BF.%26aulast%3DPetty%26aufirst%3DE.%2BH.%26atitle%3DGeneral%2520route%2520to%2520highly%2520functionalized%2520cyclopentane%2520derivatives%2520by%2520intermolecular%2520C%25E2%2580%2593H%2520insertion%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1982%26volume%3D47%26spage%3D4808%26epage%3D4809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Nugent, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobbs, F. W.,  Jr.</span><span> </span><span class="NLM_article-title">Improved route to 3-vinyl substituted cyclopentanones. Synthesis of (±)-mitsugashiwalactone</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3376</span><span class="NLM_x">–</span> <span class="NLM_lpage">3378</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00367a027" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1986&pages=3376-3378&author=W.+A.+Nugentauthor=F.+W.+Hobbs&title=Improved+route+to+3-vinyl+substituted+cyclopentanones.+Synthesis+of+%28%C2%B1%29-mitsugashiwalactone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjo00367a027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00367a027%26sid%3Dliteratum%253Aachs%26aulast%3DNugent%26aufirst%3DW.%2BA.%26aulast%3DHobbs%26aufirst%3DF.%2BW.%26atitle%3DImproved%2520route%2520to%25203-vinyl%2520substituted%2520cyclopentanones.%2520Synthesis%2520of%2520%2528%25C2%25B1%2529-mitsugashiwalactone%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1986%26volume%3D51%26spage%3D3376%26epage%3D3378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarkowsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huffman, M. A.</span><span> </span><span class="NLM_article-title">Direct and convenient conversion of alcohols to fluorides</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1465</span><span class="NLM_x">–</span> <span class="NLM_lpage">1468</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol049672a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Whurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=1465-1468&author=J.+Yinauthor=D.+S.+Zarkowskyauthor=D.+W.+Thomasauthor=M.+M.+Zhaoauthor=M.+A.+Huffman&title=Direct+and+convenient+conversion+of+alcohols+to+fluorides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Direct and convenient conversion of alcohols to fluorides</span></div><div class="casAuthors">Yin, Jingjun; Zarkowsky, Devin S.; Thomas, David W.; Zhao, Matthew M.; Huffman, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1465-1468</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Directly mixing primary, secondary, and tertiary alcs. with nC4F9SO2F-NR3(HF)3-NR3 resulted in formation of fluorides, e.g., I, in high yields.  The readily available reagents were easy to handle, and the mild, almost neutral, reaction conditions allowed for excellent functional group compatibility.  A NR3(HF)3/NR3 ratio of ≤1:2 gave the highest reactivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi8LHzVOsjF7Vg90H21EOLACvtfcHk0ljV2z3BuE3fug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Whurs%253D&md5=83c3f9aefc44f02e18e60b17cf2a5d37</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fol049672a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol049672a%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DZarkowsky%26aufirst%3DD.%2BS.%26aulast%3DThomas%26aufirst%3DD.%2BW.%26aulast%3DZhao%26aufirst%3DM.%2BM.%26aulast%3DHuffman%26aufirst%3DM.%2BA.%26atitle%3DDirect%2520and%2520convenient%2520conversion%2520of%2520alcohols%2520to%2520fluorides%26jtitle%3DOrg.%2520Lett.%26date%3D2004%26volume%3D6%26spage%3D1465%26epage%3D1468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Fujii, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashiguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uematsu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikariya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noyori, R.</span><span> </span><span class="NLM_article-title">Ruthenium (II)-catalyzed asymmetric transfer hydrogenation of ketones using a formic acid–triethylamine mixture</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">2521</span><span class="NLM_x">–</span> <span class="NLM_lpage">2522</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja954126l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=2521-2522&author=A.+Fujiiauthor=S.+Hashiguchiauthor=N.+Uematsuauthor=T.+Ikariyaauthor=R.+Noyori&title=Ruthenium+%28II%29-catalyzed+asymmetric+transfer+hydrogenation+of+ketones+using+a+formic+acid%E2%80%93triethylamine+mixture"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fja954126l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja954126l%26sid%3Dliteratum%253Aachs%26aulast%3DFujii%26aufirst%3DA.%26aulast%3DHashiguchi%26aufirst%3DS.%26aulast%3DUematsu%26aufirst%3DN.%26aulast%3DIkariya%26aufirst%3DT.%26aulast%3DNoyori%26aufirst%3DR.%26atitle%3DRuthenium%2520%2528II%2529-catalyzed%2520asymmetric%2520transfer%2520hydrogenation%2520of%2520ketones%2520using%2520a%2520formic%2520acid%25E2%2580%2593triethylamine%2520mixture%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1996%26volume%3D118%26spage%3D2521%26epage%3D2522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Middleton, W. J.</span><span> </span><span class="NLM_article-title">New fluorinating reagents. Dialkylaminosulfur fluorides</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">574</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00893a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADyaE2MXhtFWms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1975&pages=574-578&author=W.+J.+Middleton&title=New+fluorinating+reagents.+Dialkylaminosulfur+fluorides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">New fluorinating reagents.  Dialkylaminosulfur fluorides</span></div><div class="casAuthors">Middleton, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">574-8</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Trifluorides R2NSF3 (I; R = Me, Et, Me2CH; or R2N = pyrrolidino) were prepd. by the reaction of R2NSiMe3 with SF4 in FCCl3 at -78°; I reacted with R21NSiMe3 to give R2NSF2NR21 (II; R, R1 = Me, Et; or R12 = piperidino).  I and II were used to fluorinate alcs., aldehydes, or ketones.  E.g., I (R = Et) reacted with Me2CHCH2OH in diglyme at -50 to -78° to give 49% Me2CHCH2F and 21% Me3CF.  EtCHO with I (R = Et) in FCCl3 at 25° gave 80% EtCHF2.  Among ∼23 other compds. fluorinated were: cyclooctanol, BzH, 1-naphthaldehyde, and menthol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2t9GSp_UF5bVg90H21EOLACvtfcHk0ljV2z3BuE3fug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXhtFWms74%253D&md5=d981d018df795514d4f7ffbeb8f4baa8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjo00893a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00893a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiddleton%26aufirst%3DW.%2BJ.%26atitle%3DNew%2520fluorinating%2520reagents.%2520Dialkylaminosulfur%2520fluorides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1975%26volume%3D40%26spage%3D574%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onomura, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, T.</span><span> </span><span class="NLM_article-title">A convenient method for synthesis of enantiomerically enriched methylphenidate from <i>N</i>-methoxycarbonylpiperidine</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol9905046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1999&pages=175-178&author=Y.+Matsumuraauthor=Y.+Kandaauthor=K.+Shiraiauthor=O.+Onomuraauthor=T.+Maki&title=A+convenient+method+for+synthesis+of+enantiomerically+enriched+methylphenidate+from+N-methoxycarbonylpiperidine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1021%2Fol9905046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol9905046%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DShirai%26aufirst%3DK.%26aulast%3DOnomura%26aufirst%3DO.%26aulast%3DMaki%26aufirst%3DT.%26atitle%3DA%2520convenient%2520method%2520for%2520synthesis%2520of%2520enantiomerically%2520enriched%2520methylphenidate%2520from%2520N-methoxycarbonylpiperidine%26jtitle%3DOrg.%2520Lett.%26date%3D1999%26volume%3D1%26spage%3D175%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onomura, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, T.</span><span> </span><span class="NLM_article-title">A convenient method for synthesis of optically active methylphenidate from <i>N</i>-methoxycarbonylpiperidine by utilizing electrochemical oxidation and Evans aldol-type reaction</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7411</span><span class="NLM_x">–</span> <span class="NLM_lpage">7422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2000&pages=7411-7422&author=Y.+Matsumuraauthor=Y.+Kandaauthor=K.+Shiraiauthor=O.+Onomuraauthor=T.+Maki&title=A+convenient+method+for+synthesis+of+optically+active+methylphenidate+from+N-methoxycarbonylpiperidine+by+utilizing+electrochemical+oxidation+and+Evans+aldol-type+reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DShirai%26aufirst%3DK.%26aulast%3DOnomura%26aufirst%3DO.%26aulast%3DMaki%26aufirst%3DT.%26atitle%3DA%2520convenient%2520method%2520for%2520synthesis%2520of%2520optically%2520active%2520methylphenidate%2520from%2520N-methoxycarbonylpiperidine%2520by%2520utilizing%2520electrochemical%2520oxidation%2520and%2520Evans%2520aldol-type%2520reaction%26jtitle%3DTetrahedron%26date%3D2000%26volume%3D56%26spage%3D7411%26epage%3D7422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Pilli, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Böckelmann, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Fatima Alves, C.</span><span> </span><span class="NLM_article-title">The stereochemistry of the addition of chlorotitanium enolates of <i>N</i>-acyl oxazolidin-2-ones to 5- and 6-membered <i>N</i>-acyliminium ions</span> <span class="citation_source-journal">J. Braz. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">634</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.1590%2FS0103-50532001000500007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntlSjtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=634-651&author=R.+A.+Pilliauthor=M.+A.+B%C3%B6ckelmannauthor=C.+de+Fatima+Alves&title=The+stereochemistry+of+the+addition+of+chlorotitanium+enolates+of+N-acyl+oxazolidin-2-ones+to+5-+and+6-membered+N-acyliminium+ions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">The stereochemistry of the addition of chlorotitanium enolates of N-acyl oxazolidin-2-ones to 5- and 6-membered N-acyliminium ions</span></div><div class="casAuthors">Pilli, Ronaldo A.; Bockelmann, Maria Alice; Alves, Conceicao de Fatima</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Brazilian Chemical Society</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">634-651</span>CODEN:
                <span class="NLM_cas:coden">JOCSET</span>;
        ISSN:<span class="NLM_cas:issn">0103-5053</span>.
    
            (<span class="NLM_cas:orgname">Sociedade Brasileira de Quimica</span>)
        </div><div class="casAbstract">The stereoselective addn. of in situ chiral and achiral titanium enolates, derived from the corresponding N-acyloxazolidin-2-ones, to five- and six-membered N-acyl iminium ions afforded 2-substituted pyrrolidines in moderate to good diastereoisomeric ratios (5:1 to 14:1).  Lower diastereoselection was generally obsd. in the formation of the corresponding 2-substituted piperidines.  The stereochem. outcome was found to be modulated by the nature of the cyclic N-acyl iminium ion and of its carbamate and by the N-acyl group in the enolate precursor.  The preferential lk topol. approach seems to be dictated mainly by the minimization of non-bonding interactions between the N-acyl group in the chlorotitanium(IV) enolate and the carbamate and methylene groups in the cyclic N-acyl iminium ion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoiRBXMBIj67Vg90H21EOLACvtfcHk0lg86PPRp62L3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntlSjtbc%253D&md5=f1d203ce5a88afe020df8fc615ad8f34</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1590%2FS0103-50532001000500007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1590%252FS0103-50532001000500007%26sid%3Dliteratum%253Aachs%26aulast%3DPilli%26aufirst%3DR.%2BA.%26aulast%3DB%25C3%25B6ckelmann%26aufirst%3DM.%2BA.%26aulast%3Dde%2BFatima%2BAlves%26aufirst%3DC.%26atitle%3DThe%2520stereochemistry%2520of%2520the%2520addition%2520of%2520chlorotitanium%2520enolates%2520of%2520N-acyl%2520oxazolidin-2-ones%2520to%25205-%2520and%25206-membered%2520N-acyliminium%2520ions%26jtitle%3DJ.%2520Braz.%2520Chem.%2520Soc.%26date%3D2001%26volume%3D12%26spage%3D634%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Kallan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heizer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bencsik, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G. P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span> </span><span class="NLM_article-title">Discovery and SAR of spirochromane Akt inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2410</span><span class="NLM_x">–</span> <span class="NLM_lpage">2414</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2410-2414&author=N.+C.+Kallanauthor=K.+L.+Spencerauthor=J.+F.+Blakeauthor=R.+Xuauthor=J.+Heizerauthor=J.+R.+Bencsikauthor=I.+S.+Mitchellauthor=S.+L.+Gloorauthor=M.+Martinsonauthor=T.+Risomauthor=S.+D.+Grossauthor=T.+H.+Moralesauthor=G.+P.+A.+Vigersauthor=B.+J.+Brandhuberauthor=N.+J.+Skelton&title=Discovery+and+SAR+of+spirochromane+Akt+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKallan%26aufirst%3DN.%2BC.%26aulast%3DSpencer%26aufirst%3DK.%2BL.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DHeizer%26aufirst%3DJ.%26aulast%3DBencsik%26aufirst%3DJ.%2BR.%26aulast%3DMitchell%26aufirst%3DI.%2BS.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DGross%26aufirst%3DS.%2BD.%26aulast%3DMorales%26aufirst%3DT.%2BH.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520spirochromane%2520Akt%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2410%26epage%3D2414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="note"><p class="first last">The inhibition against a panel of kinases was determined at Upstate, Charlottesville, VA.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="note"><p class="first last">The crystallographic data described have been deposited with the RCSB Protein Data Bank (PDB code for <b>28</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EKL">4EKL</a>).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Milletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storchi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goracci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span> </span><span class="NLM_article-title">Extending p<i>K</i><sub><i>a</i></sub> prediction accuracy: high-throughput p<i>K</i><sub><i>a</i></sub> measurements to understand p<i>K</i><sub><i>a</i></sub> modulation of new chemical series</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4270</span><span class="NLM_x">–</span> <span class="NLM_lpage">4279</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.1016%2Fj.ejmech.2010.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=20633962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=4270-4279&author=F.+Millettiauthor=L.+Storchiauthor=L.+Goracciauthor=S.+Bendelsauthor=B.+Wagnerauthor=M.+Kansyauthor=G.+Cruciani&title=Extending+pKa+prediction+accuracy%3A+high-throughput+pKa+measurements+to+understand+pKa+modulation+of+new+chemical+series"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Extending pKa prediction accuracy: High-throughput pKa measurements to understand pKa modulation of new chemical series</span></div><div class="casAuthors">Milletti, Francesca; Storchi, Loriano; Goracci, Laura; Bendels, Stefanie; Wagner, Bjoern; Kansy, Manfred; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4270-4279</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We have recently developed a tool, MoKα, to predict the pKa of org. compds. using a large dataset of over 26,500 literature pKa values as a training set.  However, predicting accurately pKa (<0.5 pH units) remains challenging for novel series, and this can be a drawback in the optimization of activity and ADME properties of lead compds.  To address this issue it is important to expand our knowledge of pKa determinants, therefore we have conducted high-throughput pKa measurements by using Spectral Gradient Anal. (SGA) on novel series of compds. selected from vendor databases.  Here we report our findings on the effect of specific chem. groups and steric constraints on the pKa of common functionalities in medicinal chem., such as amines, sulfonamides, and amides.  Furthermore, we report the pKa of ionizable groups that were not well represented in the database of literature pKa of MoKα, such as hydrazide derivs.  These findings helped us to enhance MoKα, which is here benchmarked on a set of exptl. pKa values from the Roche inhouse library (N = 5581; RMSE = 1.09; R2 = 0.82).  The accuracy of the predictions was greatly improved (RMSE = 0.49, R2 = 0.96) after training the software by using the automated tool Kibitzer with 6226 pK a values taken from a different set of Roche compds. appropriately selected, and this demonstrates the value of using high-throughput pKa measurements to expand the training set of pKa values used by the software MoKα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxQ9UJOAhB-rVg90H21EOLACvtfcHk0lhtmHbPuikzNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D&md5=e4c579032df7fa37ec3551c69a09257a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DMilletti%26aufirst%3DF.%26aulast%3DStorchi%26aufirst%3DL.%26aulast%3DGoracci%26aufirst%3DL.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DExtending%2520pKa%2520prediction%2520accuracy%253A%2520high-throughput%2520pKa%2520measurements%2520to%2520understand%2520pKa%2520modulation%2520of%2520new%2520chemical%2520series%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D4270%26epage%3D4279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourbeau, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wohlhieter, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monenschein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rider, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lofgren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tominey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamane, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viswanadhan, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hungate, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span> </span><span class="NLM_article-title">2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1652</span><span class="NLM_x">–</span> <span class="NLM_lpage">1656</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1652-1656&author=Q.+Zengauthor=M.+P.+Bourbeauauthor=G.+E.+Wohlhieterauthor=G.+Yaoauthor=H.+Monenscheinauthor=J.+T.+Riderauthor=M.+R.+Leeauthor=S.+Zhangauthor=J.+Lofgrenauthor=D.+Freemanauthor=C.+Liauthor=E.+Tomineyauthor=X.+Huangauthor=D.+Hoffmanauthor=H.+Yamaneauthor=A.+S.+Taskerauthor=C.+Dominguezauthor=V.+N.+Viswanadhanauthor=R.+Hungateauthor=X.+Zhang&title=2-Aminothiadiazole+inhibitors+of+AKT1+as+potential+cancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DBourbeau%26aufirst%3DM.%2BP.%26aulast%3DWohlhieter%26aufirst%3DG.%2BE.%26aulast%3DYao%26aufirst%3DG.%26aulast%3DMonenschein%26aufirst%3DH.%26aulast%3DRider%26aufirst%3DJ.%2BT.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLofgren%26aufirst%3DJ.%26aulast%3DFreeman%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTominey%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DYamane%26aufirst%3DH.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3D2-Aminothiadiazole%2520inhibitors%2520of%2520AKT1%2520as%2520potential%2520cancer%2520therapeutics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1652%26epage%3D1656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Han, E. K-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leverson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGonigal1, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span> </span><span class="NLM_article-title">Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5655</span><span class="NLM_x">–</span> <span class="NLM_lpage">5661</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=5655-5661&author=E.+K-H.+Hanauthor=J.+D.+Leversonauthor=T.+McGonigal1author=O.+J.+Shahauthor=K.+W.+Woodsauthor=T.+Hunterauthor=V.+L.+Girandaauthor=Y.+Luo&title=Akt+inhibitor+A-443654+induces+rapid+Akt+Ser-473+phosphorylation+independent+of+mTORC1+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DE.%2BK-H.%26aulast%3DLeverson%26aufirst%3DJ.%2BD.%26aulast%3DMcGonigal1%26aufirst%3DT.%26aulast%3DShah%26aufirst%3DO.%2BJ.%26aulast%3DWoods%26aufirst%3DK.%2BW.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DLuo%26aufirst%3DY.%26atitle%3DAkt%2520inhibitor%2520A-443654%2520induces%2520rapid%2520Akt%2520Ser-473%2520phosphorylation%2520independent%2520of%2520mTORC1%2520inhibition%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D5655%26epage%3D5661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Rhodes, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerding, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duckett, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberwein, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knick, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansing, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConnell, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahana, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geske, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleymenova, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhry, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leber, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minthorn, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strum, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span> </span><span class="NLM_article-title">Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">2366</span><span class="NLM_x">–</span> <span class="NLM_lpage">2374</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=2366-2374&author=N.+Rhodesauthor=D.+A.+Heerdingauthor=D.+R.+Duckettauthor=D.+J.+Eberweinauthor=V.+B.+Knickauthor=T.+J.+Lansingauthor=R.+T.+McConnellauthor=T.+M.+Gilmerauthor=S.+Y.+Zhangauthor=K.+Robellauthor=J.+A.+Kahanaauthor=R.+S.+Geskeauthor=E.+V.+Kleymenovaauthor=A.+E.+Choudhryauthor=Z.+Laiauthor=J.+D.+Leberauthor=E.+A.+Minthornauthor=S.+L.+Strumauthor=E.+R.+Woodauthor=P.+S.+Huangauthor=R.+A.+Copelandauthor=R.+Kumar&title=Characterization+of+an+Akt+kinase+inhibitor+with+potent+pharmacodynamic+and+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DDuckett%26aufirst%3DD.%2BR.%26aulast%3DEberwein%26aufirst%3DD.%2BJ.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLansing%26aufirst%3DT.%2BJ.%26aulast%3DMcConnell%26aufirst%3DR.%2BT.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DRobell%26aufirst%3DK.%26aulast%3DKahana%26aufirst%3DJ.%2BA.%26aulast%3DGeske%26aufirst%3DR.%2BS.%26aulast%3DKleymenova%26aufirst%3DE.%2BV.%26aulast%3DChoudhry%26aufirst%3DA.%2BE.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DMinthorn%26aufirst%3DE.%2BA.%26aulast%3DStrum%26aufirst%3DS.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DHuang%26aufirst%3DP.%2BS.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520an%2520Akt%2520kinase%2520inhibitor%2520with%2520potent%2520pharmacodynamic%2520and%2520antitumor%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D2366%26epage%3D2374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Grimshaw, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaton, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seavers, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span> </span><span class="NLM_article-title">AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1100</span><span class="NLM_x">–</span> <span class="NLM_lpage">1110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.1158%2F1535-7163.MCT-09-0986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=20423992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsleksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1100-1110&author=K.+M.+Grimshawauthor=L.+J.+Hunterauthor=T.+A.+Yapauthor=S.+P.+Heatonauthor=M.+I.+Waltonauthor=S.+J.+Woodheadauthor=L.+Fazalauthor=M.+Reuleauthor=T.+G.+Daviesauthor=L.+C.+Seaversauthor=V.+Lockauthor=J.+F.+Lyonsauthor=N.+T.+Thompsonauthor=P.+Workmanauthor=M.+D.+Garrett&title=AT7867+is+a+potent+and+oral+inhibitor+of+AKT+and+p70+S6+kinase+that+induces+pharmacodynamic+changes+and+inhibits+human+tumor+xenograft+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth</span></div><div class="casAuthors">Grimshaw, Kyla M.; Hunter, Lisa-Jane K.; Yap, Timothy A.; Heaton, Simon P.; Walton, Mike I.; Woodhead, Steven J.; Fazal, Lynsey; Reule, Matthias; Davies, Thomas G.; Seavers, Lisa C.; Lock, Victoria; Lyons, John F.; Thompson, Neil T.; Workman, Paul; Garrett, Michelle D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1100-1110</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The serine/threonine kinase AKT plays a pivotal role in signal transduction events involved in malignant transformation and chemoresistance and is an attractive target for the development of cancer therapeutics.  Fragment-based lead discovery, combined with structure-based drug design, has recently identified AT7867 as a novel and potent inhibitor of both AKT and the downstream kinase p70 S6 kinase (p70S6K) and also of protein kinase A.  This ATP-competitive small mol. potently inhibits both AKT and p70S6K activity at the cellular level, as measured by inhibition of GSK3β and S6 ribosomal protein phosphorylation, and also causes growth inhibition in a range of human cancer cell lines as a single agent.  Induction of apoptosis was detected by multiple methods in tumor cells following AT7867 treatment.  Administration of AT7867 (90 mg/kg p.o. or 20 mg/kg i.p.) to athymic mice implanted with the PTEN-deficient U87MG human glioblastoma xenograft model caused inhibition of phosphorylation of downstream substrates of both AKT and p70S6K and induction of apoptosis, confirming the observations made in vitro.  These doses of AT7867 also resulted in inhibition of human tumor growth in PTEN-deficient xenograft models.  These data suggest that the novel strategy of AKT and p70S6K blockade may have therapeutic value and supports further evaluation of AT7867 as a single-agent anticancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7gZJRET_nqrVg90H21EOLACvtfcHk0li5beDt14ChcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsleksrs%253D&md5=9ac4069c4cf2833d2e2e5e0f88e6d935</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0986%26sid%3Dliteratum%253Aachs%26aulast%3DGrimshaw%26aufirst%3DK.%2BM.%26aulast%3DHunter%26aufirst%3DL.%2BJ.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DHeaton%26aufirst%3DS.%2BP.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DWoodhead%26aufirst%3DS.%2BJ.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DSeavers%26aufirst%3DL.%2BC.%26aulast%3DLock%26aufirst%3DV.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26atitle%3DAT7867%2520is%2520a%2520potent%2520and%2520oral%2520inhibitor%2520of%2520AKT%2520and%2520p70%2520S6%2520kinase%2520that%2520induces%2520pharmacodynamic%2520changes%2520and%2520inhibits%2520human%2520tumor%2520xenograft%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1100%26epage%3D1110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G. P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span> </span><span class="NLM_article-title">An ATP-site on-off switch that restricts phosphatase accessibility of Akt</span> <span class="citation_source-journal">Sci. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">ra37</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.1126%2Fscisignal.2002618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=22569334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A280%3ADC%252BC38nhsFGgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=ra37&author=K.+Linauthor=J.+Linauthor=W.-I.+Wuauthor=J.+Ballardauthor=B.+B.+Leeauthor=S.+L.+Gloorauthor=G.+P.+A.+Vigersauthor=T.+H.+Moralesauthor=L.+S.+Friedmanauthor=N.+J.+Skeltonauthor=B.+J.+Brandhuber&title=An+ATP-site+on-off+switch+that+restricts+phosphatase+accessibility+of+Akt"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An ATP-site on-off switch that restricts phosphatase accessibility of Akt</span></div><div class="casAuthors">Lin Kui; Lin Jie; Wu Wen-I; Ballard Joshua; Lee Brian B; Gloor Susan L; Vigers Guy P A; Morales Tony H; Friedman Lori S; Skelton Nicholas; Brandhuber Barbara J</div><div class="citationInfo"><span class="NLM_cas:title">Science signaling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">223</span>),
    <span class="NLM_cas:pages">ra37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The protein serine-threonine kinase Akt undergoes a substantial conformational change upon activation, which is induced by the phosphorylation of two critical regulatory residues, threonine 308 and serine 473.  Paradoxically, treating cells with adenosine 5'-triphosphate (ATP)-competitive inhibitors of Akt results in increased phosphorylation of both residues.  We show that binding of ATP-competitive inhibitors stabilized a conformation in which both phosphorylated sites were inaccessible to phosphatases.  ATP binding also produced this protection of the phosphorylated sites, whereas interaction with its hydrolysis product adenosine 5'-diphosphate (ADP) or allosteric Akt inhibitors resulted in increased accessibility of these phosphorylated residues.  ATP-competitive inhibitors mimicked ATP by targeting active Akt.  Forms of Akt activated by an oncogenic mutation or myristoylation were more potently inhibited by the ATP-competitive inhibitors than was wild-type Akt.  These data support a new model of kinase regulation, wherein nucleotides modulate an on-off switch in Akt through conformational changes, which is disrupted by ATP-competitive inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnztGy5MRl7DToTC3aBaesfW6udTcc2eaBYPBwcpLpDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38nhsFGgsA%253D%253D&md5=3bfded195b532ddc579e74cb830437b3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2002618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2002618%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DW.-I.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DB.%2BB.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DMorales%26aufirst%3DT.%2BH.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26atitle%3DAn%2520ATP-site%2520on-off%2520switch%2520that%2520restricts%2520phosphatase%2520accessibility%2520of%2520Akt%26jtitle%3DSci.%2520Signaling%26date%3D2012%26volume%3D5%26spage%3Dra37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Zaki, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemeth, J. A.</span><span> </span><span class="NLM_article-title">CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">592</span><span class="NLM_x">–</span> <span class="NLM_lpage">595</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.1002%2Fijc.20270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=15239138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsFequro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2004&pages=592-595&author=M.+H.+Zakiauthor=J.+A.+Nemeth&title=CNTO+328%2C+a+monoclonal+antibody+to+IL-6%2C+inhibits+human+tumor-induced+cachexia+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice</span></div><div class="casAuthors">Zaki, Mohamed H.; Nemeth, Jeffrey A.; Trikha, Mohit</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">592-595</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">IL-6 is a multifunctional cytokine implicated in several cancers.  IL-6 is a growth factor for certain tumors and contributes to drug resistance, cachexia and bone resorption.  Cachexia is characterized by progressive wt. loss and depletion of host reserves of adipose tissue and skeletal muscle.  We have developed CNTO 328 (cCLB8), a human-mouse chimeric MAb to IL-6 (Kd approx. 10-12 M) that inhibits IL-6 function.  A phase I study with CNTO 328 in multiple myeloma patients demonstrated that the antibody was safe and had a circulating half-life of approx. 17 days.  Since IL-6 is implicated in cachexia, we hypothesized that CNTO 328 could inhibit tumor-induced cachexia.  We used 2 human tumor-induced cachexia models in nude mice.  In the first model, human melanoma cells were inoculated in female nude mice.  Control treated animals lost 19% (±7.7%) body wt. from day 0 to day 31, whereas CNTO 328 (10 mg/kg)-treated animals lost only 1.5% (±1.3%) body wt. from day 0 to day 31 (p = 0.023).  In the second cachexia model, human prostate tumor cells were injected into male nude mice.  By day 29, control treated animals lost 6% (±3.5%) body wt., whereas CNTO 328 (10 mg/kg)-treated animals gained 7% (±4%) body wt. (p = 0.01).  Since CNTO 328 blocks human IL-6 but not mouse IL-6, the data indicate that tumor cell-secreted IL-6 directly contributes to body wt. loss, highlighting the potential role for CNTO 328 as an anticachectic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolKIGMjJm-t7Vg90H21EOLACvtfcHk0lhORDKSNs91dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsFequro%253D&md5=2c102c2fd9f8b874d57a8307a3459955</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fijc.20270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.20270%26sid%3Dliteratum%253Aachs%26aulast%3DZaki%26aufirst%3DM.%2BH.%26aulast%3DNemeth%26aufirst%3DJ.%2BA.%26atitle%3DCNTO%2520328%252C%2520a%2520monoclonal%2520antibody%2520to%2520IL-6%252C%2520inhibits%2520human%2520tumor-induced%2520cachexia%2520in%2520nude%2520mice%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2004%26volume%3D111%26spage%3D592%26epage%3D595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2a','cit2b','cit2c'],'ref3':['cit3'],'ref4':['cit4a','cit4b','cit4c'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b','cit13c'],'ref14':['cit14'],'ref15':[],'ref16':[],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 84 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Svenja Wiechmann, Benjamin Ruprecht, Theresa Siekmann, Runsheng Zheng, Martin Frejno, Elena Kunold, Thomas Bajaj, Daniel P. Zolg, Stephan A. Sieber, Nils C. Gassen, <span class="NLM_string-name hlFld-ContribAuthor">Bernhard Kuster</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical Phosphoproteomics Sheds New Light on the Targets and Modes of Action of AKT Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 631-641. <a href="https://doi.org/10.1021/acschembio.0c00872" title="DOI URL">https://doi.org/10.1021/acschembio.0c00872</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.0c00872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.0c00872%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DChemical%252BPhosphoproteomics%252BSheds%252BNew%252BLight%252Bon%252Bthe%252BTargets%252Band%252BModes%252Bof%252BAction%252Bof%252BAKT%252BInhibitors%26aulast%3DWiechmann%26aufirst%3DSvenja%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D09112020%26date%3D12032021%26date%3D23032021%26volume%3D16%26issue%3D4%26spage%3D631%26epage%3D641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sayumi Yamazoe, Jeffrey Tom, Yue Fu, Wenqiong Wu, Liang Zeng, Changlei Sun, Qi Liu, Jie Lin, Kui Lin, Wayne J. Fairbrother, <span class="NLM_string-name hlFld-ContribAuthor">Steven T. Staben</span>. </span><span class="cited-content_cbyCitation_article-title">Heterobifunctional Molecules Induce Dephosphorylation of Kinases–A Proof of Concept Study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (6)
                                     , 2807-2813. <a href="https://doi.org/10.1021/acs.jmedchem.9b01167" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01167</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01167%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHeterobifunctional%252BMolecules%252BInduce%252BDephosphorylation%252Bof%252BKinases%2525E2%252580%252593A%252BProof%252Bof%252BConcept%252BStudy%26aulast%3DYamazoe%26aufirst%3DSayumi%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D24072019%26date%3D14012020%26date%3D24122019%26volume%3D63%26issue%3D6%26spage%3D2807%26epage%3D2813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaowu Dong, Wenhu Zhan, Mengting Zhao, Jinxin Che, Xiaoyang Dai, Yizhe Wu, Lei Xu, Yubo Zhou, Yanmei Zhao, Tian Tian, Gang Cheng, Zegao Jin, Jia Li, Yanfei Shao, Qiaojun He, Bo Yang, Qinjie Weng, <span class="NLM_string-name hlFld-ContribAuthor">Yongzhou Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (15)
                                     , 7264-7288. <a href="https://doi.org/10.1021/acs.jmedchem.9b00891" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00891</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00891%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B3%25252C4%25252C6-Trisubstituted%252BPiperidine%252BDerivatives%252Bas%252BOrally%252BActive%25252C%252BLow%252BhERG%252BBlocking%252BAkt%252BInhibitors%252Bvia%252BConformational%252BRestriction%252Band%252BStructure-Based%252BDesign%26aulast%3DDong%26aufirst%3DXiaowu%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03062019%26date%3D24072019%26date%3D12072019%26volume%3D62%26issue%3D15%26spage%3D7264%26epage%3D7288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jia-Hong Jian, Chih-Lung Hsu, Jin-Fong Syu, Ting-Shen Kuo, Ming-Kang Tsai, Ping-Yu Wu, <span class="NLM_string-name hlFld-ContribAuthor">Hsyueh-Liang Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Access to β2-Amino Acids via Enantioselective 1,4-Arylation of β-Nitroacrylates Catalyzed by Chiral Rhodium Catalysts. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (19)
                                     , 12184-12191. <a href="https://doi.org/10.1021/acs.joc.8b00586" title="DOI URL">https://doi.org/10.1021/acs.joc.8b00586</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b00586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b00586%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAccess%252Bto%252B%2525CE%2525B22-Amino%252BAcids%252Bvia%252BEnantioselective%252B1%25252C4-Arylation%252Bof%252B%2525CE%2525B2-Nitroacrylates%252BCatalyzed%252Bby%252BChiral%252BRhodium%252BCatalysts%26aulast%3DJian%26aufirst%3DJia-Hong%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D05032018%26date%3D12092018%26date%3D29082018%26volume%3D83%26issue%3D19%26spage%3D12184%26epage%3D12191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chong  Han</span>, <span class="hlFld-ContribAuthor ">Scott  Savage</span>, <span class="hlFld-ContribAuthor ">Mohammad  Al-Sayah</span>, <span class="hlFld-ContribAuthor ">Herbert  Yajima</span>, <span class="hlFld-ContribAuthor ">Travis  Remarchuk</span>, <span class="hlFld-ContribAuthor ">Reinhard  Reents</span>, <span class="hlFld-ContribAuthor ">Beat  Wirz</span>, <span class="hlFld-ContribAuthor ">Hans  Iding</span>, <span class="hlFld-ContribAuthor ">Stephan  Bachmann</span>, <span class="hlFld-ContribAuthor ">Serena M.  Fantasia</span>, <span class="hlFld-ContribAuthor ">Michelangelo  Scalone</span>, <span class="hlFld-ContribAuthor ">André  Hell</span>, <span class="hlFld-ContribAuthor ">Pirmin  Hidber</span>, and <span class="hlFld-ContribAuthor ">Francis  Gosselin</span>  . </span><span class="cited-content_cbyCitation_article-title">Asymmetric Synthesis of Akt Kinase Inhibitor Ipatasertib. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2017,</strong> <em>19 </em>
                                    (18)
                                     , 4806-4809. <a href="https://doi.org/10.1021/acs.orglett.7b02228" title="DOI URL">https://doi.org/10.1021/acs.orglett.7b02228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.7b02228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.7b02228%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DAsymmetric%252BSynthesis%252Bof%252BAkt%252BKinase%252BInhibitor%252BIpatasertib%26aulast%3DHan%26aufirst%3DChong%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D21072017%26date%3D31082017%26date%3D15092017%26volume%3D19%26issue%3D18%26spage%3D4806%26epage%3D4809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (22)
                                     , 10030-10066. <a href="https://doi.org/10.1021/acs.jmedchem.6b00618" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BBrain%252BCancer%26aulast%3DHeffron%26aufirst%3DTimothy%2BP.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D21042016%26date%3D03082016%26date%3D23112016%26date%3D14072016%26volume%3D59%26issue%3D22%26spage%3D10030%26epage%3D10066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Travis  Remarchuk</span>, <span class="hlFld-ContribAuthor ">Frederic  St-Jean</span>, <span class="hlFld-ContribAuthor ">Diane  Carrera</span>, <span class="hlFld-ContribAuthor ">Scott  Savage</span>, <span class="hlFld-ContribAuthor ">Herbert  Yajima</span>, <span class="hlFld-ContribAuthor ">Brian  Wong</span>, <span class="hlFld-ContribAuthor ">Srinivasan  Babu</span>, <span class="hlFld-ContribAuthor ">Alan  Deese</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Stults</span>, <span class="hlFld-ContribAuthor ">Michael W.  Dong</span>, <span class="hlFld-ContribAuthor ">David  Askin</span>, <span class="hlFld-ContribAuthor ">Jonathan W.  Lane</span>, and <span class="hlFld-ContribAuthor ">Keith L.  Spencer</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of Akt Inhibitor Ipatasertib. Part 2. Total Synthesis and First Kilogram Scale-up. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2014,</strong> <em>18 </em>
                                    (12)
                                     , 1652-1666. <a href="https://doi.org/10.1021/op500270z" title="DOI URL">https://doi.org/10.1021/op500270z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/op500270z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fop500270z%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DSynthesis%252Bof%252BAkt%252BInhibitor%252BIpatasertib.%252BPart%252B2.%252BTotal%252BSynthesis%252Band%252BFirst%252BKilogram%252BScale-up%26aulast%3DRemarchuk%26aufirst%3DTravis%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D20082014%26date%3D19112014%26date%3D19122014%26date%3D02112014%26volume%3D18%26issue%3D12%26spage%3D1652%26epage%3D1666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonathan W.  Lane</span>, <span class="hlFld-ContribAuthor ">Keith L.  Spencer</span>, <span class="hlFld-ContribAuthor ">Sagar R.  Shakya</span>, <span class="hlFld-ContribAuthor ">Nicholas C.  Kallan</span>, <span class="hlFld-ContribAuthor ">Peter J.  Stengel</span>, and <span class="hlFld-ContribAuthor ">Travis  Remarchuk</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of Akt Inhibitor Ipatasertib. Part 1. Route Scouting and Early Process Development of a Challenging Cyclopentylpyrimidine Intermediate. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2014,</strong> <em>18 </em>
                                    (12)
                                     , 1641-1651. <a href="https://doi.org/10.1021/op500271w" title="DOI URL">https://doi.org/10.1021/op500271w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/op500271w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fop500271w%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DSynthesis%252Bof%252BAkt%252BInhibitor%252BIpatasertib.%252BPart%252B1.%252BRoute%252BScouting%252Band%252BEarly%252BProcess%252BDevelopment%252Bof%252Ba%252BChallenging%252BCyclopentylpyrimidine%252BIntermediate%26aulast%3DLane%26aufirst%3DJonathan%2BW.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D20082014%26date%3D19112014%26date%3D19122014%26date%3D26102014%26volume%3D18%26issue%3D12%26spage%3D1641%26epage%3D1651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Travis  Remarchuk</span>, <span class="hlFld-ContribAuthor ">Srinivasan  Babu</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Stults</span>, <span class="hlFld-ContribAuthor ">Antonio  Zanotti-Gerosa</span>, <span class="hlFld-ContribAuthor ">Stephen  Roseblade</span>, <span class="hlFld-ContribAuthor ">Shaohui  Yang</span>, <span class="hlFld-ContribAuthor ">Ping  Huang</span>, <span class="hlFld-ContribAuthor ">Chunbo  Sha</span>, and <span class="hlFld-ContribAuthor ">Youchu  Wang</span>  . </span><span class="cited-content_cbyCitation_article-title">An Efficient Catalytic Asymmetric Synthesis of a β2-Amino Acid on Multikilogram Scale. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2014,</strong> <em>18 </em>
                                    (1)
                                     , 135-141. <a href="https://doi.org/10.1021/op4002966" title="DOI URL">https://doi.org/10.1021/op4002966</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/op4002966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fop4002966%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DAn%252BEfficient%252BCatalytic%252BAsymmetric%252BSynthesis%252Bof%252Ba%252B%2525CE%2525B22-Amino%252BAcid%252Bon%252BMultikilogram%252BScale%26aulast%3DRemarchuk%26aufirst%3DTravis%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D17102013%26date%3D26122013%26date%3D17012014%26volume%3D18%26issue%3D1%26spage%3D135%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fiona  Pachl</span>, <span class="hlFld-ContribAuthor ">Patrik  Plattner</span>, <span class="hlFld-ContribAuthor ">Benjamin  Ruprecht</span>, <span class="hlFld-ContribAuthor ">Guillaume  Médard</span>, <span class="hlFld-ContribAuthor ">Norbert  Sewald</span>, and <span class="hlFld-ContribAuthor ">Bernhard  Kuster</span>  . </span><span class="cited-content_cbyCitation_article-title">Characterization of a Chemical Affinity Probe Targeting Akt Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Proteome Research</span><span> <strong>2013,</strong> <em>12 </em>
                                    (8)
                                     , 3792-3800. <a href="https://doi.org/10.1021/pr400455j" title="DOI URL">https://doi.org/10.1021/pr400455j</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/pr400455j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fpr400455j%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Proteome%2520Research%26atitle%3DCharacterization%252Bof%252Ba%252BChemical%252BAffinity%252BProbe%252BTargeting%252BAkt%252BKinases%26aulast%3DPachl%26aufirst%3DFiona%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D15052013%26date%3D03072013%26date%3D02082013%26date%3D25062013%26volume%3D12%26issue%3D8%26spage%3D3792%26epage%3D3800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matt  Addie</span>, <span class="hlFld-ContribAuthor ">Peter  Ballard</span>, <span class="hlFld-ContribAuthor ">David  Buttar</span>, <span class="hlFld-ContribAuthor ">Claire  Crafter</span>, <span class="hlFld-ContribAuthor ">Gordon  Currie</span>, <span class="hlFld-ContribAuthor ">Barry R.  Davies</span>, <span class="hlFld-ContribAuthor ">Judit  Debreczeni</span>, <span class="hlFld-ContribAuthor ">Hannah  Dry</span>, <span class="hlFld-ContribAuthor ">Philippa  Dudley</span>, <span class="hlFld-ContribAuthor ">Ryan  Greenwood</span>, <span class="hlFld-ContribAuthor ">Paul D.  Johnson</span>, <span class="hlFld-ContribAuthor ">Jason G.  Kettle</span>, <span class="hlFld-ContribAuthor ">Clare  Lane</span>, <span class="hlFld-ContribAuthor ">Gillian  Lamont</span>, <span class="hlFld-ContribAuthor ">Andrew  Leach</span>, <span class="hlFld-ContribAuthor ">Richard W. A.  Luke</span>, <span class="hlFld-ContribAuthor ">Jeff  Morris</span>, <span class="hlFld-ContribAuthor ">Donald  Ogilvie</span>, <span class="hlFld-ContribAuthor ">Ken  Page</span>, <span class="hlFld-ContribAuthor ">Martin  Pass</span>, <span class="hlFld-ContribAuthor ">Stuart  Pearson</span>, and <span class="hlFld-ContribAuthor ">Linette  Ruston</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (5)
                                     , 2059-2073. <a href="https://doi.org/10.1021/jm301762v" title="DOI URL">https://doi.org/10.1021/jm301762v</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301762v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301762v%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-Amino-N-%25255B%2525281S%252529-1-%2525284-chlorophenyl%252529-3-hydroxypropyl%25255D-1-%2525287H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-yl%252529piperidine-4-carboxamide%252B%252528AZD5363%252529%25252C%252Ban%252BOrally%252BBioavailable%25252C%252BPotent%252BInhibitor%252Bof%252BAkt%252BKinases%26aulast%3DAddie%26aufirst%3DMatt%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D29112012%26date%3D26022013%26date%3D14032013%26date%3D11022013%26volume%3D56%26issue%3D5%26spage%3D2059%26epage%3D2073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rebecca  Dent</span>, <span class="hlFld-ContribAuthor ">Mafalda  Oliveira</span>, <span class="hlFld-ContribAuthor ">Steven J.  Isakoff</span>, <span class="hlFld-ContribAuthor ">Seock-Ah  Im</span>, <span class="hlFld-ContribAuthor ">Marc  Espié</span>, <span class="hlFld-ContribAuthor ">Sibel  Blau</span>, <span class="hlFld-ContribAuthor ">Antoinette R.  Tan</span>, <span class="hlFld-ContribAuthor ">Cristina  Saura</span>, <span class="hlFld-ContribAuthor ">Matthew J.  Wongchenko</span>, <span class="hlFld-ContribAuthor ">Na  Xu</span>, <span class="hlFld-ContribAuthor ">Denise  Bradley</span>, <span class="hlFld-ContribAuthor ">Sarah-Jayne  Reilly</span>, <span class="hlFld-ContribAuthor ">Aruna  Mani</span>, <span class="hlFld-ContribAuthor ">Sung-Bae  Kim</span>, , <span class="hlFld-ContribAuthor ">K. S.  Lee</span>, <span class="hlFld-ContribAuthor ">J. H.  Sohn</span>, <span class="hlFld-ContribAuthor ">J. H.  Kim</span>, <span class="hlFld-ContribAuthor ">J. H.  Seo</span>, <span class="hlFld-ContribAuthor ">J. S.  Kim</span>, <span class="hlFld-ContribAuthor ">S.  Park</span>, <span class="hlFld-ContribAuthor ">M.  Velez</span>, <span class="hlFld-ContribAuthor ">S.  Dakhil</span>, <span class="hlFld-ContribAuthor ">S.  Hurvitz</span>, <span class="hlFld-ContribAuthor ">V.  Valero</span>, <span class="hlFld-ContribAuthor ">G.  Vidal</span>, <span class="hlFld-ContribAuthor ">R.  Figlin</span>, <span class="hlFld-ContribAuthor ">M. A. K.  Allison</span>, <span class="hlFld-ContribAuthor ">D.  Chan</span>, <span class="hlFld-ContribAuthor ">M.  Cobleigh</span>, <span class="hlFld-ContribAuthor ">V.  Hansen</span>, <span class="hlFld-ContribAuthor ">N.  Iannotti</span>, <span class="hlFld-ContribAuthor ">W.  Lawler</span>, <span class="hlFld-ContribAuthor ">M.  Salkini</span>, <span class="hlFld-ContribAuthor ">L.  Seigel</span>, <span class="hlFld-ContribAuthor ">G.  Romieu</span>, <span class="hlFld-ContribAuthor ">M.  Debled</span>, <span class="hlFld-ContribAuthor ">C.  Levy</span>, <span class="hlFld-ContribAuthor ">A.  Hardy-Bessard</span>, <span class="hlFld-ContribAuthor ">S.  Guiu</span>, <span class="hlFld-ContribAuthor ">L. Garcia  Estevez</span>, <span class="hlFld-ContribAuthor ">R.  Villanueva</span>, <span class="hlFld-ContribAuthor ">A. Gonzalez  Martin</span>, <span class="hlFld-ContribAuthor ">P. Sanchez  Rovira</span>, <span class="hlFld-ContribAuthor ">A.  Montaño</span>, <span class="hlFld-ContribAuthor ">M. I. Calvo  Plaza</span>, <span class="hlFld-ContribAuthor ">J. A. García  Saenz</span>, <span class="hlFld-ContribAuthor ">I.  Garau</span>, <span class="hlFld-ContribAuthor ">B.  Bermejo</span>, <span class="hlFld-ContribAuthor ">E. Vega  Alonso</span>, <span class="hlFld-ContribAuthor ">H.-C.  Wang</span>, <span class="hlFld-ContribAuthor ">C.-S.  Huang</span>, <span class="hlFld-ContribAuthor ">S.-C.  Chen</span>, <span class="hlFld-ContribAuthor ">Y.-H.  Chen</span>, <span class="hlFld-ContribAuthor ">L.-M.  Tseng</span>, <span class="hlFld-ContribAuthor ">A.  Wong</span>, <span class="hlFld-ContribAuthor ">C. S. P.  Ang</span>, <span class="hlFld-ContribAuthor ">M.  De Laurentiis</span>, <span class="hlFld-ContribAuthor ">P. F.  Conte</span>, <span class="hlFld-ContribAuthor ">F.  De Braud</span>, <span class="hlFld-ContribAuthor ">F.  Montemurro</span>, <span class="hlFld-ContribAuthor ">L.  Gianni</span>, <span class="hlFld-ContribAuthor ">L.  Dirix</span>. </span><span class="cited-content_cbyCitation_article-title">Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Breast Cancer Research and Treatment</span><span> <strong>2021,</strong> <em>4 </em><a href="https://doi.org/10.1007/s10549-021-06143-5" title="DOI URL">https://doi.org/10.1007/s10549-021-06143-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10549-021-06143-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10549-021-06143-5%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Research%2520and%2520Treatment%26atitle%3DFinal%252Bresults%252Bof%252Bthe%252Bdouble-blind%252Bplacebo-controlled%252Brandomized%252Bphase%252B2%252BLOTUS%252Btrial%252Bof%252Bfirst-line%252Bipatasertib%252Bplus%252Bpaclitaxel%252Bfor%252Binoperable%252Blocally%252Badvanced%25252Fmetastatic%252Btriple-negative%252Bbreast%252Bcancer%26aulast%3DDent%26aufirst%3DRebecca%26date%3D2021%26date%3D2021%26volume%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher  Sweeney</span>, <span class="hlFld-ContribAuthor ">Sergio  Bracarda</span>, <span class="hlFld-ContribAuthor ">Cora N  Sternberg</span>, <span class="hlFld-ContribAuthor ">Kim N  Chi</span>, <span class="hlFld-ContribAuthor ">David  Olmos</span>, <span class="hlFld-ContribAuthor ">Shahneen  Sandhu</span>, <span class="hlFld-ContribAuthor ">Christophe  Massard</span>, <span class="hlFld-ContribAuthor ">Nobuaki  Matsubara</span>, <span class="hlFld-ContribAuthor ">Boris  Alekseev</span>, <span class="hlFld-ContribAuthor ">Francis  Parnis</span>, <span class="hlFld-ContribAuthor ">Vagif  Atduev</span>, <span class="hlFld-ContribAuthor ">Gary L  Buchschacher</span>, <span class="hlFld-ContribAuthor ">Rustem  Gafanov</span>, <span class="hlFld-ContribAuthor ">Luis  Corrales</span>, <span class="hlFld-ContribAuthor ">Michael  Borre</span>, <span class="hlFld-ContribAuthor ">Daniil  Stroyakovskiy</span>, <span class="hlFld-ContribAuthor ">Gustavo Vasconcelos  Alves</span>, <span class="hlFld-ContribAuthor ">Evangelos  Bournakis</span>, <span class="hlFld-ContribAuthor ">Javier  Puente</span>, <span class="hlFld-ContribAuthor ">Marie-Laurence  Harle-Yge</span>, <span class="hlFld-ContribAuthor ">Jorge  Gallo</span>, <span class="hlFld-ContribAuthor ">Geng  Chen</span>, <span class="hlFld-ContribAuthor ">Justin  Hanover</span>, <span class="hlFld-ContribAuthor ">Matthew J  Wongchenko</span>, <span class="hlFld-ContribAuthor ">Josep  Garcia</span>, <span class="hlFld-ContribAuthor ">Johann S  de Bono</span>. </span><span class="cited-content_cbyCitation_article-title">Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. </span><span class="cited-content_cbyCitation_journal-name">The Lancet</span><span> <strong>2021,</strong> <em>398 </em>
                                    (10295)
                                     , 131-142. <a href="https://doi.org/10.1016/S0140-6736(21)00580-8" title="DOI URL">https://doi.org/10.1016/S0140-6736(21)00580-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S0140-6736(21)00580-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS0140-6736%2821%2900580-8%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Lancet%26atitle%3DIpatasertib%252Bplus%252Babiraterone%252Band%252Bprednisolone%252Bin%252Bmetastatic%252Bcastration-resistant%252Bprostate%252Bcancer%252B%252528IPATential150%252529%25253A%252Ba%252Bmulticentre%25252C%252Brandomised%25252C%252Bdouble-blind%25252C%252Bphase%252B3%252Btrial%26aulast%3DSweeney%26aufirst%3DChristopher%26date%3D2021%26volume%3D398%26issue%3D10295%26spage%3D131%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Zhao</span>, <span class="hlFld-ContribAuthor ">Chang  Shu</span>, <span class="hlFld-ContribAuthor ">Claire M.  Young</span>, <span class="hlFld-ContribAuthor ">Cameron  Carpenter‐Warren</span>, <span class="hlFld-ContribAuthor ">Alexandra M. Z.  Slawin</span>, <span class="hlFld-ContribAuthor ">Andrew D.  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective Synthesis of α‐Aryl‐β
              2
              ‐Amino‐Esters by Cooperative Isothiourea and Brønsted Acid Catalysis. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (21)
                                     , 11892-11900. <a href="https://doi.org/10.1002/anie.202016220" title="DOI URL">https://doi.org/10.1002/anie.202016220</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202016220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202016220%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DEnantioselective%252BSynthesis%252Bof%252B%2525CE%2525B1%2525E2%252580%252590Aryl%2525E2%252580%252590%2525CE%2525B2%252B2%252B%2525E2%252580%252590Amino%2525E2%252580%252590Esters%252Bby%252BCooperative%252BIsothiourea%252Band%252BBr%2525C3%2525B8nsted%252BAcid%252BCatalysis%26aulast%3DZhao%26aufirst%3DFeng%26date%3D2021%26date%3D2021%26volume%3D60%26issue%3D21%26spage%3D11892%26epage%3D11900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Zhao</span>, <span class="hlFld-ContribAuthor ">Chang  Shu</span>, <span class="hlFld-ContribAuthor ">Claire M.  Young</span>, <span class="hlFld-ContribAuthor ">Cameron  Carpenter‐Warren</span>, <span class="hlFld-ContribAuthor ">Alexandra M. Z.  Slawin</span>, <span class="hlFld-ContribAuthor ">Andrew D.  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective Synthesis of α‐Aryl‐β
              2
              ‐Amino‐Esters by Cooperative Isothiourea and Brønsted Acid Catalysis. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (21)
                                     , 11999-12007. <a href="https://doi.org/10.1002/ange.202016220" title="DOI URL">https://doi.org/10.1002/ange.202016220</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202016220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202016220%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DEnantioselective%252BSynthesis%252Bof%252B%2525CE%2525B1%2525E2%252580%252590Aryl%2525E2%252580%252590%2525CE%2525B2%252B2%252B%2525E2%252580%252590Amino%2525E2%252580%252590Esters%252Bby%252BCooperative%252BIsothiourea%252Band%252BBr%2525C3%2525B8nsted%252BAcid%252BCatalysis%26aulast%3DZhao%26aufirst%3DFeng%26date%3D2021%26date%3D2021%26volume%3D133%26issue%3D21%26spage%3D11999%26epage%3D12007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Guo</span>, <span class="hlFld-ContribAuthor ">Yizhen  Jin</span>, <span class="hlFld-ContribAuthor ">Bingxue  Qu</span>, <span class="hlFld-ContribAuthor ">Yu  Zhang</span>, <span class="hlFld-ContribAuthor ">Jinxin  Che</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">An updated patent review of Akt inhibitors (2016-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>129 </em>, 1-13. <a href="https://doi.org/10.1080/13543776.2021.1915291" title="DOI URL">https://doi.org/10.1080/13543776.2021.1915291</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1915291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1915291%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DAn%252Bupdated%252Bpatent%252Breview%252Bof%252BAkt%252Binhibitors%252B%2525282016-present%252529%26aulast%3DGuo%26aufirst%3DYu%26date%3D2021%26date%3D2021%26volume%3D129%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Albentosa-González</span>, <span class="hlFld-ContribAuthor ">Nereida  Jimenez de Oya</span>, <span class="hlFld-ContribAuthor ">Armando  Arias</span>, <span class="hlFld-ContribAuthor ">Pilar  Clemente-Casares</span>, <span class="hlFld-ContribAuthor ">Miguel Ángel  Martin-Acebes</span>, <span class="hlFld-ContribAuthor ">Juan Carlos  Saiz</span>, <span class="hlFld-ContribAuthor ">Rosario  Sabariegos</span>, <span class="hlFld-ContribAuthor ">Antonio  Mas</span>. </span><span class="cited-content_cbyCitation_article-title">Akt Kinase Intervenes in Flavivirus Replication by Interacting with Viral Protein NS5. </span><span class="cited-content_cbyCitation_journal-name">Viruses</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 896. <a href="https://doi.org/10.3390/v13050896" title="DOI URL">https://doi.org/10.3390/v13050896</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/v13050896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fv13050896%26sid%3Dliteratum%253Aachs%26jtitle%3DViruses%26atitle%3DAkt%252BKinase%252BIntervenes%252Bin%252BFlavivirus%252BReplication%252Bby%252BInteracting%252Bwith%252BViral%252BProtein%252BNS5%26aulast%3DAlbentosa-Gonz%25C3%25A1lez%26aufirst%3DLaura%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Frances V.  Hundley</span>, <span class="hlFld-ContribAuthor ">Nerea  Sanvisens Delgado</span>, <span class="hlFld-ContribAuthor ">Harold C.  Marin</span>, <span class="hlFld-ContribAuthor ">Kaili L.  Carr</span>, <span class="hlFld-ContribAuthor ">Ruilin  Tian</span>, <span class="hlFld-ContribAuthor ">David P.  Toczyski</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive phenotypic CRISPR-Cas9 screen of the ubiquitin pathway uncovers roles of ubiquitin ligases in mitosis. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cell</span><span> <strong>2021,</strong> <em>81 </em>
                                    (6)
                                     , 1319-1336.e9. <a href="https://doi.org/10.1016/j.molcel.2021.01.014" title="DOI URL">https://doi.org/10.1016/j.molcel.2021.01.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molcel.2021.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molcel.2021.01.014%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cell%26atitle%3DA%252Bcomprehensive%252Bphenotypic%252BCRISPR-Cas9%252Bscreen%252Bof%252Bthe%252Bubiquitin%252Bpathway%252Buncovers%252Broles%252Bof%252Bubiquitin%252Bligases%252Bin%252Bmitosis%26aulast%3DHundley%26aufirst%3DFrances%2BV.%26date%3D2021%26volume%3D81%26issue%3D6%26spage%3D1319%26epage%3D1336.e9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aditi  Khatpe</span>, <span class="hlFld-ContribAuthor ">Adedeji  Adebayo</span>, <span class="hlFld-ContribAuthor ">Christopher  Herodotou</span>, <span class="hlFld-ContribAuthor ">Brijesh  Kumar</span>, <span class="hlFld-ContribAuthor ">Harikrishna  Nakshatri</span>. </span><span class="cited-content_cbyCitation_article-title">Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (3)
                                     , 369. <a href="https://doi.org/10.3390/cancers13030369" title="DOI URL">https://doi.org/10.3390/cancers13030369</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13030369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13030369%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DNexus%252Bbetween%252BPI3K%25252FAKT%252Band%252BEstrogen%252BReceptor%252BSignaling%252Bin%252BBreast%252BCancer%26aulast%3DKhatpe%26aufirst%3DAditi%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D3%26spage%3D369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Albentosa-González</span>, <span class="hlFld-ContribAuthor ">Rosario  Sabariegos</span>, <span class="hlFld-ContribAuthor ">Armando  Arias</span>, <span class="hlFld-ContribAuthor ">Pilar  Clemente-Casares</span>, <span class="hlFld-ContribAuthor ">Antonio  Mas</span>. </span><span class="cited-content_cbyCitation_article-title">Akt Interacts with Usutu Virus Polymerase, and Its Activity Modulates Viral Replication. </span><span class="cited-content_cbyCitation_journal-name">Pathogens</span><span> <strong>2021,</strong> <em>10 </em>
                                    (2)
                                     , 244. <a href="https://doi.org/10.3390/pathogens10020244" title="DOI URL">https://doi.org/10.3390/pathogens10020244</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pathogens10020244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpathogens10020244%26sid%3Dliteratum%253Aachs%26jtitle%3DPathogens%26atitle%3DAkt%252BInteracts%252Bwith%252BUsutu%252BVirus%252BPolymerase%25252C%252Band%252BIts%252BActivity%252BModulates%252BViral%252BReplication%26aulast%3DAlbentosa-Gonz%25C3%25A1lez%26aufirst%3DLaura%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D2%26spage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kelly E.  McCann</span>, <span class="hlFld-ContribAuthor ">Sara A.  Hurvitz</span>. </span><span class="cited-content_cbyCitation_article-title">Innovations in targeted therapies for triple negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Obstetrics & Gynecology</span><span> <strong>2021,</strong> <em>33 </em>
                                    (1)
                                     , 34-47. <a href="https://doi.org/10.1097/GCO.0000000000000671" title="DOI URL">https://doi.org/10.1097/GCO.0000000000000671</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/GCO.0000000000000671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FGCO.0000000000000671%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Obstetrics%2520%2526%2520Gynecology%26atitle%3DInnovations%252Bin%252Btargeted%252Btherapies%252Bfor%252Btriple%252Bnegative%252Bbreast%252Bcancer%26aulast%3DMcCann%26aufirst%3DKelly%2BE.%26date%3D2021%26date%3D2020%26volume%3D33%26issue%3D1%26spage%3D34%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Basak  Celtikci</span>. </span><span class="cited-content_cbyCitation_article-title">A Crosstalk Between Dual-Specific Phosphatases and Dual-Specific Protein Kinases Can Be A Potential Therapeutic Target for Anti-cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 357-382. <a href="https://doi.org/10.1007/978-3-030-49844-3_14" title="DOI URL">https://doi.org/10.1007/978-3-030-49844-3_14</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-49844-3_14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-49844-3_14%26sid%3Dliteratum%253Aachs%26atitle%3DA%252BCrosstalk%252BBetween%252BDual-Specific%252BPhosphatases%252Band%252BDual-Specific%252BProtein%252BKinases%252BCan%252BBe%252BA%252BPotential%252BTherapeutic%252BTarget%252Bfor%252BAnti-cancer%252BTherapy%26aulast%3DCeltikci%26aufirst%3DBasak%26date%3D2021%26date%3D2021%26spage%3D357%26epage%3D382%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProtein%252BKinase-mediated%252BDecisions%252BBetween%252BLife%252Band%252BDeath%26aulast%3DEngin%26aufirst%3DAyse%2BBasak%26date%3D2021%26volume%3D1275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">彦凯  王</span>. </span><span class="cited-content_cbyCitation_article-title">Research Progress of Small Molecule Inhibitors of Akt Kinase—Overview of ATP Competitive Inhibitor Research. </span><span class="cited-content_cbyCitation_journal-name">Journal of Organic Chemistry Research</span><span> <strong>2021,</strong> <em>09 </em>
                                    (02)
                                     , 13-21. <a href="https://doi.org/10.12677/JOCR.2021.92003" title="DOI URL">https://doi.org/10.12677/JOCR.2021.92003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12677/JOCR.2021.92003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12677%2FJOCR.2021.92003%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Organic%2520Chemistry%2520Research%26atitle%3DResearch%252BProgress%252Bof%252BSmall%252BMolecule%252BInhibitors%252Bof%252BAkt%252BKinase%2525E2%252580%252594Overview%252Bof%252BATP%252BCompetitive%252BInhibitor%252BResearch%26aulast%3D%25E7%258E%258B%26aufirst%3D%25E5%25BD%25A6%25E5%2587%25AF%26date%3D2021%26volume%3D09%26issue%3D02%26spage%3D13%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying  Liu</span>, <span class="hlFld-ContribAuthor ">Chunzheng  Ma</span>, <span class="hlFld-ContribAuthor ">Weijie  Jiao</span>, <span class="hlFld-ContribAuthor ">Yanhua  Yang</span>, <span class="hlFld-ContribAuthor ">Huifang  Zhang</span>, <span class="hlFld-ContribAuthor ">Lei  Du</span>, <span class="hlFld-ContribAuthor ">Ming  Ma</span>, <span class="hlFld-ContribAuthor ">Pin  Sun</span>, <span class="hlFld-ContribAuthor ">Xiaokun  Li</span>, <span class="hlFld-ContribAuthor ">Jianshe  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacokinetics and bioavailability of ipatasertib in dog plasma using LC/MS/MS. </span><span class="cited-content_cbyCitation_journal-name">Biomedical Chromatography</span><span> <strong>2020,</strong> <em>34 </em>
                                    (10)
                                     <a href="https://doi.org/10.1002/bmc.4923" title="DOI URL">https://doi.org/10.1002/bmc.4923</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bmc.4923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbmc.4923%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedical%2520Chromatography%26atitle%3DPharmacokinetics%252Band%252Bbioavailability%252Bof%252Bipatasertib%252Bin%252Bdog%252Bplasma%252Busing%252BLC%25252FMS%25252FMS%26aulast%3DLiu%26aufirst%3DYing%26date%3D2020%26date%3D2020%26volume%3D34%26issue%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Remi  Adelaiye-Ogala</span>, <span class="hlFld-ContribAuthor ">Berkley E.  Gryder</span>, <span class="hlFld-ContribAuthor ">Yen Thi Minh  Nguyen</span>, <span class="hlFld-ContribAuthor ">Aian Neil  Alilin</span>, <span class="hlFld-ContribAuthor ">Adlai R.  Grayson</span>, <span class="hlFld-ContribAuthor ">Wardah  Bajwa</span>, <span class="hlFld-ContribAuthor ">Keith H.  Jansson</span>, <span class="hlFld-ContribAuthor ">Michael L.  Beshiri</span>, <span class="hlFld-ContribAuthor ">Supreet  Agarwal</span>, <span class="hlFld-ContribAuthor ">Jose Antonio  Rodriguez-Nieves</span>, <span class="hlFld-ContribAuthor ">Brian  Capaldo</span>, <span class="hlFld-ContribAuthor ">Kathleen  Kelly</span>, <span class="hlFld-ContribAuthor ">David J.  VanderWeele</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (7)
                                     , 1436-1447. <a href="https://doi.org/10.1158/1535-7163.MCT-19-0936" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-0936</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-0936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-0936%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DTargeting%252Bthe%252BPI3K%25252FAKT%252BPathway%252BOvercomes%252BEnzalutamide%252BResistance%252Bby%252BInhibiting%252BInduction%252Bof%252Bthe%252BGlucocorticoid%252BReceptor%26aulast%3DAdelaiye-Ogala%26aufirst%3DRemi%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D7%26spage%3D1436%26epage%3D1447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefania  Cocco</span>, <span class="hlFld-ContribAuthor ">Michela  Piezzo</span>, <span class="hlFld-ContribAuthor ">Alessandra  Calabrese</span>, <span class="hlFld-ContribAuthor ">Daniela  Cianniello</span>, <span class="hlFld-ContribAuthor ">Roberta  Caputo</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Di Lauro</span>, <span class="hlFld-ContribAuthor ">Giuseppina  Fusco</span>, <span class="hlFld-ContribAuthor ">Germira  di Gioia</span>, <span class="hlFld-ContribAuthor ">Marina  Licenziato</span>, <span class="hlFld-ContribAuthor ">Michelino  de Laurentiis</span>. </span><span class="cited-content_cbyCitation_article-title">Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (13)
                                     , 4579. <a href="https://doi.org/10.3390/ijms21134579" title="DOI URL">https://doi.org/10.3390/ijms21134579</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21134579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21134579%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DBiomarkers%252Bin%252BTriple-Negative%252BBreast%252BCancer%25253A%252BState-of-the-Art%252Band%252BFuture%252BPerspectives%26aulast%3DCocco%26aufirst%3DStefania%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D13%26spage%3D4579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nne E.  Uko</span>, <span class="hlFld-ContribAuthor ">Osman F.  Güner</span>, <span class="hlFld-ContribAuthor ">Diane F.  Matesic</span>, <span class="hlFld-ContribAuthor ">J. Phillip  Bowen</span>. </span><span class="cited-content_cbyCitation_article-title">Akt Pathway Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (10)
                                     , 883-900. <a href="https://doi.org/10.2174/1568026620666200224101808" title="DOI URL">https://doi.org/10.2174/1568026620666200224101808</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200224101808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200224101808%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DAkt%252BPathway%252BInhibitors%26aulast%3DUko%26aufirst%3DNne%2BE.%26date%3D2020%26volume%3D20%26issue%3D10%26spage%3D883%26epage%3D900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.J.  Isakoff</span>, <span class="hlFld-ContribAuthor ">J.  Tabernero</span>, <span class="hlFld-ContribAuthor ">L.R.  Molife</span>, <span class="hlFld-ContribAuthor ">J.-C.  Soria</span>, <span class="hlFld-ContribAuthor ">A.  Cervantes</span>, <span class="hlFld-ContribAuthor ">N.J.  Vogelzang</span>, <span class="hlFld-ContribAuthor ">M.R.  Patel</span>, <span class="hlFld-ContribAuthor ">M.  Hussain</span>, <span class="hlFld-ContribAuthor ">A.  Baron</span>, <span class="hlFld-ContribAuthor ">G.  Argilés</span>, <span class="hlFld-ContribAuthor ">P.R.  Conkling</span>, <span class="hlFld-ContribAuthor ">D.  Sampath</span>, <span class="hlFld-ContribAuthor ">D.  Maslyar</span>, <span class="hlFld-ContribAuthor ">P.  Patel</span>, <span class="hlFld-ContribAuthor ">W.  Chan</span>, <span class="hlFld-ContribAuthor ">S.  Gendreau</span>, <span class="hlFld-ContribAuthor ">L.  Musib</span>, <span class="hlFld-ContribAuthor ">N.  Xu</span>, <span class="hlFld-ContribAuthor ">H.  Ma</span>, <span class="hlFld-ContribAuthor ">K.  Lin</span>, <span class="hlFld-ContribAuthor ">J.  Bendell</span>. </span><span class="cited-content_cbyCitation_article-title">Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors. </span><span class="cited-content_cbyCitation_journal-name">Annals of Oncology</span><span> <strong>2020,</strong> <em>31 </em>
                                    (5)
                                     , 626-633. <a href="https://doi.org/10.1016/j.annonc.2020.02.007" title="DOI URL">https://doi.org/10.1016/j.annonc.2020.02.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.annonc.2020.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.annonc.2020.02.007%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Oncology%26atitle%3DAntitumor%252Bactivity%252Bof%252Bipatasertib%252Bcombined%252Bwith%252Bchemotherapy%25253A%252Bresults%252Bfrom%252Ba%252Bphase%252BIb%252Bstudy%252Bin%252Bsolid%252Btumors%26aulast%3DIsakoff%26aufirst%3DS.J.%26date%3D2020%26volume%3D31%26issue%3D5%26spage%3D626%26epage%3D633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Priya  Mahajan</span>, <span class="hlFld-ContribAuthor ">Bhumika  Wadhwa</span>, <span class="hlFld-ContribAuthor ">Manas Ranjan  Barik</span>, <span class="hlFld-ContribAuthor ">Fayaz  Malik</span>, <span class="hlFld-ContribAuthor ">Amit  Nargotra</span>. </span><span class="cited-content_cbyCitation_article-title">Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2020,</strong> <em>24 </em>
                                    (1)
                                     , 45-60. <a href="https://doi.org/10.1007/s11030-019-09924-9" title="DOI URL">https://doi.org/10.1007/s11030-019-09924-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-019-09924-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-019-09924-9%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DCombining%252Bligand-%252Band%252Bstructure-based%252Bin%252Bsilico%252Bmethods%252Bfor%252Bthe%252Bidentification%252Bof%252Bnatural%252Bproduct-based%252Binhibitors%252Bof%252BAkt1%26aulast%3DMahajan%26aufirst%3DPriya%26date%3D2020%26date%3D2019%26volume%3D24%26issue%3D1%26spage%3D45%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Inchul  You</span>, <span class="hlFld-ContribAuthor ">Emily C.  Erickson</span>, <span class="hlFld-ContribAuthor ">Katherine A.  Donovan</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Eleuteri</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>, <span class="hlFld-ContribAuthor ">Alex  Toker</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2020,</strong> <em>27 </em>
                                    (1)
                                     , 66-73.e7. <a href="https://doi.org/10.1016/j.chembiol.2019.11.014" title="DOI URL">https://doi.org/10.1016/j.chembiol.2019.11.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2019.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2019.11.014%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DDiscovery%252Bof%252Ban%252BAKT%252BDegrader%252Bwith%252BProlonged%252BInhibition%252Bof%252BDownstream%252BSignaling%26aulast%3DYou%26aufirst%3DInchul%26date%3D2020%26volume%3D27%26issue%3D1%26spage%3D66%26epage%3D73.e7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Franziska Maria  Ippen</span>, <span class="hlFld-ContribAuthor ">Julia Katharina  Grosch</span>, <span class="hlFld-ContribAuthor ">Megha  Subramanian</span>, <span class="hlFld-ContribAuthor ">Benjamin Macfarlane  Kuter</span>, <span class="hlFld-ContribAuthor ">Bianca M  Liederer</span>, <span class="hlFld-ContribAuthor ">Emile G  Plise</span>, <span class="hlFld-ContribAuthor ">Joana Liliana  Mora</span>, <span class="hlFld-ContribAuthor ">Naema  Nayyar</span>, <span class="hlFld-ContribAuthor ">Stephen Paul  Schmidt</span>, <span class="hlFld-ContribAuthor ">Anita  Giobbie-Hurder</span>, <span class="hlFld-ContribAuthor ">Maria  Martinez-Lage</span>, <span class="hlFld-ContribAuthor ">Scott L  Carter</span>, <span class="hlFld-ContribAuthor ">Daniel P  Cahill</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Wakimoto</span>, <span class="hlFld-ContribAuthor ">Priscilla Kaliopi  Brastianos</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. </span><span class="cited-content_cbyCitation_journal-name">Neuro-Oncology</span><span> <strong>2019,</strong> <em>21 </em>
                                    (11)
                                     , 1401-1411. <a href="https://doi.org/10.1093/neuonc/noz105" title="DOI URL">https://doi.org/10.1093/neuonc/noz105</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/neuonc/noz105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fneuonc%2Fnoz105%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuro-Oncology%26atitle%3DTargeting%252Bthe%252BPI3K%25252FAkt%25252FmTOR%252Bpathway%252Bwith%252Bthe%252Bpan-Akt%252Binhibitor%252BGDC-0068%252Bin%252BPIK3CA-mutant%252Bbreast%252Bcancer%252Bbrain%252Bmetastases%26aulast%3DIppen%26aufirst%3DFranziska%2BMaria%26date%3D2019%26date%3D2019%26volume%3D21%26issue%3D11%26spage%3D1401%26epage%3D1411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maryam  Shariati</span>, <span class="hlFld-ContribAuthor ">Funda  Meric-Bernstam</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting AKT for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2019,</strong> <em>28 </em>
                                    (11)
                                     , 977-988. <a href="https://doi.org/10.1080/13543784.2019.1676726" title="DOI URL">https://doi.org/10.1080/13543784.2019.1676726</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2019.1676726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2019.1676726%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DTargeting%252BAKT%252Bfor%252Bcancer%252Btherapy%26aulast%3DShariati%26aufirst%3DMaryam%26date%3D2019%26date%3D2019%26volume%3D28%26issue%3D11%26spage%3D977%26epage%3D988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicola  Bougen-Zhukov</span>, <span class="hlFld-ContribAuthor ">Yasmin  Nouri</span>, <span class="hlFld-ContribAuthor ">Tanis  Godwin</span>, <span class="hlFld-ContribAuthor ">Megan  Taylor</span>, <span class="hlFld-ContribAuthor ">Christopher  Hakkaart</span>, <span class="hlFld-ContribAuthor ">Andrew  Single</span>, <span class="hlFld-ContribAuthor ">Tom  Brew</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Permina</span>, <span class="hlFld-ContribAuthor ">Augustine  Chen</span>, <span class="hlFld-ContribAuthor ">Michael A.  Black</span>, <span class="hlFld-ContribAuthor ">Parry  Guilford</span>. </span><span class="cited-content_cbyCitation_article-title">Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2019,</strong> <em>11 </em>
                                    (9)
                                     , 1359. <a href="https://doi.org/10.3390/cancers11091359" title="DOI URL">https://doi.org/10.3390/cancers11091359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers11091359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers11091359%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DAllosteric%252BAKT%252BInhibitors%252BTarget%252BSynthetic%252BLethal%252BVulnerabilities%252Bin%252BE-Cadherin-Deficient%252BCells%26aulast%3DBougen-Zhukov%26aufirst%3DNicola%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D9%26spage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaiwen  Guo</span>, <span class="hlFld-ContribAuthor ">Wendi  Tang</span>, <span class="hlFld-ContribAuthor ">Huijun  Zhuo</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advance of Akt Inhibitors in Clinical Trials. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2019,</strong> <em>4 </em>
                                    (31)
                                     , 9040-9044. <a href="https://doi.org/10.1002/slct.201901293" title="DOI URL">https://doi.org/10.1002/slct.201901293</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201901293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201901293%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DRecent%252BAdvance%252Bof%252BAkt%252BInhibitors%252Bin%252BClinical%252BTrials%26aulast%3DGuo%26aufirst%3DKaiwen%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D31%26spage%3D9040%26epage%3D9044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Toshihiko  Doi</span>, <span class="hlFld-ContribAuthor ">Yutaka  Fujiwara</span>, <span class="hlFld-ContribAuthor ">Nobuaki  Matsubara</span>, <span class="hlFld-ContribAuthor ">Junichi  Tomomatsu</span>, <span class="hlFld-ContribAuthor ">Satoru  Iwasa</span>, <span class="hlFld-ContribAuthor ">Akari  Tanaka</span>, <span class="hlFld-ContribAuthor ">Chihiro  Endo-Tsukude</span>, <span class="hlFld-ContribAuthor ">Shintaro  Nakagawa</span>, <span class="hlFld-ContribAuthor ">Shunji  Takahashi</span>. </span><span class="cited-content_cbyCitation_article-title">Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors. </span><span class="cited-content_cbyCitation_journal-name">Cancer Chemotherapy and Pharmacology</span><span> <strong>2019,</strong> <em>84 </em>
                                    (2)
                                     , 393-404. <a href="https://doi.org/10.1007/s00280-019-03882-7" title="DOI URL">https://doi.org/10.1007/s00280-019-03882-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00280-019-03882-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00280-019-03882-7%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Chemotherapy%2520and%2520Pharmacology%26atitle%3DPhase%252BI%252Bstudy%252Bof%252Bipatasertib%252Bas%252Ba%252Bsingle%252Bagent%252Band%252Bin%252Bcombination%252Bwith%252Babiraterone%252Bplus%252Bprednisolone%252Bin%252BJapanese%252Bpatients%252Bwith%252Badvanced%252Bsolid%252Btumors%26aulast%3DDoi%26aufirst%3DToshihiko%26date%3D2019%26date%3D2019%26volume%3D84%26issue%3D2%26spage%3D393%26epage%3D404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kun  Chen</span>, <span class="hlFld-ContribAuthor ">Houqiang  Xu</span>, <span class="hlFld-ContribAuthor ">Jiafu  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Bloom Syndrome Protein Activates AKT and PRAS40 in Prostate Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Oxidative Medicine and Cellular Longevity</span><span> <strong>2019,</strong> <em>2019 </em>, 1-19. <a href="https://doi.org/10.1155/2019/3685817" title="DOI URL">https://doi.org/10.1155/2019/3685817</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2019/3685817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2019%2F3685817%26sid%3Dliteratum%253Aachs%26jtitle%3DOxidative%2520Medicine%2520and%2520Cellular%2520Longevity%26atitle%3DBloom%252BSyndrome%252BProtein%252BActivates%252BAKT%252Band%252BPRAS40%252Bin%252BProstate%252BCancer%252BCells%26aulast%3DChen%26aufirst%3DKun%26date%3D2019%26volume%3D2019%26spage%3D1%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanhao  Lv</span>, <span class="hlFld-ContribAuthor ">Tingting  Du</span>, <span class="hlFld-ContribAuthor ">Ming  Ji</span>, <span class="hlFld-ContribAuthor ">Chunyang  Wang</span>, <span class="hlFld-ContribAuthor ">Songwen  Lin</span>, <span class="hlFld-ContribAuthor ">Nina  Xue</span>, <span class="hlFld-ContribAuthor ">Jing  Jin</span>, <span class="hlFld-ContribAuthor ">Heng  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">A novel PI3K/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC. </span><span class="cited-content_cbyCitation_journal-name">Journal of Drug Targeting</span><span> <strong>2019,</strong> <em>27 </em>
                                    (4)
                                     , 451-459. <a href="https://doi.org/10.1080/1061186X.2018.1542533" title="DOI URL">https://doi.org/10.1080/1061186X.2018.1542533</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1061186X.2018.1542533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1061186X.2018.1542533%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Drug%2520Targeting%26atitle%3DA%252Bnovel%252BPI3K%25252FmTOR%252Bdual%252Binhibitor%252BXH002%252Bexhibited%252Brobust%252Bantitumor%252Bactivity%252Bin%252BNSCLC%26aulast%3DLv%26aufirst%3DYuanhao%26date%3D2019%26date%3D2018%26volume%3D27%26issue%3D4%26spage%3D451%26epage%3D459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mengqiu  Song</span>, <span class="hlFld-ContribAuthor ">Ann M.  Bode</span>, <span class="hlFld-ContribAuthor ">Zigang  Dong</span>, <span class="hlFld-ContribAuthor ">Mee-Hyun  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">AKT as a Therapeutic Target for Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2019,</strong> <em>79 </em>
                                    (6)
                                     , 1019-1031. <a href="https://doi.org/10.1158/0008-5472.CAN-18-2738" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-18-2738</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-18-2738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-18-2738%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DAKT%252Bas%252Ba%252BTherapeutic%252BTarget%252Bfor%252BCancer%26aulast%3DSong%26aufirst%3DMengqiu%26date%3D2019%26date%3D2019%26volume%3D79%26issue%3D6%26spage%3D1019%26epage%3D1031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Y.-J.  Bang</span>, <span class="hlFld-ContribAuthor ">Y.-K.  Kang</span>, <span class="hlFld-ContribAuthor ">M.  Ng</span>, <span class="hlFld-ContribAuthor ">H.C.  Chung</span>, <span class="hlFld-ContribAuthor ">Z.A.  Wainberg</span>, <span class="hlFld-ContribAuthor ">S.  Gendreau</span>, <span class="hlFld-ContribAuthor ">W.Y.  Chan</span>, <span class="hlFld-ContribAuthor ">N.  Xu</span>, <span class="hlFld-ContribAuthor ">D.  Maslyar</span>, <span class="hlFld-ContribAuthor ">R.  Meng</span>, <span class="hlFld-ContribAuthor ">I.  Chau</span>, <span class="hlFld-ContribAuthor ">J.A.  Ajani</span>. </span><span class="cited-content_cbyCitation_article-title">A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Cancer</span><span> <strong>2019,</strong> <em>108 </em>, 17-24. <a href="https://doi.org/10.1016/j.ejca.2018.11.017" title="DOI URL">https://doi.org/10.1016/j.ejca.2018.11.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejca.2018.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejca.2018.11.017%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Cancer%26atitle%3DA%252Bphase%252BII%25252C%252Brandomised%252Bstudy%252Bof%252BmFOLFOX6%252Bwith%252Bor%252Bwithout%252Bthe%252BAkt%252Binhibitor%252Bipatasertib%252Bin%252Bpatients%252Bwith%252Blocally%252Badvanced%252Bor%252Bmetastatic%252Bgastric%252Bor%252Bgastroesophageal%252Bjunction%252Bcancer%26aulast%3DBang%26aufirst%3DY.-J.%26date%3D2019%26volume%3D108%26spage%3D17%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Johann S.  de Bono</span>, <span class="hlFld-ContribAuthor ">Ugo  De Giorgi</span>, <span class="hlFld-ContribAuthor ">Daniel Nava  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Christophe  Massard</span>, <span class="hlFld-ContribAuthor ">Sergio  Bracarda</span>, <span class="hlFld-ContribAuthor ">Albert  Font</span>, <span class="hlFld-ContribAuthor ">Jose Angel  Arranz Arija</span>, <span class="hlFld-ContribAuthor ">Kent C.  Shih</span>, <span class="hlFld-ContribAuthor ">George Daniel  Radavoi</span>, <span class="hlFld-ContribAuthor ">Na  Xu</span>, <span class="hlFld-ContribAuthor ">Wai Y.  Chan</span>, <span class="hlFld-ContribAuthor ">Han  Ma</span>, <span class="hlFld-ContribAuthor ">Steven  Gendreau</span>, <span class="hlFld-ContribAuthor ">Ruth  Riisnaes</span>, <span class="hlFld-ContribAuthor ">Premal H.  Patel</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Maslyar</span>, <span class="hlFld-ContribAuthor ">Viorel  Jinga</span>. </span><span class="cited-content_cbyCitation_article-title">Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2019,</strong> <em>25 </em>
                                    (3)
                                     , 928-936. <a href="https://doi.org/10.1158/1078-0432.CCR-18-0981" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-18-0981</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-18-0981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-18-0981%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DRandomized%252BPhase%252BII%252BStudy%252BEvaluating%252BAkt%252BBlockade%252Bwith%252BIpatasertib%25252C%252Bin%252BCombination%252Bwith%252BAbiraterone%25252C%252Bin%252BPatients%252Bwith%252BMetastatic%252BProstate%252BCancer%252Bwith%252Band%252Bwithout%252BPTEN%252BLoss%26aulast%3Dde%2BBono%26aufirst%3DJohann%2BS.%26date%3D2019%26date%3D2018%26volume%3D25%26issue%3D3%26spage%3D928%26epage%3D936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  McKenna</span>, <span class="hlFld-ContribAuthor ">Sarah  McGarrigle</span>, <span class="hlFld-ContribAuthor ">Graham P.  Pidgeon</span>. </span><span class="cited-content_cbyCitation_article-title">The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Reviews on Cancer</span><span> <strong>2018,</strong> <em>1870 </em>
                                    (2)
                                     , 185-197. <a href="https://doi.org/10.1016/j.bbcan.2018.08.001" title="DOI URL">https://doi.org/10.1016/j.bbcan.2018.08.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbcan.2018.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbcan.2018.08.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Reviews%2520on%2520Cancer%26atitle%3DThe%252Bnext%252Bgeneration%252Bof%252BPI3K-Akt-mTOR%252Bpathway%252Binhibitors%252Bin%252Bbreast%252Bcancer%252Bcohorts%26aulast%3DMcKenna%26aufirst%3DMichael%26date%3D2018%26volume%3D1870%26issue%3D2%26spage%3D185%26epage%3D197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Sun</span>, <span class="hlFld-ContribAuthor ">Yuan  Huang</span>, <span class="hlFld-ContribAuthor ">Yeying  Liu</span>, <span class="hlFld-ContribAuthor ">Yujie  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaoxiao  He</span>, <span class="hlFld-ContribAuthor ">Lingling  Zhang</span>, <span class="hlFld-ContribAuthor ">Feng  Wang</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2018,</strong> <em>9 </em>
                                    (9)
                                     <a href="https://doi.org/10.1038/s41419-018-0943-9" title="DOI URL">https://doi.org/10.1038/s41419-018-0943-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41419-018-0943-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41419-018-0943-9%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DIpatasertib%25252C%252Ba%252Bnovel%252BAkt%252Binhibitor%25252C%252Binduces%252Btranscription%252Bfactor%252BFoxO3a%252Band%252BNF-%2525CE%2525BAB%252Bdirectly%252Bregulates%252BPUMA-dependent%252Bapoptosis%26aulast%3DSun%26aufirst%3DLi%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nam  Chu</span>, <span class="hlFld-ContribAuthor ">Antonieta L.  Salguero</span>, <span class="hlFld-ContribAuthor ">Albert Z.  Liu</span>, <span class="hlFld-ContribAuthor ">Zan  Chen</span>, <span class="hlFld-ContribAuthor ">Daniel R.  Dempsey</span>, <span class="hlFld-ContribAuthor ">Scott B.  Ficarro</span>, <span class="hlFld-ContribAuthor ">William M.  Alexander</span>, <span class="hlFld-ContribAuthor ">Jarrod A.  Marto</span>, <span class="hlFld-ContribAuthor ">Yana  Li</span>, <span class="hlFld-ContribAuthor ">L. Mario  Amzel</span>, <span class="hlFld-ContribAuthor ">Sandra B.  Gabelli</span>, <span class="hlFld-ContribAuthor ">Philip A.  Cole</span>. </span><span class="cited-content_cbyCitation_article-title">Akt Kinase Activation Mechanisms Revealed Using Protein Semisynthesis. </span><span class="cited-content_cbyCitation_journal-name">Cell</span><span> <strong>2018,</strong> <em>174 </em>
                                    (4)
                                     , 897-907.e14. <a href="https://doi.org/10.1016/j.cell.2018.07.003" title="DOI URL">https://doi.org/10.1016/j.cell.2018.07.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cell.2018.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cell.2018.07.003%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%26atitle%3DAkt%252BKinase%252BActivation%252BMechanisms%252BRevealed%252BUsing%252BProtein%252BSemisynthesis%26aulast%3DChu%26aufirst%3DNam%26date%3D2018%26volume%3D174%26issue%3D4%26spage%3D897%26epage%3D907.e14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahmoud A.  Al-Sha’er</span>, <span class="hlFld-ContribAuthor ">Mutasem O.  Taha</span>. </span><span class="cited-content_cbyCitation_article-title">Ligand-based modeling of Akt3 lead to potent dual Akt1/Akt3 inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2018,</strong> <em>83 </em>, 153-166. <a href="https://doi.org/10.1016/j.jmgm.2018.02.001" title="DOI URL">https://doi.org/10.1016/j.jmgm.2018.02.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2018.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2018.02.001%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DLigand-based%252Bmodeling%252Bof%252BAkt3%252Blead%252Bto%252Bpotent%252Bdual%252BAkt1%25252FAkt3%252Binhibitor%26aulast%3DAl-Sha%25E2%2580%2599er%26aufirst%3DMahmoud%2BA.%26date%3D2018%26volume%3D83%26spage%3D153%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saravanan  Parthasarathy</span>, <span class="hlFld-ContribAuthor ">Kenneth  Henry</span>, <span class="hlFld-ContribAuthor ">Huaxing  Pei</span>, <span class="hlFld-ContribAuthor ">Josh  Clayton</span>, <span class="hlFld-ContribAuthor ">Mark  Rempala</span>, <span class="hlFld-ContribAuthor ">Deidre  Johns</span>, <span class="hlFld-ContribAuthor ">Oscar  De Frutos</span>, <span class="hlFld-ContribAuthor ">Pablo  Garcia</span>, <span class="hlFld-ContribAuthor ">Carlos  Mateos</span>, <span class="hlFld-ContribAuthor ">Sehila  Pleite</span>, <span class="hlFld-ContribAuthor ">Yong  Wang</span>, <span class="hlFld-ContribAuthor ">Stephanie  Stout</span>, <span class="hlFld-ContribAuthor ">Bradley  Condon</span>, <span class="hlFld-ContribAuthor ">Sheela  Ashok</span>, <span class="hlFld-ContribAuthor ">Zhohai  Lu</span>, <span class="hlFld-ContribAuthor ">William  Ehlhardt</span>, <span class="hlFld-ContribAuthor ">Tom  Raub</span>, <span class="hlFld-ContribAuthor ">Mei  Lai</span>, <span class="hlFld-ContribAuthor ">Sandaruwan  Geeganage</span>, <span class="hlFld-ContribAuthor ">Timothy P.  Burkholder</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (10)
                                     , 1887-1891. <a href="https://doi.org/10.1016/j.bmcl.2018.03.092" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.03.092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.03.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.03.092%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bchiral%252Bdihydropyridopyrimidinones%252Bas%252Bpotent%25252C%252Bselective%252Band%252Borally%252Bbioavailable%252Binhibitors%252Bof%252BAKT%26aulast%3DParthasarathy%26aufirst%3DSaravanan%26date%3D2018%26volume%3D28%26issue%3D10%26spage%3D1887%26epage%3D1891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Iris  Eke</span>, <span class="hlFld-ContribAuthor ">Adeola Y.  Makinde</span>, <span class="hlFld-ContribAuthor ">Molykutty J.  Aryankalayil</span>, <span class="hlFld-ContribAuthor ">Veit  Sandfort</span>, <span class="hlFld-ContribAuthor ">Sanjeewani T.  Palayoor</span>, <span class="hlFld-ContribAuthor ">Barbara H.  Rath</span>, <span class="hlFld-ContribAuthor ">Lance  Liotta</span>, <span class="hlFld-ContribAuthor ">Mariaelena  Pierobon</span>, <span class="hlFld-ContribAuthor ">Emanuel F.  Petricoin</span>, <span class="hlFld-ContribAuthor ">Matthew F.  Brown</span>, <span class="hlFld-ContribAuthor ">Jayne M.  Stommel</span>, <span class="hlFld-ContribAuthor ">Mansoor M.  Ahmed</span>, <span class="hlFld-ContribAuthor ">C. Norman  Coleman</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2018,</strong> <em>17 </em>
                                    (2)
                                     , 355-367. <a href="https://doi.org/10.1158/1535-7163.MCT-17-0262" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-17-0262</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-17-0262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-17-0262%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DExploiting%252BRadiation-Induced%252BSignaling%252Bto%252BIncrease%252Bthe%252BSusceptibility%252Bof%252BResistant%252BCancer%252BCells%252Bto%252BTargeted%252BDrugs%25253A%252BAKT%252Band%252BmTOR%252BInhibitors%252Bas%252Ban%252BExample%26aulast%3DEke%26aufirst%3DIris%26date%3D2018%26date%3D2017%26volume%3D17%26issue%3D2%26spage%3D355%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daoguang  Zhang</span>, <span class="hlFld-ContribAuthor ">Dongdong  Tong</span>, <span class="hlFld-ContribAuthor ">Dezhi  Yang</span>, <span class="hlFld-ContribAuthor ">Jing  Sun</span>, <span class="hlFld-ContribAuthor ">Fenghe  Zhang</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (8)
                                     , 1340-1350. <a href="https://doi.org/10.1039/C8MD00197A" title="DOI URL">https://doi.org/10.1039/C8MD00197A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8MD00197A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8MD00197A%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252BAKT%252Binhibitors%252Bbearing%252Ba%252Bpiperidin-4-yl%252Bappendant%26aulast%3DZhang%26aufirst%3DDaoguang%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D8%26spage%3D1340%26epage%3D1350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert B.  Cameron</span>, <span class="hlFld-ContribAuthor ">Yuri K.  Peterson</span>, <span class="hlFld-ContribAuthor ">Craig C.  Beeson</span>, <span class="hlFld-ContribAuthor ">Rick G.  Schnellmann</span>. </span><span class="cited-content_cbyCitation_article-title">Structural and pharmacological basis for the induction of mitochondrial biogenesis by formoterol but not clenbuterol. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2017,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-017-11030-5" title="DOI URL">https://doi.org/10.1038/s41598-017-11030-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-017-11030-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-017-11030-5%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DStructural%252Band%252Bpharmacological%252Bbasis%252Bfor%252Bthe%252Binduction%252Bof%252Bmitochondrial%252Bbiogenesis%252Bby%252Bformoterol%252Bbut%252Bnot%252Bclenbuterol%26aulast%3DCameron%26aufirst%3DRobert%2BB.%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haiyan  Qian</span>, <span class="hlFld-ContribAuthor ">Shifeng  Chen</span>, <span class="hlFld-ContribAuthor ">Youlu  Pan</span>, <span class="hlFld-ContribAuthor ">Jianzhong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Understanding the relative affinity and specificity of the substrate binding site of protein kinase B for substrate-mimetic inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Simulation</span><span> <strong>2017,</strong> <em>43 </em>
                                    (17)
                                     , 1459-1471. <a href="https://doi.org/10.1080/08927022.2017.1319062" title="DOI URL">https://doi.org/10.1080/08927022.2017.1319062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/08927022.2017.1319062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F08927022.2017.1319062%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Simulation%26atitle%3DUnderstanding%252Bthe%252Brelative%252Baffinity%252Band%252Bspecificity%252Bof%252Bthe%252Bsubstrate%252Bbinding%252Bsite%252Bof%252Bprotein%252Bkinase%252BB%252Bfor%252Bsubstrate-mimetic%252Binhibitors%26aulast%3DQian%26aufirst%3DHaiyan%26date%3D2017%26date%3D2017%26volume%3D43%26issue%3D17%26spage%3D1459%26epage%3D1471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dezhi  Yang</span>, <span class="hlFld-ContribAuthor ">Dongdong  Tong</span>, <span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongtao  Wang</span>, <span class="hlFld-ContribAuthor ">Jing  Sun</span>, <span class="hlFld-ContribAuthor ">Fenghe  Zhang</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and evaluation of novel Akt1 inhibitors based on an indole scaffold. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2017,</strong> <em>90 </em>
                                    (5)
                                     , 791-803. <a href="https://doi.org/10.1111/cbdd.13000" title="DOI URL">https://doi.org/10.1111/cbdd.13000</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13000%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bevaluation%252Bof%252Bnovel%252BAkt1%252Binhibitors%252Bbased%252Bon%252Ban%252Bindole%252Bscaffold%26aulast%3DYang%26aufirst%3DDezhi%26date%3D2017%26date%3D2017%26volume%3D90%26issue%3D5%26spage%3D791%26epage%3D803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Floriana  Morgillo</span>, <span class="hlFld-ContribAuthor ">Carminia Maria  Della Corte</span>, <span class="hlFld-ContribAuthor ">Anna  Diana</span>, <span class="hlFld-ContribAuthor ">Concetta  di Mauro</span>, <span class="hlFld-ContribAuthor ">Vincenza  Ciaramella</span>, <span class="hlFld-ContribAuthor ">Giusi  Barra</span>, <span class="hlFld-ContribAuthor ">Valentina  Belli</span>, <span class="hlFld-ContribAuthor ">Elisena  Franzese</span>, <span class="hlFld-ContribAuthor ">Roberto  Bianco</span>, <span class="hlFld-ContribAuthor ">Evaristo  Maiello</span>, <span class="hlFld-ContribAuthor ">Ferdinando  De Vita</span>, <span class="hlFld-ContribAuthor ">Fortunato  Ciardiello</span>, <span class="hlFld-ContribAuthor ">Michele  Orditura</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (44)
                                     , 76479-76491. <a href="https://doi.org/10.18632/oncotarget.20385" title="DOI URL">https://doi.org/10.18632/oncotarget.20385</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.20385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.20385%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DPhosphatidylinositol%252B3-kinase%252B%252528PI3K%2525CE%2525B1%252529%25252FAKT%252Baxis%252Bblockade%252Bwith%252Btaselisib%252Bor%252Bipatasertib%252Benhances%252Bthe%252Befficacy%252Bof%252Banti-microtubule%252Bdrugs%252Bin%252Bhuman%252Bbreast%252Bcancer%252Bcells%26aulast%3DMorgillo%26aufirst%3DFloriana%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D44%26spage%3D76479%26epage%3D76491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bayard R.  Huck</span>, <span class="hlFld-ContribAuthor ">Igor  Mochalkin</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress towards clinically relevant ATP-competitive Akt inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (13)
                                     , 2838-2848. <a href="https://doi.org/10.1016/j.bmcl.2017.04.090" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.04.090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.04.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.04.090%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRecent%252Bprogress%252Btowards%252Bclinically%252Brelevant%252BATP-competitive%252BAkt%252Binhibitors%26aulast%3DHuck%26aufirst%3DBayard%2BR.%26date%3D2017%26volume%3D27%26issue%3D13%26spage%3D2838%26epage%3D2848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bhumika  Wadhwa</span>, <span class="hlFld-ContribAuthor ">Ubaid  Makhdoomi</span>, <span class="hlFld-ContribAuthor ">Ram  Vishwakarma</span>, <span class="hlFld-ContribAuthor ">Fayaz  Malik</span>. </span><span class="cited-content_cbyCitation_article-title">Protein kinase B. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Drugs</span><span> <strong>2017,</strong> <em>28 </em>
                                    (6)
                                     , 569-580. <a href="https://doi.org/10.1097/CAD.0000000000000496" title="DOI URL">https://doi.org/10.1097/CAD.0000000000000496</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/CAD.0000000000000496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FCAD.0000000000000496%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Drugs%26atitle%3DProtein%252Bkinase%252BB%26aulast%3DWadhwa%26aufirst%3DBhumika%26date%3D2017%26volume%3D28%26issue%3D6%26spage%3D569%26epage%3D580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.  Oeck</span>, <span class="hlFld-ContribAuthor ">K.  Al-Refae</span>, <span class="hlFld-ContribAuthor ">H.  Riffkin</span>, <span class="hlFld-ContribAuthor ">G.  Wiel</span>, <span class="hlFld-ContribAuthor ">R.  Handrick</span>, <span class="hlFld-ContribAuthor ">D.  Klein</span>, <span class="hlFld-ContribAuthor ">G.  Iliakis</span>, <span class="hlFld-ContribAuthor ">V.  Jendrossek</span>. </span><span class="cited-content_cbyCitation_article-title">Activating Akt1 mutations alter DNA double strand break repair and radiosensitivity. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2017,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/srep42700" title="DOI URL">https://doi.org/10.1038/srep42700</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/srep42700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fsrep42700%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DActivating%252BAkt1%252Bmutations%252Balter%252BDNA%252Bdouble%252Bstrand%252Bbreak%252Brepair%252Band%252Bradiosensitivity%26aulast%3DOeck%26aufirst%3DS.%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessica S.  Brown</span>, <span class="hlFld-ContribAuthor ">Udai  Banerji</span>. </span><span class="cited-content_cbyCitation_article-title">Maximising the potential of AKT inhibitors as anti-cancer treatments. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2017,</strong> <em>172 </em>, 101-115. <a href="https://doi.org/10.1016/j.pharmthera.2016.12.001" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2016.12.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2016.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2016.12.001%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DMaximising%252Bthe%252Bpotential%252Bof%252BAKT%252Binhibitors%252Bas%252Banti-cancer%252Btreatments%26aulast%3DBrown%26aufirst%3DJessica%2BS.%26date%3D2017%26volume%3D172%26spage%3D101%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Olivier  Calvayrac</span>, <span class="hlFld-ContribAuthor ">Julien  Mazières</span>, <span class="hlFld-ContribAuthor ">Sarah  Figarol</span>, <span class="hlFld-ContribAuthor ">Claire  Marty‐Detraves</span>, <span class="hlFld-ContribAuthor ">Isabelle  Raymond‐Letron</span>, <span class="hlFld-ContribAuthor ">Emilie  Bousquet</span>, <span class="hlFld-ContribAuthor ">Magali  Farella</span>, <span class="hlFld-ContribAuthor ">Estelle  Clermont‐Taranchon</span>, <span class="hlFld-ContribAuthor ">Julie  Milia</span>, <span class="hlFld-ContribAuthor ">Isabelle  Rouquette</span>, <span class="hlFld-ContribAuthor ">Nicolas  Guibert</span>, <span class="hlFld-ContribAuthor ">Amélie  Lusque</span>, <span class="hlFld-ContribAuthor ">Jacques  Cadranel</span>, <span class="hlFld-ContribAuthor ">Nathalie  Mathiot</span>, <span class="hlFld-ContribAuthor ">Ariel  Savina</span>, <span class="hlFld-ContribAuthor ">Anne  Pradines</span>, <span class="hlFld-ContribAuthor ">Gilles  Favre</span>. </span><span class="cited-content_cbyCitation_article-title">The
              RAS
              ‐related
              GTP
              ase
              RHOB
              confers resistance to
              EGFR
              ‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an
              AKT
              ‐dependent mechanism. </span><span class="cited-content_cbyCitation_journal-name">EMBO Molecular Medicine</span><span> <strong>2017,</strong> <em>9 </em>
                                    (2)
                                     , 238-250. <a href="https://doi.org/10.15252/emmm.201606646" title="DOI URL">https://doi.org/10.15252/emmm.201606646</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.15252/emmm.201606646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.15252%2Femmm.201606646%26sid%3Dliteratum%253Aachs%26jtitle%3DEMBO%2520Molecular%2520Medicine%26atitle%3DThe%252BRAS%252B%2525E2%252580%252590related%252BGTP%252Base%252BRHOB%252Bconfers%252Bresistance%252Bto%252BEGFR%252B%2525E2%252580%252590tyrosine%252Bkinase%252Binhibitors%252Bin%252Bnon%2525E2%252580%252590small%2525E2%252580%252590cell%252Blung%252Bcancer%252Bvia%252Ban%252BAKT%252B%2525E2%252580%252590dependent%252Bmechanism%26aulast%3DCalvayrac%26aufirst%3DOlivier%26date%3D2017%26date%3D2016%26volume%3D9%26issue%3D2%26spage%3D238%26epage%3D250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudio  Festuccia</span>. </span><span class="cited-content_cbyCitation_article-title">Investigational serine/threonine kinase inhibitors against prostate cancer metastases. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2017,</strong> <em>26 </em>
                                    (1)
                                     , 25-34. <a href="https://doi.org/10.1080/13543784.2016.1266337" title="DOI URL">https://doi.org/10.1080/13543784.2016.1266337</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2016.1266337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2016.1266337%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DInvestigational%252Bserine%25252Fthreonine%252Bkinase%252Binhibitors%252Bagainst%252Bprostate%252Bcancer%252Bmetastases%26aulast%3DFestuccia%26aufirst%3DClaudio%26date%3D2017%26date%3D2016%26volume%3D26%26issue%3D1%26spage%3D25%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Dai</span>, <span class="hlFld-ContribAuthor ">Wenlong  Ren</span>, <span class="hlFld-ContribAuthor ">Wenju  Chang</span>, <span class="hlFld-ContribAuthor ">Ping  Zhang</span>, <span class="hlFld-ContribAuthor ">Yian  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">An effective route to β
              2
              -amino acid derivatives via Pd-catalyzed regioselective hydrocarboxylation of 1,2-disubstituted enimides. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2017,</strong> <em>4 </em>
                                    (2)
                                     , 297-302. <a href="https://doi.org/10.1039/C6QO00353B" title="DOI URL">https://doi.org/10.1039/C6QO00353B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6QO00353B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6QO00353B%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DAn%252Beffective%252Broute%252Bto%252B%2525CE%2525B2%252B2%252B-amino%252Bacid%252Bderivatives%252Bvia%252BPd-catalyzed%252Bregioselective%252Bhydrocarboxylation%252Bof%252B1%25252C2-disubstituted%252Benimides%26aulast%3DDai%26aufirst%3DJie%26date%3D2017%26date%3D2017%26volume%3D4%26issue%3D2%26spage%3D297%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristina  Saura</span>, <span class="hlFld-ContribAuthor ">Desamparados  Roda</span>, <span class="hlFld-ContribAuthor ">Susana  Roselló</span>, <span class="hlFld-ContribAuthor ">Mafalda  Oliveira</span>, <span class="hlFld-ContribAuthor ">Teresa  Macarulla</span>, <span class="hlFld-ContribAuthor ">José Alejandro  Pérez-Fidalgo</span>, <span class="hlFld-ContribAuthor ">Rafael  Morales-Barrera</span>, <span class="hlFld-ContribAuthor ">Juan Manuel  Sanchis-García</span>, <span class="hlFld-ContribAuthor ">Luna  Musib</span>, <span class="hlFld-ContribAuthor ">Nageshwar  Budha</span>, <span class="hlFld-ContribAuthor ">Jin  Zhu</span>, <span class="hlFld-ContribAuthor ">Michelle  Nannini</span>, <span class="hlFld-ContribAuthor ">Wai Y.  Chan</span>, <span class="hlFld-ContribAuthor ">Sandra M.  Sanabria Bohórquez</span>, <span class="hlFld-ContribAuthor ">Raymond D.  Meng</span>, <span class="hlFld-ContribAuthor ">Kui  Lin</span>, <span class="hlFld-ContribAuthor ">Yibing  Yan</span>, <span class="hlFld-ContribAuthor ">Premal  Patel</span>, <span class="hlFld-ContribAuthor ">José  Baselga</span>, <span class="hlFld-ContribAuthor ">Josep  Tabernero</span>, <span class="hlFld-ContribAuthor ">Andrés  Cervantes</span>. </span><span class="cited-content_cbyCitation_article-title">A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Cancer Discovery</span><span> <strong>2017,</strong> <em>7 </em>
                                    (1)
                                     , 102-113. <a href="https://doi.org/10.1158/2159-8290.CD-16-0512" title="DOI URL">https://doi.org/10.1158/2159-8290.CD-16-0512</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/2159-8290.CD-16-0512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F2159-8290.CD-16-0512%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Discovery%26atitle%3DA%252BFirst-in-Human%252BPhase%252BI%252BStudy%252Bof%252Bthe%252BATP-Competitive%252BAKT%252BInhibitor%252BIpatasertib%252BDemonstrates%252BRobust%252Band%252BSafe%252BTargeting%252Bof%252BAKT%252Bin%252BPatients%252Bwith%252BSolid%252BTumors%26aulast%3DSaura%26aufirst%3DCristina%26date%3D2017%26date%3D2016%26volume%3D7%26issue%3D1%26spage%3D102%26epage%3D113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Casey  Stottrup</span>, <span class="hlFld-ContribAuthor ">Tiffany  Tsang</span>, <span class="hlFld-ContribAuthor ">Y. Rebecca  Chin</span>. </span><span class="cited-content_cbyCitation_article-title">Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2016,</strong> <em>15 </em>
                                    (8)
                                     , 1964-1974. <a href="https://doi.org/10.1158/1535-7163.MCT-15-0748" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-15-0748</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-15-0748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-15-0748%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DUpregulation%252Bof%252BAKT3%252BConfers%252BResistance%252Bto%252Bthe%252BAKT%252BInhibitor%252BMK2206%252Bin%252BBreast%252BCancer%26aulast%3DStottrup%26aufirst%3DCasey%26date%3D2016%26date%3D2016%26volume%3D15%26issue%3D8%26spage%3D1964%26epage%3D1974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia  Wang</span>, <span class="hlFld-ContribAuthor ">James  Sinnett-Smith</span>, <span class="hlFld-ContribAuthor ">Jan V.  Stevens</span>, <span class="hlFld-ContribAuthor ">Steven H.  Young</span>, <span class="hlFld-ContribAuthor ">Enrique  Rozengurt</span>. </span><span class="cited-content_cbyCitation_article-title">Biphasic Regulation of Yes-associated Protein (YAP) Cellular Localization, Phosphorylation, and Activity by G Protein-coupled Receptor Agonists in Intestinal Epithelial Cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2016,</strong> <em>291 </em>
                                    (34)
                                     , 17988-18005. <a href="https://doi.org/10.1074/jbc.M115.711275" title="DOI URL">https://doi.org/10.1074/jbc.M115.711275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.M115.711275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.M115.711275%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DBiphasic%252BRegulation%252Bof%252BYes-associated%252BProtein%252B%252528YAP%252529%252BCellular%252BLocalization%25252C%252BPhosphorylation%25252C%252Band%252BActivity%252Bby%252BG%252BProtein-coupled%252BReceptor%252BAgonists%252Bin%252BIntestinal%252BEpithelial%252BCells%26aulast%3DWang%26aufirst%3DJia%26date%3D2016%26volume%3D291%26issue%3D34%26spage%3D17988%26epage%3D18005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenhu  Zhan</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>, <span class="hlFld-ContribAuthor ">Jun  Dong</span>, <span class="hlFld-ContribAuthor ">Xiao  Yi</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Ni  Qiu</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Bo  Yang</span>, <span class="hlFld-ContribAuthor ">Yubo  Zhou</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>117 </em>, 47-58. <a href="https://doi.org/10.1016/j.ejmech.2016.03.074" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.03.074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.03.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.03.074%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bpyrazol-furan%252Bcarboxamide%252Banalogues%252Bas%252Bnovel%252BAkt%252Bkinase%252Binhibitors%26aulast%3DZhan%26aufirst%3DWenhu%26date%3D2016%26volume%3D117%26spage%3D47%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yoshito  Nakanishi</span>, <span class="hlFld-ContribAuthor ">Kimberly  Walter</span>, <span class="hlFld-ContribAuthor ">Jill M.  Spoerke</span>, <span class="hlFld-ContribAuthor ">Carol  O'Brien</span>, <span class="hlFld-ContribAuthor ">Ling Y.  Huw</span>, <span class="hlFld-ContribAuthor ">Garret M.  Hampton</span>, <span class="hlFld-ContribAuthor ">Mark R.  Lackner</span>. </span><span class="cited-content_cbyCitation_article-title">Activating Mutations in
              PIK3CB
              Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2016,</strong> <em>76 </em>
                                    (5)
                                     , 1193-1203. <a href="https://doi.org/10.1158/0008-5472.CAN-15-2201" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-15-2201</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-15-2201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-15-2201%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DActivating%252BMutations%252Bin%252BPIK3CB%252BConfer%252BResistance%252Bto%252BPI3K%252BInhibition%252Band%252BDefine%252Ba%252BNovel%252BOncogenic%252BRole%252Bfor%252Bp110%2525CE%2525B2%26aulast%3DNakanishi%26aufirst%3DYoshito%26date%3D2016%26date%3D2016%26volume%3D76%26issue%3D5%26spage%3D1193%26epage%3D1203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">GEORGE MIHAI  NITULESCU</span>, <span class="hlFld-ContribAuthor ">DENISA  MARGINA</span>, <span class="hlFld-ContribAuthor ">PETRAS  JUZENAS</span>, <span class="hlFld-ContribAuthor ">QIAN  PENG</span>, <span class="hlFld-ContribAuthor ">OCTAVIAN TUDOREL  OLARU</span>, <span class="hlFld-ContribAuthor ">EMMANOUIL  SALOUSTROS</span>, <span class="hlFld-ContribAuthor ">CONCETTINA  FENGA</span>, <span class="hlFld-ContribAuthor ">DEMETRIOS A.  SPANDIDOS</span>, <span class="hlFld-ContribAuthor ">MASSIMO  LIBRA</span>, <span class="hlFld-ContribAuthor ">ARISTIDIS M.  TSATSAKIS</span>. </span><span class="cited-content_cbyCitation_article-title">Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review). </span><span class="cited-content_cbyCitation_journal-name">International Journal of Oncology</span><span> <strong>2016,</strong> <em>48 </em>
                                    (3)
                                     , 869-885. <a href="https://doi.org/10.3892/ijo.2015.3306" title="DOI URL">https://doi.org/10.3892/ijo.2015.3306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/ijo.2015.3306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fijo.2015.3306%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Oncology%26atitle%3DAkt%252Binhibitors%252Bin%252Bcancer%252Btreatment%25253A%252BThe%252Blong%252Bjourney%252Bfrom%252Bdrug%252Bdiscovery%252Bto%252Bclinical%252Buse%252B%252528Review%252529%26aulast%3DNITULESCU%26aufirst%3DGEORGE%2BMIHAI%26date%3D2016%26date%3D2015%26volume%3D48%26issue%3D3%26spage%3D869%26epage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi  Yu</span>, <span class="hlFld-ContribAuthor ">Ronald E.  Savage</span>, <span class="hlFld-ContribAuthor ">Sudharshan  Eathiraj</span>, <span class="hlFld-ContribAuthor ">Justin  Meade</span>, <span class="hlFld-ContribAuthor ">Michael J.  Wick</span>, <span class="hlFld-ContribAuthor ">Terence  Hall</span>, <span class="hlFld-ContribAuthor ">Giovanni  Abbadessa</span>, <span class="hlFld-ContribAuthor ">Brian  Schwartz</span>, . </span><span class="cited-content_cbyCitation_article-title">Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2015,</strong> <em>10 </em>
                                    (10)
                                     , e0140479. <a href="https://doi.org/10.1371/journal.pone.0140479" title="DOI URL">https://doi.org/10.1371/journal.pone.0140479</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0140479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0140479%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DTargeting%252BAKT1-E17K%252Band%252Bthe%252BPI3K%25252FAKT%252BPathway%252Bwith%252Ban%252BAllosteric%252BAKT%252BInhibitor%25252C%252BARQ%252B092%26aulast%3DYu%26aufirst%3DYi%26date%3D2015%26date%3D2015%26volume%3D10%26issue%3D10%26spage%3De0140479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ke  Wu</span>, <span class="hlFld-ContribAuthor ">Jingzhi  Pang</span>, <span class="hlFld-ContribAuthor ">Dong  Song</span>, <span class="hlFld-ContribAuthor ">Ying  Zhu</span>, <span class="hlFld-ContribAuthor ">Congwen  Wu</span>, <span class="hlFld-ContribAuthor ">Tianqu  Shao</span>, <span class="hlFld-ContribAuthor ">Haifeng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Selectivity Mechanism of ATP-Competitive Inhibitors for PKB and PKA. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2015,</strong> <em>86 </em>
                                    (1)
                                     , 9-18. <a href="https://doi.org/10.1111/cbdd.12472" title="DOI URL">https://doi.org/10.1111/cbdd.12472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12472%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DSelectivity%252BMechanism%252Bof%252BATP-Competitive%252BInhibitors%252Bfor%252BPKB%252Band%252BPKA%26aulast%3DWu%26aufirst%3DKe%26date%3D2015%26date%3D2014%26volume%3D86%26issue%3D1%26spage%3D9%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ellen R.  Laird</span>. </span><span class="cited-content_cbyCitation_article-title">Case Studies: Selective Inhibitors of Protein Kinases - Exploiting Demure Features. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 413-434. <a href="https://doi.org/10.1002/9783527673643.ch18" title="DOI URL">https://doi.org/10.1002/9783527673643.ch18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527673643.ch18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527673643.ch18%26sid%3Dliteratum%253Aachs%26atitle%3DCase%252BStudies%25253A%252BSelective%252BInhibitors%252Bof%252BProtein%252BKinases%252B-%252BExploiting%252BDemure%252BFeatures%26aulast%3DLaird%26aufirst%3DEllen%2BR.%26date%3D2015%26date%3D2015%26spage%3D413%26epage%3D434%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DAntitargets%252Band%252BDrug%252BSafety%26aulast%3DUrb%25C3%25A1n%26aufirst%3DL%25C3%25A1szl%25C3%25B3%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenhu  Zhan</span>, <span class="hlFld-ContribAuthor ">Sendong  Lin</span>, <span class="hlFld-ContribAuthor ">Jing  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>, <span class="hlFld-ContribAuthor ">Jianbo  Chu</span>, <span class="hlFld-ContribAuthor ">Wenting  Du</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2015,</strong> <em>85 </em>
                                    (6)
                                     , 770-779. <a href="https://doi.org/10.1111/cbdd.12489" title="DOI URL">https://doi.org/10.1111/cbdd.12489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12489%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DDesign%25252C%252BSynthesis%25252C%252BBiological%252BEvaluation%25252C%252Band%252BMolecular%252BDocking%252Bof%252BNovel%252BBenzopyran%252Band%252BPhenylpyrazole%252BDerivatives%252Bas%252BAkt%252BInhibitors%26aulast%3DZhan%26aufirst%3DWenhu%26date%3D2015%26date%3D2014%26volume%3D85%26issue%3D6%26spage%3D770%26epage%3D779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carmen  Avendaño</span>, <span class="hlFld-ContribAuthor ">J. Carlos  Menéndez</span>. </span><span class="cited-content_cbyCitation_article-title">Drugs That Inhibit Signaling Pathways for Tumor Cell Growth and Proliferation. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 391-491. <a href="https://doi.org/10.1016/B978-0-444-62649-3.00010-7" title="DOI URL">https://doi.org/10.1016/B978-0-444-62649-3.00010-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-444-62649-3.00010-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-444-62649-3.00010-7%26sid%3Dliteratum%253Aachs%26atitle%3DDrugs%252BThat%252BInhibit%252BSignaling%252BPathways%252Bfor%252BTumor%252BCell%252BGrowth%252Band%252BProliferation%26aulast%3DAvenda%25C3%25B1o%26aufirst%3DCarmen%26date%3D2015%26spage%3D391%26epage%3D491%26pub%3DElsevier%26atitle%3DMedicinal%252BChemistry%252Bof%252BAnticancer%252BDrugs%26date%3D2015%26volume%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng Jun  Wang</span>, <span class="hlFld-ContribAuthor ">Shan Shan  Gong</span>, <span class="hlFld-ContribAuthor ">Qi  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of an Akt Inhibitor-IV Analogue via an Amine-Exchange Reaction. </span><span class="cited-content_cbyCitation_journal-name">Advanced Materials Research</span><span> <strong>2014,</strong> <em>1023 </em>, 47-50. <a href="https://doi.org/10.4028/www.scientific.net/AMR.1023.47" title="DOI URL">https://doi.org/10.4028/www.scientific.net/AMR.1023.47</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4028/www.scientific.net/AMR.1023.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4028%2Fwww.scientific.net%2FAMR.1023.47%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Materials%2520Research%26atitle%3DSynthesis%252Bof%252Ban%252BAkt%252BInhibitor-IV%252BAnalogue%252Bvia%252Ban%252BAmine-Exchange%252BReaction%26aulast%3DWang%26aufirst%3DCheng%2BJun%26date%3D2014%26date%3D2014%26volume%3D1023%26spage%3D47%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Susan  Heavey</span>, <span class="hlFld-ContribAuthor ">Kenneth J.  O’Byrne</span>, <span class="hlFld-ContribAuthor ">Kathy  Gately</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. </span><span class="cited-content_cbyCitation_journal-name">Cancer Treatment Reviews</span><span> <strong>2014,</strong> <em>40 </em>
                                    (3)
                                     , 445-456. <a href="https://doi.org/10.1016/j.ctrv.2013.08.006" title="DOI URL">https://doi.org/10.1016/j.ctrv.2013.08.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ctrv.2013.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ctrv.2013.08.006%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Treatment%2520Reviews%26atitle%3DStrategies%252Bfor%252Bco-targeting%252Bthe%252BPI3K%25252FAKT%25252FmTOR%252Bpathway%252Bin%252BNSCLC%26aulast%3DHeavey%26aufirst%3DSusan%26date%3D2014%26volume%3D40%26issue%3D3%26spage%3D445%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenhu  Zhan</span>, <span class="hlFld-ContribAuthor ">Daqiang  Li</span>, <span class="hlFld-ContribAuthor ">Jinxin  Che</span>, <span class="hlFld-ContribAuthor ">Liangren  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Yang</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: Toward the discovery of novel Akt1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>75 </em>, 11-20. <a href="https://doi.org/10.1016/j.ejmech.2014.01.019" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.01.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.01.019%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIntegrating%252Bdocking%252Bscores%25252C%252Binteraction%252Bprofiles%252Band%252Bmolecular%252Bdescriptors%252Bto%252Bimprove%252Bthe%252Baccuracy%252Bof%252Bmolecular%252Bdocking%25253A%252BToward%252Bthe%252Bdiscovery%252Bof%252Bnovel%252BAkt1%252Binhibitors%26aulast%3DZhan%26aufirst%3DWenhu%26date%3D2014%26volume%3D75%26spage%3D11%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oya Gursoy  Yilmaz</span>, <span class="hlFld-ContribAuthor ">Elif Ozkirimli  Olmez</span>, <span class="hlFld-ContribAuthor ">Kutlu O.  Ulgen</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the Akt1 allosteric site to identify novel scaffolds through virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2014,</strong> <em>48 </em>, 1-13. <a href="https://doi.org/10.1016/j.compbiolchem.2013.10.005" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2013.10.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2013.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2013.10.005%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DTargeting%252Bthe%252BAkt1%252Ballosteric%252Bsite%252Bto%252Bidentify%252Bnovel%252Bscaffolds%252Bthrough%252Bvirtual%252Bscreening%26aulast%3DYilmaz%26aufirst%3DOya%2BGursoy%26date%3D2014%26volume%3D48%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dmitriy M.  Volochnyuk</span>, <span class="hlFld-ContribAuthor ">Oleksandr O.  Grygorenko</span>, <span class="hlFld-ContribAuthor ">Alina O.  Gorlova</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine Containing Diazines. Synthesis and Properties. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 291-575. <a href="https://doi.org/10.1007/978-3-319-04435-4_6" title="DOI URL">https://doi.org/10.1007/978-3-319-04435-4_6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-04435-4_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-04435-4_6%26sid%3Dliteratum%253Aachs%26atitle%3DFluorine%252BContaining%252BDiazines.%252BSynthesis%252Band%252BProperties%26aulast%3DVolochnyuk%26aufirst%3DDmitriy%2BM.%26date%3D2014%26date%3D2014%26spage%3D291%26epage%3D575%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DFluorine%252Bin%252BHeterocyclic%252BChemistry%252BVolume%252B2%26aulast%3DNenajdenko%26aufirst%3DValentine%26date%3D2014%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Mortlock</span>, <span class="hlFld-ContribAuthor ">K.  Foote</span>, <span class="hlFld-ContribAuthor ">J.  Kettle</span>, <span class="hlFld-ContribAuthor ">B.  Aquila</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.11033-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.11033-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.11033-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.11033-9%26sid%3Dliteratum%253Aachs%26atitle%3DKinase%252BInhibitors%252Bin%252BCancer%26aulast%3DMortlock%26aufirst%3DA.%26date%3D2014%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2014%26volume%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mrinal K  Bera</span>, <span class="hlFld-ContribAuthor ">Moisés  Domínguez</span>, <span class="hlFld-ContribAuthor ">Paul  Hommes</span>, <span class="hlFld-ContribAuthor ">Hans-Ulrich  Reissig</span>. </span><span class="cited-content_cbyCitation_article-title">The Flögel-three-component reaction with dicarboxylic acids – an approach to bis(β-alkoxy-β-ketoenamides) for the synthesis of complex pyridine and pyrimidine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Beilstein Journal of Organic Chemistry</span><span> <strong>2014,</strong> <em>10 </em>, 394-404. <a href="https://doi.org/10.3762/bjoc.10.37" title="DOI URL">https://doi.org/10.3762/bjoc.10.37</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3762/bjoc.10.37&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3762%2Fbjoc.10.37%26sid%3Dliteratum%253Aachs%26jtitle%3DBeilstein%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DThe%252BFl%2525C3%2525B6gel-three-component%252Breaction%252Bwith%252Bdicarboxylic%252Bacids%252B%2525E2%252580%252593%252Ban%252Bapproach%252Bto%252Bbis%252528%2525CE%2525B2-alkoxy-%2525CE%2525B2-ketoenamides%252529%252Bfor%252Bthe%252Bsynthesis%252Bof%252Bcomplex%252Bpyridine%252Band%252Bpyrimidine%252Bderivatives%26aulast%3DBera%26aufirst%3DMrinal%2BK%26date%3D2014%26date%3D2014%26volume%3D10%26spage%3D394%26epage%3D404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yibing  Yan</span>, <span class="hlFld-ContribAuthor ">Violeta  Serra</span>, <span class="hlFld-ContribAuthor ">Ludmila  Prudkin</span>, <span class="hlFld-ContribAuthor ">Maurizio  Scaltriti</span>, <span class="hlFld-ContribAuthor ">Sumati  Murli</span>, <span class="hlFld-ContribAuthor ">Olga  Rodríguez</span>, <span class="hlFld-ContribAuthor ">Marta  Guzman</span>, <span class="hlFld-ContribAuthor ">Deepak  Sampath</span>, <span class="hlFld-ContribAuthor ">Michelle  Nannini</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Xiao</span>, <span class="hlFld-ContribAuthor ">Marie-Claire  Wagle</span>, <span class="hlFld-ContribAuthor ">Jenny Q.  Wu</span>, <span class="hlFld-ContribAuthor ">Matthew  Wongchenko</span>, <span class="hlFld-ContribAuthor ">Garret  Hampton</span>, <span class="hlFld-ContribAuthor ">Vanitha  Ramakrishnan</span>, <span class="hlFld-ContribAuthor ">Mark R.  Lackner</span>, <span class="hlFld-ContribAuthor ">Cristina  Saura</span>, <span class="hlFld-ContribAuthor ">Desamparados  Roda</span>, <span class="hlFld-ContribAuthor ">Andrés  Cervantes</span>, <span class="hlFld-ContribAuthor ">Josep  Tabernero</span>, <span class="hlFld-ContribAuthor ">Premal  Patel</span>, <span class="hlFld-ContribAuthor ">José  Baselga</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2013,</strong> <em>19 </em>
                                    (24)
                                     , 6976-6986. <a href="https://doi.org/10.1158/1078-0432.CCR-13-0978" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-13-0978</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-13-0978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-13-0978%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DEvaluation%252Band%252BClinical%252BAnalyses%252Bof%252BDownstream%252BTargets%252Bof%252Bthe%252BAkt%252BInhibitor%252BGDC-0068%26aulast%3DYan%26aufirst%3DYibing%26date%3D2013%26date%3D2013%26volume%3D19%26issue%3D24%26spage%3D6976%26epage%3D6986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Annette O.  Walter</span>, <span class="hlFld-ContribAuthor ">Robert Tjin Tham  Sjin</span>, <span class="hlFld-ContribAuthor ">Henry J.  Haringsma</span>, <span class="hlFld-ContribAuthor ">Kadoaki  Ohashi</span>, <span class="hlFld-ContribAuthor ">Jing  Sun</span>, <span class="hlFld-ContribAuthor ">Kwangho  Lee</span>, <span class="hlFld-ContribAuthor ">Aleksandr  Dubrovskiy</span>, <span class="hlFld-ContribAuthor ">Matthew  Labenski</span>, <span class="hlFld-ContribAuthor ">Zhendong  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhigang  Wang</span>, <span class="hlFld-ContribAuthor ">Michael  Sheets</span>, <span class="hlFld-ContribAuthor ">Thia  St Martin</span>, <span class="hlFld-ContribAuthor ">Russell  Karp</span>, <span class="hlFld-ContribAuthor ">Dan  van Kalken</span>, <span class="hlFld-ContribAuthor ">Prasoon  Chaturvedi</span>, <span class="hlFld-ContribAuthor ">Deqiang  Niu</span>, <span class="hlFld-ContribAuthor ">Mariana  Nacht</span>, <span class="hlFld-ContribAuthor ">Russell C.  Petter</span>, <span class="hlFld-ContribAuthor ">William  Westlin</span>, <span class="hlFld-ContribAuthor ">Kevin  Lin</span>, <span class="hlFld-ContribAuthor ">Sarah  Jaw-Tsai</span>, <span class="hlFld-ContribAuthor ">Mitch  Raponi</span>, <span class="hlFld-ContribAuthor ">Terry  Van Dyke</span>, <span class="hlFld-ContribAuthor ">Jeff  Etter</span>, <span class="hlFld-ContribAuthor ">Zoe  Weaver</span>, <span class="hlFld-ContribAuthor ">William  Pao</span>, <span class="hlFld-ContribAuthor ">Juswinder  Singh</span>, <span class="hlFld-ContribAuthor ">Andrew D.  Simmons</span>, <span class="hlFld-ContribAuthor ">Thomas C.  Harding</span>, <span class="hlFld-ContribAuthor ">Andrew  Allen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC. </span><span class="cited-content_cbyCitation_journal-name">Cancer Discovery</span><span> <strong>2013,</strong> <em>3 </em>
                                    (12)
                                     , 1404-1415. <a href="https://doi.org/10.1158/2159-8290.CD-13-0314" title="DOI URL">https://doi.org/10.1158/2159-8290.CD-13-0314</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Discovery%26atitle%3DDiscovery%252Bof%252Ba%252BMutant-Selective%252BCovalent%252BInhibitor%252Bof%252BEGFR%252Bthat%252BOvercomes%252BT790M-Mediated%252BResistance%252Bin%252BNSCLC%26aulast%3DWalter%26aufirst%3DAnnette%2BO.%26date%3D2013%26date%3D2013%26volume%3D3%26issue%3D12%26spage%3D1404%26epage%3D1415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shi-Feng  Chen</span>, <span class="hlFld-ContribAuthor ">Yang  Cao</span>, <span class="hlFld-ContribAuthor ">Jiong-Jiong  Chen</span>, <span class="hlFld-ContribAuthor ">Jian-Zhong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Binding selectivity studies of PKBα using molecular dynamics simulation and free energy calculations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Modeling</span><span> <strong>2013,</strong> <em>19 </em>
                                    (11)
                                     , 5097-5112. <a href="https://doi.org/10.1007/s00894-013-1997-3" title="DOI URL">https://doi.org/10.1007/s00894-013-1997-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00894-013-1997-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00894-013-1997-3%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Modeling%26atitle%3DBinding%252Bselectivity%252Bstudies%252Bof%252BPKB%2525CE%2525B1%252Busing%252Bmolecular%252Bdynamics%252Bsimulation%252Band%252Bfree%252Benergy%252Bcalculations%26aulast%3DChen%26aufirst%3DShi-Feng%26date%3D2013%26date%3D2013%26volume%3D19%26issue%3D11%26spage%3D5097%26epage%3D5112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark E.  Welker</span>, <span class="hlFld-ContribAuthor ">George  Kulik</span>. </span><span class="cited-content_cbyCitation_article-title">Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2013,</strong> <em>21 </em>
                                    (14)
                                     , 4063-4091. <a href="https://doi.org/10.1016/j.bmc.2013.04.083" title="DOI URL">https://doi.org/10.1016/j.bmc.2013.04.083</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2013.04.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2013.04.083%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bsyntheses%252Bof%252BPI3K%25252FAkt%25252FmTOR%252Bsignaling%252Bpathway%252Binhibitors%26aulast%3DWelker%26aufirst%3DMark%2BE.%26date%3D2013%26volume%3D21%26issue%3D14%26spage%3D4063%26epage%3D4091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Asami  Takashima</span>, <span class="hlFld-ContribAuthor ">Douglas V  Faller</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the RAS oncogene. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Targets</span><span> <strong>2013,</strong> <em>17 </em>
                                    (5)
                                     , 507-531. <a href="https://doi.org/10.1517/14728222.2013.764990" title="DOI URL">https://doi.org/10.1517/14728222.2013.764990</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/14728222.2013.764990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F14728222.2013.764990%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Targets%26atitle%3DTargeting%252Bthe%252BRAS%252Boncogene%26aulast%3DTakashima%26aufirst%3DAsami%26date%3D2013%26date%3D2013%26volume%3D17%26issue%3D5%26spage%3D507%26epage%3D531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sjoerd  Klarenbeek</span>, <span class="hlFld-ContribAuthor ">Martine H.  van Miltenburg</span>, <span class="hlFld-ContribAuthor ">Jos  Jonkers</span>. </span><span class="cited-content_cbyCitation_article-title">Genetically engineered mouse models of PI3K signaling in breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecular Oncology</span><span> <strong>2013,</strong> <em>7 </em>
                                    (2)
                                     , 146-164. <a href="https://doi.org/10.1016/j.molonc.2013.02.003" title="DOI URL">https://doi.org/10.1016/j.molonc.2013.02.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molonc.2013.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molonc.2013.02.003%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Oncology%26atitle%3DGenetically%252Bengineered%252Bmouse%252Bmodels%252Bof%252BPI3K%252Bsignaling%252Bin%2525C2%2525A0breast%252Bcancer%26aulast%3DKlarenbeek%26aufirst%3DSjoerd%26date%3D2013%26date%3D2013%26volume%3D7%26issue%3D2%26spage%3D146%26epage%3D164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Lin</span>, <span class="hlFld-ContribAuthor ">Deepak  Sampath</span>, <span class="hlFld-ContribAuthor ">Michelle A.  Nannini</span>, <span class="hlFld-ContribAuthor ">Brian B.  Lee</span>, <span class="hlFld-ContribAuthor ">Michael  Degtyarev</span>, <span class="hlFld-ContribAuthor ">Jason  Oeh</span>, <span class="hlFld-ContribAuthor ">Heidi  Savage</span>, <span class="hlFld-ContribAuthor ">Zhengyu  Guan</span>, <span class="hlFld-ContribAuthor ">Rebecca  Hong</span>, <span class="hlFld-ContribAuthor ">Robert  Kassees</span>, <span class="hlFld-ContribAuthor ">Leslie B.  Lee</span>, <span class="hlFld-ContribAuthor ">Tyler  Risom</span>, <span class="hlFld-ContribAuthor ">Stefan  Gross</span>, <span class="hlFld-ContribAuthor ">Bianca M.  Liederer</span>, <span class="hlFld-ContribAuthor ">Hartmut  Koeppen</span>, <span class="hlFld-ContribAuthor ">Nicholas J.  Skelton</span>, <span class="hlFld-ContribAuthor ">Jeffrey J.  Wallin</span>, <span class="hlFld-ContribAuthor ">Marcia  Belvin</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Punnoose</span>, <span class="hlFld-ContribAuthor ">Lori S.  Friedman</span>, <span class="hlFld-ContribAuthor ">Kui  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2013,</strong> <em>19 </em>
                                    (7)
                                     , 1760-1772. <a href="https://doi.org/10.1158/1078-0432.CCR-12-3072" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-12-3072</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-12-3072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-12-3072%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DTargeting%252BActivated%252BAkt%252Bwith%252BGDC-0068%25252C%252Ba%252BNovel%252BSelective%252BAkt%252BInhibitor%252BThat%252BIs%252BEfficacious%252Bin%252BMultiple%252BTumor%252BModels%26aulast%3DLin%26aufirst%3DJie%26date%3D2013%26date%3D2013%26volume%3D19%26issue%3D7%26spage%3D1760%26epage%3D1772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaikrit  Bhutani</span>, <span class="hlFld-ContribAuthor ">Asfandyar  Sheikh</span>, <span class="hlFld-ContribAuthor ">Asfandyar  Niazi</span>. </span><span class="cited-content_cbyCitation_article-title">Akt inhibitors: mechanism of action and implications for anticancer therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Infectious Agents and Cancer</span><span> <strong>2013,</strong> <em>8 </em>
                                    (1)
                                     , 49. <a href="https://doi.org/10.1186/1750-9378-8-49" title="DOI URL">https://doi.org/10.1186/1750-9378-8-49</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/1750-9378-8-49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2F1750-9378-8-49%26sid%3Dliteratum%253Aachs%26jtitle%3DInfectious%2520Agents%2520and%2520Cancer%26atitle%3DAkt%252Binhibitors%25253A%252Bmechanism%252Bof%252Baction%252Band%252Bimplications%252Bfor%252Banticancer%252Btherapeutics%26aulast%3DBhutani%26aufirst%3DJaikrit%26date%3D2013%26volume%3D8%26issue%3D1%26spage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Advanced proof-of-concept pan-Akt inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 5-Substituted 6,7-Dihydro-5<i>H</i>-cyclopenta[<i>d</i>]pyrimidine Cores<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) NaHCO<sub>3</sub>, Et<sub>2</sub>O, Br<sub>2</sub>, 0 °C; (ii) 21% NaOEt, EtOH, 0 °C to rt, 12 h; (iii) semicarbazide hydrochloride, NaOAc, H<sub>2</sub>O–EtOH (2:1), reflux to rt, 12 h (64%); (b) (i) ozone, EtOAc, −78 °C; (ii) zinc dust, acetic acid, 0 °C, 2 h (94%); (c) NH<sub>4</sub>OAc, MeOH, 12 h; (d) NH<sub>4</sub>CO<sub>2</sub>, formamide, 150 °C, 24 h; (e) POCl<sub>3</sub>, DCE, reflux, 6 h; (f) <i>tert</i>-butyl piperazine-1-carboxylate, DIEA, 1-BuOH, reflux, 16 h; (g) (i) ozone, DCM, −78 °C, 15 min; (ii) EtSMe, rt, 1 h; (iii) NaBH<sub>4</sub>, MeOH, 0 °C, 2 h (55%); (iv) chiral SFC separation; (h) PBSF, HF–Et<sub>3</sub>N, (80%); (i) 4 N HCl in dioxane, DCM, 12 h.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of C7-Hydroxylated and -Fluorinated Cyclopenta[<i>d</i>]pyrimidine Cores<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>m</i>-CPBA, NaHCO<sub>3</sub>, CHCl<sub>3</sub>, 0 °C to rt, 2 h (100%); (b) acetic anhydride, 100 °C, 2 h (89%); (c) LiOH, THF–H<sub>2</sub>O (5:1), 16 h (99%); (d) oxalyl chloride, DMSO, Et<sub>3</sub>N, DCM, −78 °C to rt, 12 h (71%); (e) (i) RuCl(<i>p</i>-cymene)[(<i>R</i>,<i>R</i>)-TsDPEN] (for <b>12a</b>) or RuCl(<i>p</i>-cymene)[(<i>S</i>,<i>S</i>)-TsDPEN] (for <b>13a</b>), formic acid, Et<sub>3</sub>N, DCM, 12 h (ii) 4-nitrobenzoyl chloride, Et<sub>3</sub>N, DCM, 0 °C to rt, 4 h; (iii) LiOH, THF–H<sub>2</sub>O (2:1), 0 °C to rt, 1 h; (f) DAST, DCM, −20 °C, 1 h; (g) 4 N HCl in dioxane, DCM, 12 h.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Stereoselective Synthesis of β-Phenylalanine Amino Acids<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>n</i>-BuLi, THF, −78 to −20 °C, 2-(4-chlorophenyl)acetyl chloride, 12 h (79%); (b) 1 M TiCl<sub>4</sub>, DCM, −78 °C, DIEA, rt, 1.5 h (72%); (c) DDQ, DCM, H<sub>2</sub>O, 19 h (100%); (d) LiOH–H<sub>2</sub>O, THF–H<sub>2</sub>O (3:1), 0 °C, H<sub>2</sub>O<sub>2</sub>, 12 h.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Amide Coupling and Further Elaboration of Amines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) HBTU, Hünig’s base, DCM, 1 h; (b) 4 N HCl, DCM, rt; (c) aldehyde or ketone, Na(OAc)<sub>3</sub>BH, Hünig’s base, DCE, rt, 16 h.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Alternative Synthesis of Substituted Amines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CF<sub>3</sub>CH<sub>2</sub>OTf, Hünig’s base, THF–DMF (1:1), rt, 20 h, (93%); (b) KO(TMS), THF, rt, 18 h; (c) paraformaldehyde, 10% NaOMe, DMSO, rt, 12 h; (d) MsCl, TEA, DCM, 0 °C to rt, 12 h; (e) HNR′R″, THF, 0 °C, 12 h; (f) (i) HBTU, Hünig’s base, DMF, 18 h; (ii) chiral separation.</p></p></figure><figure data-id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structure of Akt1 in complex with a dihydrothienopyrimidine inhibitor (compound 26 from ref <a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">7</a>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OW4">3OW4</a>) at 2.6 Å resolution showing the molecular surface of the pocket in the vicinity of the hinge (hydrogens added for clarity).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structure of <b>28</b> bound to Akt1, solved at 2.0 Å resolution. Hydrogen atoms added for clarity (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EKL">4EKL</a>).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. PK/PD of <b>28</b> in PC3 prostate tumors. Tumor ratios of p-PRAS40 to total PRAS40 (tPRAS40) were determined in female nude mice bearing PC3 prostate tumor xenografts (average of five animals ± SEM). Plasma concentrations of <b>28</b> were also measured. Samples were collected 3 h (A) or 8 h (B) following administration of 12.5, 25, and 100 mg/kg doses (free base equivalents formulated in 0.5% methylcellulose/0.2% Tween-80). The inhibition (%) of p-PRAS40/tPRAS40 is based on comparison to the vehicle control and stated in parentheses. Average drug levels ± SEM (μM) of <b>28</b> were determined by analysis of plasma from five animals. Two asterisks indicate <i>p</i> < 0.001, determined by Student’s <i>t</i> test to find differences in biomarker effects for dosing groups vs the vehicle control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/medium/jm-2012-01024w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of qd and bid oral dosing of <b>28</b> on PC3 prostate tumors (mean tumor volume in cubic millimeters ± SEM). Dose levels are expressed as free-base equivalents prepared in vehicle (0.5% methylcellulose/0.2% Tween-80).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-18/jm301024w/production/images/large/jm-2012-01024w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301024w&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i77">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35588" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35588" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 23 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cheng, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindsley, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, G. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicosia, S. V.</span><span> </span><span class="NLM_article-title">The Akt/PKB pathway: molecular target for cancer drug discovery</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">7482</span><span class="NLM_x">–</span> <span class="NLM_lpage">7492</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=7482-7492&author=J.+Q.+Chengauthor=C.+W.+Lindsleyauthor=G.+Z.+Chengauthor=H.+Yangauthor=S.+V.+Nicosia&title=The+Akt%2FPKB+pathway%3A+molecular+target+for+cancer+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%2BQ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DCheng%26aufirst%3DG.%2BZ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DNicosia%26aufirst%3DS.%2BV.%26atitle%3DThe%2520Akt%252FPKB%2520pathway%253A%2520molecular%2520target%2520for%2520cancer%2520drug%2520discovery%26jtitle%3DOncogene%26date%3D2005%26volume%3D24%26spage%3D7482%26epage%3D7492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Manning, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">AKT/PKB signaling: navigating downstream</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">129</span><span class="NLM_x">, </span> <span class="NLM_fpage">1261</span><span class="NLM_x">–</span> <span class="NLM_lpage">1274</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2007&pages=1261-1274&author=B.+D.+Manningauthor=L.+C.+Cantley&title=AKT%2FPKB+signaling%3A+navigating+downstream"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DB.%2BD.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DAKT%252FPKB%2520signaling%253A%2520navigating%2520downstream%26jtitle%3DCell%26date%3D2007%26volume%3D129%26spage%3D1261%26epage%3D1274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Altomare, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testa, J. R.</span><span> </span><span class="NLM_article-title">Perturbations of the AKT signaling pathway in human cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">7455</span><span class="NLM_x">–</span> <span class="NLM_lpage">7464</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=7455-7464&author=D.+A.+Altomareauthor=J.+R.+Testa&title=Perturbations+of+the+AKT+signaling+pathway+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAltomare%26aufirst%3DD.%2BA.%26aulast%3DTesta%26aufirst%3DJ.%2BR.%26atitle%3DPerturbations%2520of%2520the%2520AKT%2520signaling%2520pathway%2520in%2520human%2520cancer%26jtitle%3DOncogene%26date%3D2005%26volume%3D24%26spage%3D7455%26epage%3D7464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Vivanco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">The phosphatidylinositol 3-kinase AKT pathway in human cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.1038%2Fnrc839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=12094235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=489-501&author=I.+Vivancoauthor=C.+L.+Sawyers&title=The+phosphatidylinositol+3-kinase+AKT+pathway+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol 3-Kinase-AKT pathway in human cancer</span></div><div class="casAuthors">Vivanco, Igor; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One signal that is overactivated in a wide range of tumor types is the prodn. of a phospholipid, phosphatidylinositol (3,4,5) trisphosphate, by phosphatidylinositol 3-kinase (PI3K).  This lipid and the protein kinase that is activated by it, AKT, trigger a cascade of responses, from cell growth and proliferation to survival and motility, that drive tumor progression.  Small-mol. therapeutics that block PI3K signaling might deal a severe blow to cancer cells by blocking many aspects of the tumor-cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAQ-0qeD7pLVg90H21EOLACvtfcHk0lhXwP3aNsrOAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D&md5=c6762d32f9f1281632f4ccdbcd29268c</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fnrc839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc839%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DThe%2520phosphatidylinositol%25203-kinase%2520AKT%2520pathway%2520in%2520human%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D489%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lian, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cristofano, A.</span><span> </span><span class="NLM_article-title">Class reunion: PTEN joins the nuclear crew</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">7394</span><span class="NLM_x">–</span> <span class="NLM_lpage">7400</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=7394-7400&author=Z.+Lianauthor=A.+Di+Cristofano&title=Class+reunion%3A+PTEN+joins+the+nuclear+crew"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLian%26aufirst%3DZ.%26aulast%3DDi%2BCristofano%26aufirst%3DA.%26atitle%3DClass%2520reunion%253A%2520PTEN%2520joins%2520the%2520nuclear%2520crew%26jtitle%3DOncogene%26date%3D2005%26volume%3D24%26spage%3D7394%26epage%3D7400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Degtyarev, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Mazière, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tien, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dijk, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stern, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klumperman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span> </span><span class="NLM_article-title">Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2008&pages=101-16&author=M.+Degtyarevauthor=A.+De+Mazi%C3%A8reauthor=C.+Orrauthor=J.+Linauthor=B.+B.+Leeauthor=J.+Y.+Tienauthor=W.+W.+Priorauthor=S.+van+Dijkauthor=H.+Wuauthor=D.+C.+Grayauthor=D.+P.+Davisauthor=H.+M.+Sternauthor=L.+J.+Murrayauthor=K.+P.+Hoeflichauthor=J.+Klumpermanauthor=L.+S.+Friedmanauthor=K.+Lin&title=Akt+inhibition+promotes+autophagy+and+sensitizes+PTEN-null+tumors+to+lysosomotropic+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDegtyarev%26aufirst%3DM.%26aulast%3DDe%2BMazi%25C3%25A8re%26aufirst%3DA.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DB.%2BB.%26aulast%3DTien%26aufirst%3DJ.%2BY.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3Dvan%2BDijk%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DGray%26aufirst%3DD.%2BC.%26aulast%3DDavis%26aufirst%3DD.%2BP.%26aulast%3DStern%26aufirst%3DH.%2BM.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DKlumperman%26aufirst%3DJ.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DLin%26aufirst%3DK.%26atitle%3DAkt%2520inhibition%2520promotes%2520autophagy%2520and%2520sensitizes%2520PTEN-null%2520tumors%2520to%2520lysosomotropic%2520agents%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2008%26volume%3D183%26spage%3D101%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chen, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, P. -Y</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, H. H.</span><span> </span><span class="NLM_article-title">Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy</span> <span class="citation_source-journal">Curr. Med. Chem. Anticancer Agents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">589</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.2174%2F156801105774574649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=16305480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A280%3ADC%252BD2Mnitlymtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=575-589&author=Y.+L.+Chenauthor=P.+-Y+Lawauthor=H.+H.+Loh&title=Inhibition+of+PI3K%2FAkt+signaling%3A+an+emerging+paradigm+for+targeted+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy</span></div><div class="casAuthors">Chen Yulong L; Law Ping-Y; Loh Horace H</div><div class="citationInfo"><span class="NLM_cas:title">Current medicinal chemistry. Anti-cancer agents</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">575-89</span>
        ISSN:<span class="NLM_cas:issn">1568-0118</span>.
    </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B, PKB) signaling pathway plays a critical role in cell growth and survival.  Dysregulation of this pathway has been found in a variety of cancer cells.  Recently, constitutively active PI3K/Akt signaling has been firmly established as a major determinant for cell growth and survival in an array of cancers.  Blocking the constitutively active PI3K/AKT signaling pathway provides a new strategy for targeted cancer therapy.  Thus, inhibitors of this signaling pathway would be potential anticancer agents, particularly for cancer cells whose survival and growth are dominated by constitutively active PI3K/Akt signaling.  This review describes the current understanding of small molecule drugs targeting this pathway both in vitro and in vivo.  Inhibitors and functions of the upstream and downstream molecular targets of the PI3K/Akt pathway are discussed in the context of using the inhibitors to block this pathway for targeted cancer therapy.  Special emphasis is placed on the following targets: receptor tyrosine kinases, PI3K, Akt, and the mammalian target of rapamycin.  While the molecular therapeutic strategy holds great promise for the treatment of a variety of cancers, few small molecule inhibitors with potential high therapeutic indexes are available.  Thus, new inhibitors with high selectivity, bioavailability, and potency are greatly needed.  Novel approaches toward the development of PI3K/Akt pathway inhibitors as anticancer therapeutics are discussed in detail, with emphasis on chemical genetics-based and structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQoT7lhSKHCPe_Q9URG6Dx8fW6udTcc2eZ6RfeJNpDY7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mnitlymtg%253D%253D&md5=d9d6980724d20abbc1e71b9d1bde1279</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.2174%2F156801105774574649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156801105774574649%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DLaw%26aufirst%3DP.%2B-Y%26aulast%3DLoh%26aufirst%3DH.%2BH.%26atitle%3DInhibition%2520of%2520PI3K%252FAkt%2520signaling%253A%2520an%2520emerging%2520paradigm%2520for%2520targeted%2520cancer%2520therapy%26jtitle%3DCurr.%2520Med.%2520Chem.%2520Anticancer%2520Agents%26date%3D2005%26volume%3D5%26spage%3D575%26epage%3D589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span> </span><span class="NLM_article-title">Targeting PI3K-AKT pathway for cancer therapy</span> <span class="citation_source-journal">Rev. Clin. Exp. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">228</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=14763163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSqsLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2003&pages=205-228&author=Y.+Luauthor=H.+Wangauthor=G.+B.+Mills&title=Targeting+PI3K-AKT+pathway+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K-AKT pathway for cancer therapy</span></div><div class="casAuthors">Lu, Yiling; Wang, Hongwei; Mills, Gordon B.</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in Clinical and Experimental Hematology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-228</span>CODEN:
                <span class="NLM_cas:coden">RCEHFB</span>;
        ISSN:<span class="NLM_cas:issn">1127-0020</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The phosphatydilinositol 3-kinase/protein kinase 8 (PI3K-AKT) pathway presents an exciting new target for mol. therapeutics.  While exhibiting great promise, addnl. preclin. and clin. studies will be required to det. how best to target this pathway to improve patient outcome.  A no. of questions need to be answered prior to the implementation into patient care practices.  As described below, the PI3K-AKT pathway regulates a broad spectrum of cellular processes, some of which are necessary to maintain normal physiol. functions, which potentially contribute to the toxicity of the drugs targeting the pathway.  Elucidation of the precise function of the PI3K-AKT isoforms, could promote the development of isoform specific approaches to provide a selective action on tumor cells.  However, whether this will be possible due to conservation of structural domains is not yet clear.  Inhibition of the PI3K-AKT pathway at multiple sites or a combination with inhibitors of different signaling pathways may allow the development of an acceptable therapeutic index for cancer management.  Further, inhibition of the PI3K-AKT pathway combined with conventional chemotherapy or radiation therapy may provide a more effective strategy to improve patient outcome.  As mol. therapeutics target the underlying defects in patient tumors, mol. diagnostics are required to identify patients with particular genetic aberrations in the pathway.  It will be crit. to provide adequate therapeutic strategies tailored to each patient.  In addn., patients with different genetic backgrounds or in different health conditions could respond adversely to particular therapeutics.  Therefore, identification of patients for particular drugs based on the underlying genetic defects in the tumor as well as the characteristics of the host would be of benefit for improving patient outcome.  Linking the targeted therapeutics to mol. imaging approaches will det. appropriate biol. relevant dose for patients.  It will also define expected tumor responsiveness and eventually will improve efficacy and decrease toxicity.  In this regard, personalized mol. medicine is likely to soon provide effective cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNhTtR9V2YCbVg90H21EOLACvtfcHk0lgFun58lvvNWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSqsLvO&md5=80c1accfd7e1bf4b1ab8df10c5452ca3</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMills%26aufirst%3DG.%2BB.%26atitle%3DTargeting%2520PI3K-AKT%2520pathway%2520for%2520cancer%2520therapy%26jtitle%3DRev.%2520Clin.%2520Exp.%2520Hematol.%26date%3D2003%26volume%3D7%26spage%3D205%26epage%3D228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Mitsiades, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koutsilieris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgatti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capitani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brazil, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hemmings, B. A.</span><span> </span><span class="NLM_article-title">The Akt pathway: molecular targets for anti-cancer drug development</span> <span class="citation_source-journal">Curr. Cancer Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.2174%2F1568009043333032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=15134532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1Gnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=235-256&author=C.+S.+Mitsiadesauthor=N.+Mitsiadesauthor=M.+Koutsilierisauthor=K.+M.+Nicholsonauthor=N.+G.+Andersonauthor=L.+M.+Neriauthor=P.+Borgattiauthor=S.+Capitaniauthor=M.+Martelliauthor=D.+P.+Brazilauthor=B.+A.+Hemmings&title=The+Akt+pathway%3A+molecular+targets+for+anti-cancer+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">The Akt pathway: Molecular targets for anti-cancer drug development</span></div><div class="casAuthors">Mitsiades, Constantine S.; Mitsiades, Nicholas; Koutsilieris, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-256</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The serine/threonine kinase Akt functions intracellularly as a cardinal nodal point for a constellation of converging upstream signaling pathways, which involve stimulation of receptor tyrosine kinases such as IGR-1R, HER2/Neu, VEGF-R, PDGF-R, and an assembly of membrane-localized complexes of receptor-PI-3K and activation of Akt through the second messenger PIP3.  The integration of these intracellular signals at the level of Akt and its kinase activity, regulates the phosphorylation of its several downstream effectors, such as NF-κB, mTOR, Forkhead, Bad, GSK-3 and MDM-2.  These phosphorylation events in turn mediate the effects of Akt on cell growth, proliferation, protection from pro-apoptotic stimuli, and stimulation of neoangiogenesis.  Because Akt and its upstream regulators are deregulated in a wide range of solid tumors and hematol. malignancies, and in view of the aforementioned biol. sequelae of this pathway, the Akt pathway is considered a key determinant of biol. aggressiveness of these tumors, and a major potential target for novel anti-cancer therapies.  This review focuses on ongoing translational efforts to therapeutically target Akt and its biol. sequelae, either at the level of Akt itself or at the levels of its upstream regulators and downstream effectors.  Because Akt is also important for proliferative and anti-apoptotic signaling pathways crit. for normal cells, particular emphasis is placed on the fine-tuning the targeting of individual components of this pathway to maximize the therapeutic index of anti-cancer strategies based on the PI-3K/Akt pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGZbuqTPNYgLVg90H21EOLACvtfcHk0ljePvSwP5eFrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1Gnu78%253D&md5=299909de4babdbbf0e242bd1a7abdab1</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.2174%2F1568009043333032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009043333032%26sid%3Dliteratum%253Aachs%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DMitsiades%26aufirst%3DN.%26aulast%3DKoutsilieris%26aufirst%3DM.%26aulast%3DNicholson%26aufirst%3DK.%2BM.%26aulast%3DAnderson%26aufirst%3DN.%2BG.%26aulast%3DNeri%26aufirst%3DL.%2BM.%26aulast%3DBorgatti%26aufirst%3DP.%26aulast%3DCapitani%26aufirst%3DS.%26aulast%3DMartelli%26aufirst%3DM.%26aulast%3DBrazil%26aufirst%3DD.%2BP.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DThe%2520Akt%2520pathway%253A%2520molecular%2520targets%2520for%2520anti-cancer%2520drug%2520development%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2004%26volume%3D4%26spage%3D235%26epage%3D256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Pal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reckamp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figlin, R. A.</span><span> </span><span class="NLM_article-title">Akt inhibitors in clinical development for the treatment of cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1355</span><span class="NLM_x">–</span> <span class="NLM_lpage">1366</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=1355-1366&author=S.+K.+Palauthor=K.+Reckampauthor=H.+Yuauthor=R.+A.+Figlin&title=Akt+inhibitors+in+clinical+development+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPal%26aufirst%3DS.%2BK.%26aulast%3DReckamp%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26atitle%3DAkt%2520inhibitors%2520in%2520clinical%2520development%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2010%26volume%3D19%26spage%3D1355%26epage%3D1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bencsik, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woessner, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G. P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span> </span><span class="NLM_article-title">Discovery of pyrrolopyrimidine inhibitors of Akt</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5607</span><span class="NLM_x">–</span> <span class="NLM_lpage">5612</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5607-5612&author=J.+F.+Blakeauthor=N.+C.+Kallanauthor=D.+Xiaoauthor=R.+Xuauthor=J.+R.+Bencsikauthor=N.+J.+Skeltonauthor=K.+L.+Spencerauthor=I.+S.+Mitchellauthor=R.+D.+Woessnerauthor=S.+L.+Gloorauthor=T.+Risomauthor=S.+D.+Grossauthor=M.+Martinsonauthor=T.+H.+Moralesauthor=G.+P.+A.+Vigersauthor=B.+J.+Brandhuber&title=Discovery+of+pyrrolopyrimidine+inhibitors+of+Akt"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKallan%26aufirst%3DN.%2BC.%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DBencsik%26aufirst%3DJ.%2BR.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DSpencer%26aufirst%3DK.%2BL.%26aulast%3DMitchell%26aufirst%3DI.%2BS.%26aulast%3DWoessner%26aufirst%3DR.%2BD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DGross%26aufirst%3DS.%2BD.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DMorales%26aufirst%3DT.%2BH.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26atitle%3DDiscovery%2520of%2520pyrrolopyrimidine%2520inhibitors%2520of%2520Akt%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5607%26epage%3D5612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Bencsik, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woessner, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dizon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G. P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span> </span><span class="NLM_article-title">Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">7037</span><span class="NLM_x">–</span> <span class="NLM_lpage">7041</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.1016%2Fj.bmcl.2010.09.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=20971641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7037-7041&author=J.+R.+Bencsikauthor=D.+Xiaoauthor=J.+F.+Blakeauthor=N.+C.+Kallanauthor=I.+S.+Mitchellauthor=K.+L.+Spencerauthor=R.+Xuauthor=S.+L.+Gloorauthor=M.+Martinsonauthor=T.+Risomauthor=R.+D.+Woessnerauthor=F.+Dizonauthor=W.-I.+Wuauthor=G.+P.+A.+Vigersauthor=B.+J.+Brandhuberauthor=N.+J.+Skeltonauthor=W.+W.+Priorauthor=L.+J.+Murray&title=Discovery+of+dihydrothieno-+and+dihydrofuropyrimidines+as+potent+pan+Akt+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors</span></div><div class="casAuthors">Bencsik, Josef R.; Xiao, Dengming; Blake, James F.; Kallan, Nicholas C.; Mitchell, Ian S.; Spencer, Keith L.; Xu, Rui; Gloor, Susan L.; Martinson, Matthew; Risom, Tyler; Woessner, Richard D.; Dizon, Faith; Wu, Wen-I.; Vigers, Guy P. A.; Brandhuber, Barbara J.; Skelton, Nicholas J.; Prior, Wei Wei; Murray, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7037-7041</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis of a novel series of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors is reported.  Inhibitors displaying increased PKA and general kinase selectivity with improved tolerability compared to the progenitor pyrrolopyrimidine were developed using previous SAR and anal. of the amino acid sequences in the binding site.  Dihydrothieno compd. I was advanced into a PC3-NCI prostate mouse tumor model in which it demonstrated a dose-dependent redn. in tumor growth and stasis when dosed orally daily at 200 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8-bp6rwVWNrVg90H21EOLACvtfcHk0lgf0-X1SDJ18A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtLnJ&md5=d6aed3020c07ed85e83379c40d53394e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.09.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.09.112%26sid%3Dliteratum%253Aachs%26aulast%3DBencsik%26aufirst%3DJ.%2BR.%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKallan%26aufirst%3DN.%2BC.%26aulast%3DMitchell%26aufirst%3DI.%2BS.%26aulast%3DSpencer%26aufirst%3DK.%2BL.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DWoessner%26aufirst%3DR.%2BD.%26aulast%3DDizon%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DW.-I.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26atitle%3DDiscovery%2520of%2520dihydrothieno-%2520and%2520dihydrofuropyrimidines%2520as%2520potent%2520pan%2520Akt%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7037%26epage%3D7041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Taber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petty, E. H.</span><span> </span><span class="NLM_article-title">General route to highly functionalized cyclopentane derivatives by intermolecular C–H insertion</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4808</span><span class="NLM_x">–</span> <span class="NLM_lpage">4809</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00145a050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1982&pages=4808-4809&author=D.+F.+Taberauthor=E.+H.+Petty&title=General+route+to+highly+functionalized+cyclopentane+derivatives+by+intermolecular+C%E2%80%93H+insertion"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjo00145a050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00145a050%26sid%3Dliteratum%253Aachs%26aulast%3DTaber%26aufirst%3DD.%2BF.%26aulast%3DPetty%26aufirst%3DE.%2BH.%26atitle%3DGeneral%2520route%2520to%2520highly%2520functionalized%2520cyclopentane%2520derivatives%2520by%2520intermolecular%2520C%25E2%2580%2593H%2520insertion%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1982%26volume%3D47%26spage%3D4808%26epage%3D4809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Nugent, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobbs, F. W.,  Jr.</span><span> </span><span class="NLM_article-title">Improved route to 3-vinyl substituted cyclopentanones. Synthesis of (±)-mitsugashiwalactone</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3376</span><span class="NLM_x">–</span> <span class="NLM_lpage">3378</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00367a027" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1986&pages=3376-3378&author=W.+A.+Nugentauthor=F.+W.+Hobbs&title=Improved+route+to+3-vinyl+substituted+cyclopentanones.+Synthesis+of+%28%C2%B1%29-mitsugashiwalactone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjo00367a027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00367a027%26sid%3Dliteratum%253Aachs%26aulast%3DNugent%26aufirst%3DW.%2BA.%26aulast%3DHobbs%26aufirst%3DF.%2BW.%26atitle%3DImproved%2520route%2520to%25203-vinyl%2520substituted%2520cyclopentanones.%2520Synthesis%2520of%2520%2528%25C2%25B1%2529-mitsugashiwalactone%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1986%26volume%3D51%26spage%3D3376%26epage%3D3378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Yin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarkowsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huffman, M. A.</span><span> </span><span class="NLM_article-title">Direct and convenient conversion of alcohols to fluorides</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1465</span><span class="NLM_x">–</span> <span class="NLM_lpage">1468</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol049672a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Whurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=1465-1468&author=J.+Yinauthor=D.+S.+Zarkowskyauthor=D.+W.+Thomasauthor=M.+M.+Zhaoauthor=M.+A.+Huffman&title=Direct+and+convenient+conversion+of+alcohols+to+fluorides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Direct and convenient conversion of alcohols to fluorides</span></div><div class="casAuthors">Yin, Jingjun; Zarkowsky, Devin S.; Thomas, David W.; Zhao, Matthew M.; Huffman, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1465-1468</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Directly mixing primary, secondary, and tertiary alcs. with nC4F9SO2F-NR3(HF)3-NR3 resulted in formation of fluorides, e.g., I, in high yields.  The readily available reagents were easy to handle, and the mild, almost neutral, reaction conditions allowed for excellent functional group compatibility.  A NR3(HF)3/NR3 ratio of ≤1:2 gave the highest reactivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi8LHzVOsjF7Vg90H21EOLACvtfcHk0lgvfmXmk9N45A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Whurs%253D&md5=83c3f9aefc44f02e18e60b17cf2a5d37</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fol049672a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol049672a%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DZarkowsky%26aufirst%3DD.%2BS.%26aulast%3DThomas%26aufirst%3DD.%2BW.%26aulast%3DZhao%26aufirst%3DM.%2BM.%26aulast%3DHuffman%26aufirst%3DM.%2BA.%26atitle%3DDirect%2520and%2520convenient%2520conversion%2520of%2520alcohols%2520to%2520fluorides%26jtitle%3DOrg.%2520Lett.%26date%3D2004%26volume%3D6%26spage%3D1465%26epage%3D1468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Fujii, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashiguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uematsu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikariya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noyori, R.</span><span> </span><span class="NLM_article-title">Ruthenium (II)-catalyzed asymmetric transfer hydrogenation of ketones using a formic acid–triethylamine mixture</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">2521</span><span class="NLM_x">–</span> <span class="NLM_lpage">2522</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja954126l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=2521-2522&author=A.+Fujiiauthor=S.+Hashiguchiauthor=N.+Uematsuauthor=T.+Ikariyaauthor=R.+Noyori&title=Ruthenium+%28II%29-catalyzed+asymmetric+transfer+hydrogenation+of+ketones+using+a+formic+acid%E2%80%93triethylamine+mixture"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fja954126l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja954126l%26sid%3Dliteratum%253Aachs%26aulast%3DFujii%26aufirst%3DA.%26aulast%3DHashiguchi%26aufirst%3DS.%26aulast%3DUematsu%26aufirst%3DN.%26aulast%3DIkariya%26aufirst%3DT.%26aulast%3DNoyori%26aufirst%3DR.%26atitle%3DRuthenium%2520%2528II%2529-catalyzed%2520asymmetric%2520transfer%2520hydrogenation%2520of%2520ketones%2520using%2520a%2520formic%2520acid%25E2%2580%2593triethylamine%2520mixture%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1996%26volume%3D118%26spage%3D2521%26epage%3D2522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Middleton, W. J.</span><span> </span><span class="NLM_article-title">New fluorinating reagents. Dialkylaminosulfur fluorides</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">574</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00893a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADyaE2MXhtFWms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1975&pages=574-578&author=W.+J.+Middleton&title=New+fluorinating+reagents.+Dialkylaminosulfur+fluorides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">New fluorinating reagents.  Dialkylaminosulfur fluorides</span></div><div class="casAuthors">Middleton, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">574-8</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Trifluorides R2NSF3 (I; R = Me, Et, Me2CH; or R2N = pyrrolidino) were prepd. by the reaction of R2NSiMe3 with SF4 in FCCl3 at -78°; I reacted with R21NSiMe3 to give R2NSF2NR21 (II; R, R1 = Me, Et; or R12 = piperidino).  I and II were used to fluorinate alcs., aldehydes, or ketones.  E.g., I (R = Et) reacted with Me2CHCH2OH in diglyme at -50 to -78° to give 49% Me2CHCH2F and 21% Me3CF.  EtCHO with I (R = Et) in FCCl3 at 25° gave 80% EtCHF2.  Among ∼23 other compds. fluorinated were: cyclooctanol, BzH, 1-naphthaldehyde, and menthol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2t9GSp_UF5bVg90H21EOLACvtfcHk0lgvfmXmk9N45A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXhtFWms74%253D&md5=d981d018df795514d4f7ffbeb8f4baa8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjo00893a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00893a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiddleton%26aufirst%3DW.%2BJ.%26atitle%3DNew%2520fluorinating%2520reagents.%2520Dialkylaminosulfur%2520fluorides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1975%26volume%3D40%26spage%3D574%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onomura, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, T.</span><span> </span><span class="NLM_article-title">A convenient method for synthesis of enantiomerically enriched methylphenidate from <i>N</i>-methoxycarbonylpiperidine</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol9905046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1999&pages=175-178&author=Y.+Matsumuraauthor=Y.+Kandaauthor=K.+Shiraiauthor=O.+Onomuraauthor=T.+Maki&title=A+convenient+method+for+synthesis+of+enantiomerically+enriched+methylphenidate+from+N-methoxycarbonylpiperidine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1021%2Fol9905046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol9905046%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DShirai%26aufirst%3DK.%26aulast%3DOnomura%26aufirst%3DO.%26aulast%3DMaki%26aufirst%3DT.%26atitle%3DA%2520convenient%2520method%2520for%2520synthesis%2520of%2520enantiomerically%2520enriched%2520methylphenidate%2520from%2520N-methoxycarbonylpiperidine%26jtitle%3DOrg.%2520Lett.%26date%3D1999%26volume%3D1%26spage%3D175%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Matsumura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onomura, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, T.</span><span> </span><span class="NLM_article-title">A convenient method for synthesis of optically active methylphenidate from <i>N</i>-methoxycarbonylpiperidine by utilizing electrochemical oxidation and Evans aldol-type reaction</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7411</span><span class="NLM_x">–</span> <span class="NLM_lpage">7422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2000&pages=7411-7422&author=Y.+Matsumuraauthor=Y.+Kandaauthor=K.+Shiraiauthor=O.+Onomuraauthor=T.+Maki&title=A+convenient+method+for+synthesis+of+optically+active+methylphenidate+from+N-methoxycarbonylpiperidine+by+utilizing+electrochemical+oxidation+and+Evans+aldol-type+reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumura%26aufirst%3DY.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DShirai%26aufirst%3DK.%26aulast%3DOnomura%26aufirst%3DO.%26aulast%3DMaki%26aufirst%3DT.%26atitle%3DA%2520convenient%2520method%2520for%2520synthesis%2520of%2520optically%2520active%2520methylphenidate%2520from%2520N-methoxycarbonylpiperidine%2520by%2520utilizing%2520electrochemical%2520oxidation%2520and%2520Evans%2520aldol-type%2520reaction%26jtitle%3DTetrahedron%26date%3D2000%26volume%3D56%26spage%3D7411%26epage%3D7422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Pilli, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Böckelmann, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Fatima Alves, C.</span><span> </span><span class="NLM_article-title">The stereochemistry of the addition of chlorotitanium enolates of <i>N</i>-acyl oxazolidin-2-ones to 5- and 6-membered <i>N</i>-acyliminium ions</span> <span class="citation_source-journal">J. Braz. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">634</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.1590%2FS0103-50532001000500007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntlSjtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=634-651&author=R.+A.+Pilliauthor=M.+A.+B%C3%B6ckelmannauthor=C.+de+Fatima+Alves&title=The+stereochemistry+of+the+addition+of+chlorotitanium+enolates+of+N-acyl+oxazolidin-2-ones+to+5-+and+6-membered+N-acyliminium+ions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">The stereochemistry of the addition of chlorotitanium enolates of N-acyl oxazolidin-2-ones to 5- and 6-membered N-acyliminium ions</span></div><div class="casAuthors">Pilli, Ronaldo A.; Bockelmann, Maria Alice; Alves, Conceicao de Fatima</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Brazilian Chemical Society</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">634-651</span>CODEN:
                <span class="NLM_cas:coden">JOCSET</span>;
        ISSN:<span class="NLM_cas:issn">0103-5053</span>.
    
            (<span class="NLM_cas:orgname">Sociedade Brasileira de Quimica</span>)
        </div><div class="casAbstract">The stereoselective addn. of in situ chiral and achiral titanium enolates, derived from the corresponding N-acyloxazolidin-2-ones, to five- and six-membered N-acyl iminium ions afforded 2-substituted pyrrolidines in moderate to good diastereoisomeric ratios (5:1 to 14:1).  Lower diastereoselection was generally obsd. in the formation of the corresponding 2-substituted piperidines.  The stereochem. outcome was found to be modulated by the nature of the cyclic N-acyl iminium ion and of its carbamate and by the N-acyl group in the enolate precursor.  The preferential lk topol. approach seems to be dictated mainly by the minimization of non-bonding interactions between the N-acyl group in the chlorotitanium(IV) enolate and the carbamate and methylene groups in the cyclic N-acyl iminium ion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoiRBXMBIj67Vg90H21EOLACvtfcHk0lhHOHj4N0Htrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntlSjtbc%253D&md5=f1d203ce5a88afe020df8fc615ad8f34</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1590%2FS0103-50532001000500007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1590%252FS0103-50532001000500007%26sid%3Dliteratum%253Aachs%26aulast%3DPilli%26aufirst%3DR.%2BA.%26aulast%3DB%25C3%25B6ckelmann%26aufirst%3DM.%2BA.%26aulast%3Dde%2BFatima%2BAlves%26aufirst%3DC.%26atitle%3DThe%2520stereochemistry%2520of%2520the%2520addition%2520of%2520chlorotitanium%2520enolates%2520of%2520N-acyl%2520oxazolidin-2-ones%2520to%25205-%2520and%25206-membered%2520N-acyliminium%2520ions%26jtitle%3DJ.%2520Braz.%2520Chem.%2520Soc.%26date%3D2001%26volume%3D12%26spage%3D634%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Kallan, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heizer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bencsik, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G. P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span> </span><span class="NLM_article-title">Discovery and SAR of spirochromane Akt inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2410</span><span class="NLM_x">–</span> <span class="NLM_lpage">2414</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2410-2414&author=N.+C.+Kallanauthor=K.+L.+Spencerauthor=J.+F.+Blakeauthor=R.+Xuauthor=J.+Heizerauthor=J.+R.+Bencsikauthor=I.+S.+Mitchellauthor=S.+L.+Gloorauthor=M.+Martinsonauthor=T.+Risomauthor=S.+D.+Grossauthor=T.+H.+Moralesauthor=G.+P.+A.+Vigersauthor=B.+J.+Brandhuberauthor=N.+J.+Skelton&title=Discovery+and+SAR+of+spirochromane+Akt+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKallan%26aufirst%3DN.%2BC.%26aulast%3DSpencer%26aufirst%3DK.%2BL.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DHeizer%26aufirst%3DJ.%26aulast%3DBencsik%26aufirst%3DJ.%2BR.%26aulast%3DMitchell%26aufirst%3DI.%2BS.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DGross%26aufirst%3DS.%2BD.%26aulast%3DMorales%26aufirst%3DT.%2BH.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520spirochromane%2520Akt%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2410%26epage%3D2414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="note"><p class="first last">The inhibition against a panel of kinases was determined at Upstate, Charlottesville, VA.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="note"><p class="first last">The crystallographic data described have been deposited with the RCSB Protein Data Bank (PDB code for <b>28</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EKL">4EKL</a>).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Milletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storchi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goracci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span> </span><span class="NLM_article-title">Extending p<i>K</i><sub><i>a</i></sub> prediction accuracy: high-throughput p<i>K</i><sub><i>a</i></sub> measurements to understand p<i>K</i><sub><i>a</i></sub> modulation of new chemical series</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4270</span><span class="NLM_x">–</span> <span class="NLM_lpage">4279</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.1016%2Fj.ejmech.2010.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=20633962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=4270-4279&author=F.+Millettiauthor=L.+Storchiauthor=L.+Goracciauthor=S.+Bendelsauthor=B.+Wagnerauthor=M.+Kansyauthor=G.+Cruciani&title=Extending+pKa+prediction+accuracy%3A+high-throughput+pKa+measurements+to+understand+pKa+modulation+of+new+chemical+series"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Extending pKa prediction accuracy: High-throughput pKa measurements to understand pKa modulation of new chemical series</span></div><div class="casAuthors">Milletti, Francesca; Storchi, Loriano; Goracci, Laura; Bendels, Stefanie; Wagner, Bjoern; Kansy, Manfred; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4270-4279</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We have recently developed a tool, MoKα, to predict the pKa of org. compds. using a large dataset of over 26,500 literature pKa values as a training set.  However, predicting accurately pKa (<0.5 pH units) remains challenging for novel series, and this can be a drawback in the optimization of activity and ADME properties of lead compds.  To address this issue it is important to expand our knowledge of pKa determinants, therefore we have conducted high-throughput pKa measurements by using Spectral Gradient Anal. (SGA) on novel series of compds. selected from vendor databases.  Here we report our findings on the effect of specific chem. groups and steric constraints on the pKa of common functionalities in medicinal chem., such as amines, sulfonamides, and amides.  Furthermore, we report the pKa of ionizable groups that were not well represented in the database of literature pKa of MoKα, such as hydrazide derivs.  These findings helped us to enhance MoKα, which is here benchmarked on a set of exptl. pKa values from the Roche inhouse library (N = 5581; RMSE = 1.09; R2 = 0.82).  The accuracy of the predictions was greatly improved (RMSE = 0.49, R2 = 0.96) after training the software by using the automated tool Kibitzer with 6226 pK a values taken from a different set of Roche compds. appropriately selected, and this demonstrates the value of using high-throughput pKa measurements to expand the training set of pKa values used by the software MoKα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxQ9UJOAhB-rVg90H21EOLACvtfcHk0lgW8Ua_tpuCjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D&md5=e4c579032df7fa37ec3551c69a09257a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DMilletti%26aufirst%3DF.%26aulast%3DStorchi%26aufirst%3DL.%26aulast%3DGoracci%26aufirst%3DL.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DExtending%2520pKa%2520prediction%2520accuracy%253A%2520high-throughput%2520pKa%2520measurements%2520to%2520understand%2520pKa%2520modulation%2520of%2520new%2520chemical%2520series%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D4270%26epage%3D4279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourbeau, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wohlhieter, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monenschein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rider, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lofgren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tominey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamane, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viswanadhan, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hungate, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span> </span><span class="NLM_article-title">2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1652</span><span class="NLM_x">–</span> <span class="NLM_lpage">1656</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1652-1656&author=Q.+Zengauthor=M.+P.+Bourbeauauthor=G.+E.+Wohlhieterauthor=G.+Yaoauthor=H.+Monenscheinauthor=J.+T.+Riderauthor=M.+R.+Leeauthor=S.+Zhangauthor=J.+Lofgrenauthor=D.+Freemanauthor=C.+Liauthor=E.+Tomineyauthor=X.+Huangauthor=D.+Hoffmanauthor=H.+Yamaneauthor=A.+S.+Taskerauthor=C.+Dominguezauthor=V.+N.+Viswanadhanauthor=R.+Hungateauthor=X.+Zhang&title=2-Aminothiadiazole+inhibitors+of+AKT1+as+potential+cancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DBourbeau%26aufirst%3DM.%2BP.%26aulast%3DWohlhieter%26aufirst%3DG.%2BE.%26aulast%3DYao%26aufirst%3DG.%26aulast%3DMonenschein%26aufirst%3DH.%26aulast%3DRider%26aufirst%3DJ.%2BT.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLofgren%26aufirst%3DJ.%26aulast%3DFreeman%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTominey%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DYamane%26aufirst%3DH.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3D2-Aminothiadiazole%2520inhibitors%2520of%2520AKT1%2520as%2520potential%2520cancer%2520therapeutics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1652%26epage%3D1656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Han, E. K-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leverson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGonigal1, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span> </span><span class="NLM_article-title">Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5655</span><span class="NLM_x">–</span> <span class="NLM_lpage">5661</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=5655-5661&author=E.+K-H.+Hanauthor=J.+D.+Leversonauthor=T.+McGonigal1author=O.+J.+Shahauthor=K.+W.+Woodsauthor=T.+Hunterauthor=V.+L.+Girandaauthor=Y.+Luo&title=Akt+inhibitor+A-443654+induces+rapid+Akt+Ser-473+phosphorylation+independent+of+mTORC1+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DE.%2BK-H.%26aulast%3DLeverson%26aufirst%3DJ.%2BD.%26aulast%3DMcGonigal1%26aufirst%3DT.%26aulast%3DShah%26aufirst%3DO.%2BJ.%26aulast%3DWoods%26aufirst%3DK.%2BW.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DLuo%26aufirst%3DY.%26atitle%3DAkt%2520inhibitor%2520A-443654%2520induces%2520rapid%2520Akt%2520Ser-473%2520phosphorylation%2520independent%2520of%2520mTORC1%2520inhibition%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D5655%26epage%3D5661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Rhodes, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerding, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duckett, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberwein, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knick, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansing, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConnell, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahana, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geske, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleymenova, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhry, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leber, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minthorn, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strum, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span> </span><span class="NLM_article-title">Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">2366</span><span class="NLM_x">–</span> <span class="NLM_lpage">2374</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=2366-2374&author=N.+Rhodesauthor=D.+A.+Heerdingauthor=D.+R.+Duckettauthor=D.+J.+Eberweinauthor=V.+B.+Knickauthor=T.+J.+Lansingauthor=R.+T.+McConnellauthor=T.+M.+Gilmerauthor=S.+Y.+Zhangauthor=K.+Robellauthor=J.+A.+Kahanaauthor=R.+S.+Geskeauthor=E.+V.+Kleymenovaauthor=A.+E.+Choudhryauthor=Z.+Laiauthor=J.+D.+Leberauthor=E.+A.+Minthornauthor=S.+L.+Strumauthor=E.+R.+Woodauthor=P.+S.+Huangauthor=R.+A.+Copelandauthor=R.+Kumar&title=Characterization+of+an+Akt+kinase+inhibitor+with+potent+pharmacodynamic+and+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DDuckett%26aufirst%3DD.%2BR.%26aulast%3DEberwein%26aufirst%3DD.%2BJ.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLansing%26aufirst%3DT.%2BJ.%26aulast%3DMcConnell%26aufirst%3DR.%2BT.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DRobell%26aufirst%3DK.%26aulast%3DKahana%26aufirst%3DJ.%2BA.%26aulast%3DGeske%26aufirst%3DR.%2BS.%26aulast%3DKleymenova%26aufirst%3DE.%2BV.%26aulast%3DChoudhry%26aufirst%3DA.%2BE.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DMinthorn%26aufirst%3DE.%2BA.%26aulast%3DStrum%26aufirst%3DS.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DHuang%26aufirst%3DP.%2BS.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DCharacterization%2520of%2520an%2520Akt%2520kinase%2520inhibitor%2520with%2520potent%2520pharmacodynamic%2520and%2520antitumor%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D2366%26epage%3D2374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Grimshaw, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaton, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seavers, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span> </span><span class="NLM_article-title">AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1100</span><span class="NLM_x">–</span> <span class="NLM_lpage">1110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.1158%2F1535-7163.MCT-09-0986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=20423992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsleksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1100-1110&author=K.+M.+Grimshawauthor=L.+J.+Hunterauthor=T.+A.+Yapauthor=S.+P.+Heatonauthor=M.+I.+Waltonauthor=S.+J.+Woodheadauthor=L.+Fazalauthor=M.+Reuleauthor=T.+G.+Daviesauthor=L.+C.+Seaversauthor=V.+Lockauthor=J.+F.+Lyonsauthor=N.+T.+Thompsonauthor=P.+Workmanauthor=M.+D.+Garrett&title=AT7867+is+a+potent+and+oral+inhibitor+of+AKT+and+p70+S6+kinase+that+induces+pharmacodynamic+changes+and+inhibits+human+tumor+xenograft+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth</span></div><div class="casAuthors">Grimshaw, Kyla M.; Hunter, Lisa-Jane K.; Yap, Timothy A.; Heaton, Simon P.; Walton, Mike I.; Woodhead, Steven J.; Fazal, Lynsey; Reule, Matthias; Davies, Thomas G.; Seavers, Lisa C.; Lock, Victoria; Lyons, John F.; Thompson, Neil T.; Workman, Paul; Garrett, Michelle D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1100-1110</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The serine/threonine kinase AKT plays a pivotal role in signal transduction events involved in malignant transformation and chemoresistance and is an attractive target for the development of cancer therapeutics.  Fragment-based lead discovery, combined with structure-based drug design, has recently identified AT7867 as a novel and potent inhibitor of both AKT and the downstream kinase p70 S6 kinase (p70S6K) and also of protein kinase A.  This ATP-competitive small mol. potently inhibits both AKT and p70S6K activity at the cellular level, as measured by inhibition of GSK3β and S6 ribosomal protein phosphorylation, and also causes growth inhibition in a range of human cancer cell lines as a single agent.  Induction of apoptosis was detected by multiple methods in tumor cells following AT7867 treatment.  Administration of AT7867 (90 mg/kg p.o. or 20 mg/kg i.p.) to athymic mice implanted with the PTEN-deficient U87MG human glioblastoma xenograft model caused inhibition of phosphorylation of downstream substrates of both AKT and p70S6K and induction of apoptosis, confirming the observations made in vitro.  These doses of AT7867 also resulted in inhibition of human tumor growth in PTEN-deficient xenograft models.  These data suggest that the novel strategy of AKT and p70S6K blockade may have therapeutic value and supports further evaluation of AT7867 as a single-agent anticancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7gZJRET_nqrVg90H21EOLACvtfcHk0lh5_ALDS3nXyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsleksrs%253D&md5=9ac4069c4cf2833d2e2e5e0f88e6d935</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0986%26sid%3Dliteratum%253Aachs%26aulast%3DGrimshaw%26aufirst%3DK.%2BM.%26aulast%3DHunter%26aufirst%3DL.%2BJ.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DHeaton%26aufirst%3DS.%2BP.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DWoodhead%26aufirst%3DS.%2BJ.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DSeavers%26aufirst%3DL.%2BC.%26aulast%3DLock%26aufirst%3DV.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26atitle%3DAT7867%2520is%2520a%2520potent%2520and%2520oral%2520inhibitor%2520of%2520AKT%2520and%2520p70%2520S6%2520kinase%2520that%2520induces%2520pharmacodynamic%2520changes%2520and%2520inhibits%2520human%2520tumor%2520xenograft%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1100%26epage%3D1110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G. P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span> </span><span class="NLM_article-title">An ATP-site on-off switch that restricts phosphatase accessibility of Akt</span> <span class="citation_source-journal">Sci. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">ra37</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.1126%2Fscisignal.2002618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=22569334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A280%3ADC%252BC38nhsFGgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=ra37&author=K.+Linauthor=J.+Linauthor=W.-I.+Wuauthor=J.+Ballardauthor=B.+B.+Leeauthor=S.+L.+Gloorauthor=G.+P.+A.+Vigersauthor=T.+H.+Moralesauthor=L.+S.+Friedmanauthor=N.+J.+Skeltonauthor=B.+J.+Brandhuber&title=An+ATP-site+on-off+switch+that+restricts+phosphatase+accessibility+of+Akt"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An ATP-site on-off switch that restricts phosphatase accessibility of Akt</span></div><div class="casAuthors">Lin Kui; Lin Jie; Wu Wen-I; Ballard Joshua; Lee Brian B; Gloor Susan L; Vigers Guy P A; Morales Tony H; Friedman Lori S; Skelton Nicholas; Brandhuber Barbara J</div><div class="citationInfo"><span class="NLM_cas:title">Science signaling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">223</span>),
    <span class="NLM_cas:pages">ra37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The protein serine-threonine kinase Akt undergoes a substantial conformational change upon activation, which is induced by the phosphorylation of two critical regulatory residues, threonine 308 and serine 473.  Paradoxically, treating cells with adenosine 5'-triphosphate (ATP)-competitive inhibitors of Akt results in increased phosphorylation of both residues.  We show that binding of ATP-competitive inhibitors stabilized a conformation in which both phosphorylated sites were inaccessible to phosphatases.  ATP binding also produced this protection of the phosphorylated sites, whereas interaction with its hydrolysis product adenosine 5'-diphosphate (ADP) or allosteric Akt inhibitors resulted in increased accessibility of these phosphorylated residues.  ATP-competitive inhibitors mimicked ATP by targeting active Akt.  Forms of Akt activated by an oncogenic mutation or myristoylation were more potently inhibited by the ATP-competitive inhibitors than was wild-type Akt.  These data support a new model of kinase regulation, wherein nucleotides modulate an on-off switch in Akt through conformational changes, which is disrupted by ATP-competitive inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnztGy5MRl7DToTC3aBaesfW6udTcc2ebVZUp7GNnjVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38nhsFGgsA%253D%253D&md5=3bfded195b532ddc579e74cb830437b3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2002618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2002618%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DW.-I.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DB.%2BB.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DMorales%26aufirst%3DT.%2BH.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26atitle%3DAn%2520ATP-site%2520on-off%2520switch%2520that%2520restricts%2520phosphatase%2520accessibility%2520of%2520Akt%26jtitle%3DSci.%2520Signaling%26date%3D2012%26volume%3D5%26spage%3Dra37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Zaki, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemeth, J. A.</span><span> </span><span class="NLM_article-title">CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">592</span><span class="NLM_x">–</span> <span class="NLM_lpage">595</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm301024w&amp;key=10.1002%2Fijc.20270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm301024w&amp;key=15239138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm301024w&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsFequro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2004&pages=592-595&author=M.+H.+Zakiauthor=J.+A.+Nemeth&title=CNTO+328%2C+a+monoclonal+antibody+to+IL-6%2C+inhibits+human+tumor-induced+cachexia+in+nude+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice</span></div><div class="casAuthors">Zaki, Mohamed H.; Nemeth, Jeffrey A.; Trikha, Mohit</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">592-595</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">IL-6 is a multifunctional cytokine implicated in several cancers.  IL-6 is a growth factor for certain tumors and contributes to drug resistance, cachexia and bone resorption.  Cachexia is characterized by progressive wt. loss and depletion of host reserves of adipose tissue and skeletal muscle.  We have developed CNTO 328 (cCLB8), a human-mouse chimeric MAb to IL-6 (Kd approx. 10-12 M) that inhibits IL-6 function.  A phase I study with CNTO 328 in multiple myeloma patients demonstrated that the antibody was safe and had a circulating half-life of approx. 17 days.  Since IL-6 is implicated in cachexia, we hypothesized that CNTO 328 could inhibit tumor-induced cachexia.  We used 2 human tumor-induced cachexia models in nude mice.  In the first model, human melanoma cells were inoculated in female nude mice.  Control treated animals lost 19% (±7.7%) body wt. from day 0 to day 31, whereas CNTO 328 (10 mg/kg)-treated animals lost only 1.5% (±1.3%) body wt. from day 0 to day 31 (p = 0.023).  In the second cachexia model, human prostate tumor cells were injected into male nude mice.  By day 29, control treated animals lost 6% (±3.5%) body wt., whereas CNTO 328 (10 mg/kg)-treated animals gained 7% (±4%) body wt. (p = 0.01).  Since CNTO 328 blocks human IL-6 but not mouse IL-6, the data indicate that tumor cell-secreted IL-6 directly contributes to body wt. loss, highlighting the potential role for CNTO 328 as an anticachectic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolKIGMjJm-t7Vg90H21EOLACvtfcHk0lgJDZccgaMSqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsFequro%253D&md5=2c102c2fd9f8b874d57a8307a3459955</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fijc.20270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.20270%26sid%3Dliteratum%253Aachs%26aulast%3DZaki%26aufirst%3DM.%2BH.%26aulast%3DNemeth%26aufirst%3DJ.%2BA.%26atitle%3DCNTO%2520328%252C%2520a%2520monoclonal%2520antibody%2520to%2520IL-6%252C%2520inhibits%2520human%2520tumor-induced%2520cachexia%2520in%2520nude%2520mice%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2004%26volume%3D111%26spage%3D592%26epage%3D595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OW4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OW4','PDB','3OW4'); return false;">PDB: 3OW4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EKL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EKL','PDB','4EKL'); return false;">PDB: 4EKL</a></li><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=M63167" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=M63167','Genbank','M63167'); return false;">Genbank: M63167</a></li><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=NP_001617" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=NP_001617','Genbank','NP_001617'); return false;">Genbank: NP_001617</a></li><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=NP_005456" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=NP_005456','Genbank','NP_005456'); return false;">Genbank: NP_005456</a></li><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=X07767" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=X07767','Genbank','X07767'); return false;">Genbank: X07767</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i74"><a href="/doi/suppl/10.1021/jm301024w">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_16601"></div></div></div></div></div><hr /></hr><p class="last">Enzyme inhibition results (expressed as a percentage of the control) for compounds <b>2</b>, <b>3</b>, and <b>28</b> tested against a panel of 226, 225, and 230 kinases, respectively, performed at Upstate, Charlottesville, VA.<a class="ref ref15" href="javascript:void(0);">(15)</a> This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301024w/suppl_file/jm301024w_si_001.pdf">jm301024w_si_001.pdf (150.98 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm301024w&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-18%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm301024w" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm301024w" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992a6d982c22a8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
